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Microcirculation is key to providing enough nutrition and oxygen from head to toe. 
This is possible only through an extensive network of blood vessels spread around the 
body. Effect of microcirculation abnormalities stretch beyond one’s comprehension. 
The effects could be felt at any age, from the foetal life to the adulthood. The chapters 
present in this book describe how these abnormalities could lead to diseases such as 
atherosclerosis, thrombosis, diabetes, hypertension. Disorders of microcirculation 
could be related to the structural and/or functional damage to the inner lining of the 
blood vessels. Early identification of these disorders could benefit many ailments 
including cardiovascular and cerebrovascular diseases such as heart attack and stroke.
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Preface
Microcirculation occurs through an extensive network of vasculature spread 
throughout the body. An intact microcirculatory system is a prerequisite for 
adequate perfusion and hence normal functioning of organs in the body. 
Microcirculatory disorders could result from decreased microcirculation, 
damage to the endothelial cells, altered vascular permeability and/or changes in 
microvascular reactivity. Early identification of microcirculatory impairment 
through investigative means could help improve outcome for a large number of 
disease states.
This book entitled “Basic and Clinical Understanding of Microcirculation” 
effectively develops the very basic concepts of microvascular circulation. The first 
chapter describes the role of ion channels in regulating vascular smooth muscles. 
Subsequent chapters cover topics such as how diseases like diabetes affect the 
regulation of cerebrovascular tone and lead to neurological disorders. Later, the 
role of endothelial dysfunction, relation to nitric oxide in maintaining vasodilation, 
and abnormalities in disease states are discussed. Reading these chapters on the 
basic aspects also makes one understand how vascular dysfunction is related to the 
diseases like diabetes and atherosclerosis.
Clinical section of the book begins with describing the pivotal role of endothelial 
dysfunction in cardiovascular diseases, followed by association with the peripheral 
blood inflammatory markers and their role in depression. Similarly, when the active 
monocellular layer of cells gets affected, it could lead to atherosclerosis, thrombosis, 
diabetes, hypertension etc. 
In this book the authors thoroughly describe methods to evaluate microcirculation 
using modern diagnostic technology like laser doppler flowmetry. Last but not 
least, the readers will be intrigued with how microvascular circulation could 
be related to growth and development of newborn. I hope hhat those who read 
this book will benefit through better understanding of the various facets of 
microcirculation.
I would like to thank my co-editors Nazar Luqman Bilgrami (Cardiologist at Austin 
Health, Melbourne, Australia) and Seyed Soheil Saeedi Saravi (Cardiovascular 
Division, Harvard Medical School, Boston, USA) for their contribution towards 
compiling this book, editing the chapters, and writing the preface.
Production of this book would not have been possible without the contribution 
from the experts in the field and the continuous hard work of the Author Service 
Manager and Commissioning Editor at IntechOpen.
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Finally, I would like to emphasise that this book is meant for a broad range of 
readers including undergraduates, graduates, researchers, teachers, medical 
professionals, and cardiovascular specialists.
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Ion Channels and Their Regulation 
in Vascular Smooth Muscle
Arsalan U. Syed, Thanhmai Le, Manuel F. Navedo  
and Madeline Nieves-Cintrón
Abstract
Vascular smooth muscle excitability is exquisitely regulated by different ion 
channels that control membrane potential (Em) and the magnitude of intracellular 
calcium inside the cell to induce muscle relaxation or contraction, which signifi-
cantly influences the microcirculation. Among them, various members of the K+ 
channel family, voltage-gated Ca2+ channels, and transient receptor potential (TRP) 
channels are fundamental for control of vascular smooth muscle excitability. These 
ion channels exist in complex with numerous signaling molecules and binding part-
ners that modulate their function and, in doing so, impact vascular smooth muscle 
excitability. In this book chapter, we will review our current understanding of some 
of these ion channels and binding partners in vascular smooth muscle and discuss 
how their regulation is critical for proper control of (micro)vascular function.
Keywords: ion channels, signal transduction, vascular tone, vascular smooth muscle, 
microcirculation
1. Introduction
Vascular smooth muscle cells wrapping around small resistance arteries and 
arterioles are crucial for vascular reactivity [1]. These cells enable dynamic, 
moment-to-moment control of vessel diameter and pressure-induced contraction 
(e.g., vascular tone). This control is central to autoregulation of resistance vessels, 
maintenance of vessel caliber independently of changes in blood pressure, and 
proper perfusion to meet the metabolic demands of a given tissue.
To regulate arterial diameter, vascular smooth muscle receives and integrates 
many inputs, including changes in intraluminal pressure, vasoconstrictor and 
vasodilatory signals from endothelial cells lining the inner arterial wall, and nerve 
terminals innervating the vessels [2]. These inputs regulate vascular smooth muscle 
excitability, at least in part, by modulating the activity of a number of ion chan-
nels to control membrane potential (Em) and the magnitude of intracellular Ca2+ 
concentration ([Ca2+]i) [1]. Among the many ion channels, transient receptor 
potential (TRP) channels, voltage-gated (KV), Ca2+-activated (BKCa) and inward 
rectifier (Kir) K+ channels, and voltage-gated Ca2+ channels (VGCC) are funda-
mental in transducing mechanical force, establishing Em, and regulating [Ca2+]i 
[1]. Mechanisms for the regulation of vascular smooth muscle ion channels, includ-
ing those mentioned above, involve agonist-independent and agonist-dependent 
activation of Gq and/or Gs protein-coupled receptors (GxPCR) [3]. The optimal 
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activation and regulation of these mechanisms are often dependent on the forma-
tion of macromolecular complexes driven by scaffold proteins to target and com-
partmentalize proteins/signaling events to specific regions and substrates [4].
In this chapter, we provide a brief overview of our current understanding of the 
role of different subunits of TRP channels, several K+ channel subtypes, as well as 
key VGCCs in control of vascular smooth muscle excitability and (micro)vascular 
function. We will also discuss their regulation by signaling pathways and macromo-
lecular complexes. Note that many more studies than those cited here can be found 
in the scientific literature. Comprehensive studies exploring additional aspects of 
vascular ion channel regulation, vascular smooth muscle excitability, and (micro)
vascular function in health and disease can be found in recent reviews [1, 5–9].
2. TRP channels
The TRP channel superfamily is composed of 28 members divided into 6 
subfamilies based on their molecular and biophysical properties [10]. Functional 
TRP channels are composed of four subunits, each with six membrane-spanning 
helices that can exist in a homomeric or heteromeric form. Vascular smooth muscle 
cells express a number of these channels, including members of the TRPC, TRPV, 
TRPM, and TRPP subfamilies [7, 9]. The function of TRP channels in vascular 
smooth muscle ranges from regulating contractility to modulating the proliferative 
state of the cells. In this section, we focused our discussion on the functional role 
and regulation of specific TRP channels in vascular smooth muscle excitability.
2.1 Functional role of vascular smooth muscle TRP channels
The function of different TRP channels in vascular smooth muscle has been 
unmasked using conventional and innovative molecular, pharmacological, and 
genetic approaches. These approaches revealed distinctive roles of specific TRP 
channel subfamilies in modulating vascular smooth muscle excitability and vascular 
reactivity. For instance, studies have found that TRPC3 channels are not essential 
for pressure-induced constriction. Yet, TRPC3 channels play a key role in receptor-
mediated vasoconstriction of resistance arteries upon activation of various GqPCRs, 
including purinergic receptors, endothelin (ETA) receptors, and angiotensin II 
(AT1) receptors [7, 11, 12]. The mechanisms for TRPC3 channel activation involve 
direct coupling of the channel with IP3 receptors located in the sarcoplasmic reticu-
lum (SR) in a process that does not require SR Ca2+ release [13]. TRPC5 channels, in 
association with TRPC1 channels, have been shown to contribute to store-operated 
Ca2+ entry in vascular smooth muscle from arterioles [14], which may modulate cell 
excitability. Expression of TRPP channels in vascular smooth muscle contributes to 
stretch-activated cation currents, which causes vascular smooth muscle membrane 
depolarization. The activity of these channels has been associated with stretch-
dependent regulation of vascular tone in cerebral arteries and control of systemic 
blood pressure [15, 16]. The nonselective cation channel TRPC6 is involved in Ca2+ 
mobilization leading to vascular smooth muscle contraction [17]. More recently, 
these channels have been shown to be part of a mechanosensation complex [18]. In 
this model (see Figure 1), stretch is “sensed” by AT1 receptors. These receptors then 
induce the activation of TRPC6 channels to bolster Ca2+ release from the SR, which 
triggers TRPM4 channel activity and vascular smooth muscle contraction. This 
model reveals an exquisite and finely orchestrated macromolecular complex for 
control of stretch-induced contraction.
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Contrary to the contractile influences of the TRP channels described above, 
activation of TRPV4 channels is associated with vascular smooth muscle relaxation 
(Figure 1) [19]. The underlying mechanism involves the formation of a macro-
molecular complex between TRPV4 and BKCa channels in the plasma membrane 
and ryanodine receptors (RyR) in the SR. This complex does not depend on direct 
protein-protein interactions between TRPV4 and BKCa channels and RyR but 
requires their close physical proximity. The close association between these proteins 
facilitates Ca2+ influx via TRPV4 channels that stimulates RyR activity resulting in 
the generation of Ca2+ sparks. The ensuing Ca2+ sparks activate BKCa channels lead-
ing to vascular smooth muscle membrane potential hyperpolarization and relax-
ation [20]. Because of the high Ca2+ permeability of TRPV4 channels in vascular 
smooth muscle [21], they could potentially activate adjacent BKCa channels directly 
to regulate cell excitability and vascular reactivity. Examination of this exciting pos-
sibility is an excellent opportunity for further research. Moreover, additional work 
is needed to comprehensively define the role of TRP channels in vascular smooth 
muscle in the microcirculation during physiological and pathological conditions.
2.2 Regulation of TRP channels in vascular smooth muscle
It has been well documented that agonist-dependent activation of GqPCRs/
protein kinase C (PKC) and GsPCRs/protein kinase A (PKA) signaling regulates 
TRP channels [10]. Protein kinase G (PKG) modulation of TRP channels has also 
been reported. However, how these signaling pathways control TRP channel activ-
ity in vascular smooth muscle, as well as the underlying consequences in vascular 
Figure 1. 
Regulation of vascular smooth muscle excitability by TRP channels. Diverse TRP channels contribute to 
vascular smooth muscle relaxation or contraction. Ca2+ influx via TRPV4 channels is associated with an 
increase in the frequency of Ca2+ release through ryanodine receptors (RyR) located in the sarcoplasmic 
reticulum (e.g., Ca2+ sparks). The production of Ca2+ sparks triggers the activity of adjacent BKCa channels 
at the surface membrane to promote K+ efflux, membrane potential hyperpolarization, and vascular smooth 
muscle relaxation [18]. TRPV4 channel activity can be stimulated by activation of AT1 receptors (AT1R) by 
angiotensin II (angII) via an AKAP5-mediated PKC signaling pathway [20, 25]. This AT1R/AKAP5/PKC/
TRPV4 axis may serve as a negative feedback mechanism to offset stimulation of L-type Ca2+ channel CaV1.2 
(LTCCs) leading to contraction in response to angII. AT1R, independent of angII, has also been implicated in a 
mechanosensitive pathway that activates TRPC6 channels to boost cytosolic Ca2+ via stimulation of IP3 receptors 
(IP3R). This increase in cytosolic Ca2+ promotes the activity of TRPM4 channels leading to vascular smooth 
muscle membrane depolarization and subsequent contraction in response to stretch [17]. The orange wavelike 
lines highlight stretch-sensing proteins. The model was generated by taking in consideration studies cited and 
described above. Na+ = sodium; Ca2+ = calcium; AKAP5 = A kinase anchoring protein 5; PKC = protein kinase 
C; DAG = diacylglycerol; IP3 = inositol trisphosphate.
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(IP3R). This increase in cytosolic Ca2+ promotes the activity of TRPM4 channels leading to vascular smooth 
muscle membrane depolarization and subsequent contraction in response to stretch [17]. The orange wavelike 
lines highlight stretch-sensing proteins. The model was generated by taking in consideration studies cited and 
described above. Na+ = sodium; Ca2+ = calcium; AKAP5 = A kinase anchoring protein 5; PKC = protein kinase 
C; DAG = diacylglycerol; IP3 = inositol trisphosphate.
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reactivity are not well understood. A limited number of studies have shown that 
PKG inhibits TRPC3 channels and that this may contribute to nitric oxide (NO)-
mediated relaxation, but the mechanisms require further examination [22]. PKA 
signaling stimulates the activity of several members of the TRPV channel subfam-
ily while inhibiting TRPC5 and TRPC6 channels in vascular smooth muscle [7]. 
PKA-mediated inhibition of TRPC6 channels in response to agonist stimulation was 
shown to be dependent on phosphorylation of the TRPC6 subunit at threonine 69, 
which resulted in a reduction in angiotensin II (angII)-induced vasoconstriction 
[23], thus revealing a comprehensive mechanism for the regulation of TRP channels 
and the underlying effects in vascular reactivity.
PKC activity inhibits TRPC3 channels and activates TRPM4 and TRPV4 channels 
in smooth muscle [7, 9, 21, 24]. TRPM4 activation by PKC proceeds, at least in part, 
by stimulating channel trafficking and membrane translocation via a mechanism 
requiring PKCδ [25]. This PKCδ-dependent anterograde TRPM4 trafficking is func-
tionally relevant as it promotes vascular smooth muscle contraction. PKC-dependent 
regulation of TRPV4 channels has been suggested to be critical for counteracting the 
vasoconstriction stimulated by angII [21]. Intriguingly, TRPV4 channels are found in 
complex with the scaffold A kinase anchoring protein 5 (AKAP5 = human AKAP79 
and murine AKAP150) in vascular smooth muscle (Figure 1) [21, 26]. This scaffold 
protein provides a platform for targeting and compartmentalization of signaling 
molecules (e.g., PKA, PKC, protein phosphatase 2B = PP2B) to specific substrates 
(e.g., ion channels) [4]. With a suggested distance between them of ~200 nm [26], 
optimal AKAP5-anchored PKC modulation of TRPV4 activity is highly dependent 
on the distance between the targeted kinase and the ion channel. This tight regula-
tion of TRPV4 activity by AKAP5 may be essential for vascular smooth muscle 
excitability given the high Ca2+ permeability of these channels, as mentioned 
previously. Mechanisms regulating TRPP channels by PKA and/or PKC in vascular 
smooth muscle are currently unclear. The studies discussed above reveal the complex 
functional role of TRP channels in vascular smooth muscle and how their regulation 
alters vascular function and highlights unique opportunities for further research. 
For instance, it will be important to define the role of the AKAP5/PKC/PKA com-
plex and its association with other TRP channels in regulating vascular smooth 
muscle excitability and vascular reactivity. It also remains to be determined whether 
dynamic trafficking of other TRP channels and the involvement of the AKAP5/PKC/
PKA complex in this process also play a role in fine-tuning vascular reactivity.
3. K+ channels
The activity of K+ channels determines vascular smooth muscle membrane 
potential and is therefore key regulators of vascular tone [1]. By setting and con-
trolling the membrane potential, these channels influence the levels of [Ca2+]i and 
therefore, vascular smooth muscle contraction. Intriguingly, a subset of K+ channels 
has also been linked to regulation of vascular smooth muscle proliferation (see recent 
review on this topic in [27, 28]). Vascular smooth muscle cells express a wide variety 
of isoforms from several classes of K+ channels, including KV, BKCa, and Kir channels 
(see Figure 2). In the following sections, we will describe the expression, function, 
and regulation of these K+ channels and their control of vascular function.
3.1 KV channels
A number of KV channels isoforms are expressed in vascular smooth muscle, 
including members of the KV1 (KV1.1, KV1.2, KV1.3, KV1.5, KV1.6), KV2 (KV2.1), and 
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KV 7 (KV7.1–5), as well as several silent KV subunits (e.g., KV9.3) [1]. KV channels 
are formed by a homo- or heterotetrameric assembly of pore-forming α subunits 
and regulatory β subunits. Key examples with functional relevance in vascular 
smooth muscle excitability from multiple vascular beds are KV channels assembled 
by KV1.2/KV1.5 subunits, KV2.1 subunits with KV9.3, and KV1/KV7 subunits. These 
subunit compositions confer functional and pharmacological diversity essential 
for fine-tuning vascular smooth muscle excitability and vascular reactivity 
[29–31]. The mechanisms for this involve activation of KV channels by a depolar-
izing stimulus (e.g., stretch-induced depolarization) and their regulation by 
vasoactive agents [1, 32, 33]. The resultant K+ efflux hyperpolarizes the membrane 
potential of vascular smooth muscle leading to a decrease in the open probability 
of voltage-gated L-type Ca2+ channels CaV1.2 (LTCCs), which contributes to 
decrease [Ca2+]i and relaxation (Figure 2). Conversely, their inhibition depolarizes 
the membrane potential, which will increase the open probability of LTCCs and 
lead to an increase in global [Ca2+]i and vascular smooth muscle contraction. This 
negative feedback regulation, together with other K+ channels, is essential for fine 
control of vascular smooth muscle excitability and vascular reactivity. However, 
in the context of the microcirculation, not much is known regarding the expres-
sion, functional composition, physiological role, and regulation of KV channels in 
arteriolar vascular smooth muscle. Consideration of these issues is important as 
recent studies have implicated that impairment in KV channel expression and/or 
function in the development of channelopathies are associated with small vessel 
Figure 2. 
Regulation of vascular smooth muscle excitability by K+ channels. Vascular smooth muscle cells express a 
number of K+ channels that, upon activation, provide negative feedback regulation of membrane potential and 
vascular tone. K+ channel activation results in efflux of K+ ions that hyperpolarize the membrane potential 
(ΔEm; denoted by dotted black lines) leading to a reduction in the open probability of LTCC CaV1.2 and TTCC 
CaV3.1 that results in a decrease in global [Ca2+]i leading to vascular smooth muscle relaxation [32, 95]. As 
mentioned in Figure 1, activation of ryanodine receptors (RyR) K+ channels can be distinctively regulated by 
vasoactive agents acting through the Gs/AC/PKA, NO/sGC/PKG, and Gq/PLC/PKC axes to either increase 
or decrease their activity. An example is the regulation of KV1.X channels by β adrenergic signaling (e.g., 
through β1 adrenergic receptors) [44–46]. Here, KV1.X channel regulation by β1 adrenergic signaling requires 
PKA targeting to the channel by postsynaptic density protein 95 (PSD95). Whether PSD95 as well as further 
scaffolding of proteins by AKAP5 is required for PKA regulation of KV1.X and other K+ channels (e.g., KV2.X, 
KV7.X, Kir2.X) as well as RyR is unclear (denoted by dotted red lines in the cartoon). The model was generated 
by taking in consideration studies cited and described above. K+ = potassium; Ca2+ = calcium; AKAP5 = A 
kinase anchoring protein 5; BKCa = large-conductance Ca2+ activated potassium channels; AC = adenylyl 
cyclase; PKA = protein kinase A; NO = nitric oxide; sGC = soluble guanylyl cyclase; PKG = protein kinase G; 
PLC = phospholipase C; PKC = protein kinase C.
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(ΔEm; denoted by dotted black lines) leading to a reduction in the open probability of LTCC CaV1.2 and TTCC 
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vasoactive agents acting through the Gs/AC/PKA, NO/sGC/PKG, and Gq/PLC/PKC axes to either increase 
or decrease their activity. An example is the regulation of KV1.X channels by β adrenergic signaling (e.g., 
through β1 adrenergic receptors) [44–46]. Here, KV1.X channel regulation by β1 adrenergic signaling requires 
PKA targeting to the channel by postsynaptic density protein 95 (PSD95). Whether PSD95 as well as further 
scaffolding of proteins by AKAP5 is required for PKA regulation of KV1.X and other K+ channels (e.g., KV2.X, 
KV7.X, Kir2.X) as well as RyR is unclear (denoted by dotted red lines in the cartoon). The model was generated 
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diseases [34]. Moreover, additional pathologies such as hypertension, metabolic 
disorders, and diabetic hyperglycemia impair (micro)vascular function, at least in 
part, by altering the expression/function of KV channels, but mechanisms remain 
not fully understood (see review in [5]).
Many vasoactive agents modulate vascular function by acting on KV channels 
expressed in vascular smooth muscle. For instance, agents that trigger activation 
of GqPCRs, such as angII, phenylephrine, and endothelin 1, are known to stimulate 
vasoconstriction, at least in part, by decreasing the expression and/or function of 
KV channels, particularly those of the KV1, KV2, and KV7 subfamilies (Figure 2) 
[1, 35–37]. The effects of these vasoconstrictors are related to PKC-mediated 
phosphorylation and/or changes in surface expression of KV subunits [36, 38–40], 
perhaps via engagement of different PKC isoforms [41]. This may contribute to 
selective control of KV channel activity in response to different stimuli. In addition, 
increases in [Ca2+]i have also been associated with inhibition of KV channels [42, 
43]. Considering that activation of GqPCRs also increases [Ca2+]i, these data suggest 
that both PKC activity and elevated [Ca2+]i could synergize to exacerbate KV chan-
nel inhibition, which will result in membrane potential depolarization, activation 
of LTCCs, and vascular smooth muscle contraction.
In stark contrast to Gq signaling, activation of NO/PKG and Gs/PKA signaling 
is typically associated with stimulation of vascular KV channels, including the 
members of the KV1 and KV7 subfamilies [1]. The functional consequence of this 
regulation is vascular smooth muscle relaxation. Phosphorylation of KV channels by 
PKA is opposed by protein phosphatases such as PP2B, which will dephosphorylate 
the different subunits [44]. Whether GsPCR/PKA/PP2B regulation of KV chan-
nels requires scaffolding proteins that could target all components of the signaling 
complex within close proximity to the channels is not well understood. A recent 
series of studies have demonstrated that the scaffold protein postsynaptic density 
95 (PSD95), which was thought to be a neuronal-specific protein, is expressed in 
vascular smooth muscle (Figure 2) [45, 46]. Intriguingly, PSD95 was found to be 
necessary for basal- and isoproterenol-induced PKA-mediated activation of KV1.X 
channels that resulted in vascular smooth muscle relaxation [45–47]. This was due 
to the formation of a distinctive PSD95-mediated signaling complex involving the 
β1-adrenergic receptor (β1 AR)-, PKA-, and KV1.2-containing channels [45, 47]. 
Since PSD95 is associated with AKAP5 in neurons [48], the argument was made that 
the PSD95-AKAP5 complex may be essential for PKA targeting and regulation of 
KV1.2 function and that this will have an impact on vascular smooth muscle excit-
ability and vascular reactivity [47]. However, additional studies have found that K+ 
currents produced by KV1.X and KV2.X subunits and BKCa channels are of similar 
magnitude in wild-type and AKAP5-depleted (AKAP5−/−) vascular smooth muscle 
cells [5, 49, 50]. These results suggest that, at least basally, AKAP5 is not necessary, 
and PSD95 may be sufficient for PKA-dependent regulation of K+ channels in these 
cells. β-Adrenergic stimulation has also been found to regulate KV7 channels leading 
to vasorelaxation [51], but whether a scaffold protein is mediating these effects is 
unknown and thus requires further examination. In addition, it is also unclear how 
KV2-containing channels, which contribute about 70% of the KV current in mouse 
cerebral and mesenteric vascular smooth muscle [49], are regulated by PKA signal-
ing, presenting another area of further research.
3.2 BKCa channels
BKCa channels are abundantly expressed in vascular smooth muscle cells [52]. 
The pore-forming α subunit (BKCa α1.1) assembles into tetramers to form a func-
tional channel, but unlike TRP and KV subunits, it contains seven transmembrane 
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domains and a heavily regulated long carboxyl terminal. Further regulation of BKCa 
channel function is conferred by the association of the α subunit with accessory β1 
and LRRC26 γ subunits, which increases the Ca2+ sensitivity of the channel [52]. 
BKCa channels are sensitive to voltage and Ca2+. The Ca2+ source to activate BKCa 
channels comes from the release of Ca2+ from the SR via RyRs (Figure 2) [20]. 
This complex does not depend on direct protein-protein interactions between BKCa 
channels and RyR but requires that both of these ion channels are in close physi-
cal proximity to each other. As mentioned above, data also have suggested that 
TRPV4 is responsible for triggering RyR activity [19], and thus, these channels have 
been proposed to form part of the same signaling complex with BKCa and RyRs in 
vascular smooth muscle. Intriguingly, LTCCs have been found to have an indirect 
or “loose” coupling with RyRs that could enable their activation [53], perhaps by 
modulating the SR Ca2+ concentration [54]. Additional components of the same or 
similar signaling complexes (see T-type Ca2+ channels section) with divergent roles 
have been identified [1, 7, 13, 55], but an integrated model remains to be defined. 
Regardless, the activation of these channels should result in K+ efflux that hyperpo-
larizes the plasma membrane of vascular smooth muscle cells leading to relaxation. 
The physiological influence of BKCa channels in control of membrane potential and 
vascular tone, however, seems to be species-, stimulus-, and vessel-dependent, even 
when compared between different orders of the same vascular tree. Indeed, studies 
have reported a clear involvement of BKCa channels in tonic negative feedback regu-
lation of membrane potential and pressure-induced constriction, even in human 
resistance arteries, whereas others have failed to establish a relationship (exemplary 
studies in [56–62]). The differences may be associated with disparities in the BKCa 
channel’s Ca2+ sensitivity and/or subunit expression levels and composition in the 
different vascular beds. A recent and broader discussion on this topic can be found 
in [1]. Thus, given the distinctive role of BKCa channels in the vasculature, further 
research on how these channels are regulated to control vascular tone in different 
vascular beds during physiological and pathological conditions is warranted.
Generally, vasoactive agents that act via activation of the Gs/adenylyl cyclase 
(AC)/PKA and NO/soluble guanylyl cyclase (sGC)/PKG axes potentiate BKCa 
channel activity, whereas those acting through the Gq/phospholipase C (PLC)/PKC 
axis inhibit the channel [1, 52]. Vasoactive agents may also regulate BKCa channel 
activity indirectly by modulating the function of RyR in the SR or other ion chan-
nels (e.g., L-type CaV1.2 and T-type CaV3.2 channels) in the plasma membrane that 
are involved with direct activation of RyR or SR Ca2+ refilling [54, 63, 64]. Although 
there is some evidence that scaffold proteins such as AKAP5 may help target signal-
ing molecules to BKCa channels [65], whether this indeed occurs in native vascular 
smooth muscle cells, as well as its functional relevance, is unclear. Considering the 
role of BKCa channels in negative feedback regulation of vascular tone, the physi-
ological implications of vasoactive agents acting through distinct GxPCRs on BKCa 
channels will be either vascular smooth muscle relaxation or contraction.
3.3 Kir channels
As their name implies, Kir channels produce an inward current. This current is 
observed at a potential negative to the K+ equilibrium potential that helps stabilize 
the resting Em [1, 66]. They also produce a small outward current at depolarizing 
potentials that serves as an electrical amplifier to magnify hyperpolarization. 
Inward rectification occurs due to voltage-dependent blockade of the channel by 
polyamines and Mg2+. Kir channels are regulated by lipids (e.g., phosphatidylino-
sitol 4,5 bisphosphate (PIP2) and cholesterol) [1, 66]. Intriguingly, a recent study 
found that cholesterol, but not PIP2, regulates Kir channel activity in the cerebral 
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polyamines and Mg2+. Kir channels are regulated by lipids (e.g., phosphatidylino-
sitol 4,5 bisphosphate (PIP2) and cholesterol) [1, 66]. Intriguingly, a recent study 
found that cholesterol, but not PIP2, regulates Kir channel activity in the cerebral 
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vascular smooth muscle [67], suggesting that these channels may be distinctively 
modulated by lipids depending on their tissue distribution. A functional Kir channel 
is formed when four pore-forming α subunits, each containing two membrane-
spanning domains, come together. Two main α subunits (e.g., Kir2.1 and Kir2.2) 
have been identified in vascular smooth muscle from multiple species [68–71]. 
Intriguingly, the expression of these subunits in a specific vascular bed may be 
species-dependent. Accordingly, although Kir subunit expression and channel 
activity have been extensively reported in murine cerebral vascular smooth muscle 
[67–69, 71], minimal, if any, Kir subunit expression and channel activity were found 
in the human cerebral vascular smooth muscle [72]. The functional implication of 
the activation of these channels in vascular smooth muscle is relaxation. Kir chan-
nel activity can be modulated by vasoactive agents with those acting through the 
Gq/PLC/PKC axis, inducing channel inhibition, and those acting on the Gs/AC/
PKA pathway, promoting channel activity [1]. The physiological relevance of these 
regulatory mechanisms on Kir channels and their control of vascular function are 
less well understood and therefore are in need of further evaluation.
4. Voltage-gated Ca2+ channels
Vascular smooth muscle cells express several subtypes of VGCCs [9]. These 
channels have been shown to be important for vascular smooth muscle contraction, 
and some subtypes have been implicated in relaxation mechanisms. In this section, 
we will focus on the role of two key subtypes of VGCCs, namely, LTCCs and T-type 
Ca2+ channels (TTCCs), in regulation of vascular smooth muscle excitability.
4.1 L-type Ca2+ channel CaV1.2
The L-type Ca2+ channel CaV1.2 (i.e., LTCCs) is essential for vascular smooth 
muscle contraction and vascular reactivity. Therefore, they play a key role in 
controlling blood flow and blood pressure [33, 73]. LTCCs are comprised of a 
pore-forming α1c subunit and auxiliary β, α2δ, and γ subunits that modulate channel 
function and trafficking [74]. The α1c subunit contains four homologous domains 
(I, II, III, IV). Each domain comprises of six membrane-spanning segments (S1–
S6) with intracellular amino- and carboxyl termini, which contain many regions 
relevant for channel regulation and control of cell excitability. In vascular smooth 
muscle, expression of the α1c subunit is critical for pressure-induced constriction as 
evidenced by an absence of myogenic response after LTCC blockade and depletion 
of the CaV1.2-α1c subunit in mice (e.g., SMAKO mouse) [33, 73, 75]. The auxiliary 
subunits α2 and δ are the product of the same gene that gets proteolytically cleaved 
after translation but remains connected by disulfide bonds, which give rise to the 
mature subunit. The α2δ subunit has been linked to regulation of α1c subunit surface 
expression that controls Ca2+ influx in vascular smooth muscle and the level of myo-
genic constriction [76]. The β subunit, which remains cytoplasmic, also contributes 
to the α1c subunit surface expression and channel regulation and therefore can 
modulate vascular smooth muscle excitability in health and disease [77, 78]. Unlike 
the other subunits, the expression, regulation, and function of the γ subunit in 
vascular smooth muscle are unclear and likely the subject of further research.
LTCCs in vascular smooth muscle are distinctively regulated by the Gs/AC/
PKA, NO/sGC/PKG, and Gq/PLC/PKC axes [9, 79]. Accordingly, the NO/sGC/PKG 
signaling axis has been shown to inhibit vascular LTCCs [80]. This has been associ-
ated with a reduction in [Ca2+]i that may be part of the vasodilatory mechanism 
underlying the activation of this pathway [79]. Receptor-mediated signaling via the 
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Gq/PLC/PKC axis typically results in potentiation of LTCC activity [9, 79, 81]. The 
functional effects of this Gq/PLC/PKC-mediated activation of LTCCs are vascular 
smooth muscle contraction and an increase in vascular tone. Intriguingly, activation 
of the Gs/AC/PKA axis has been shown to inhibit, activate, or produce no effect 
on vascular LTCC activity (Figure 3) [79]. Irrespectively of this however, PKA 
signaling has been generally linked with vasodilation, thus raising questions about 
the functional relevance, if any, of this kinase in the regulation of vascular LTCCs. 
Intriguingly, recent studies revealed that elevations in extracellular D-glucose 
(HG) potentiate LTCC activity via a Gs/AC/PKA pathway in vascular smooth 
muscle [82–85]. This HG-induced PKA-dependent activation of LTCCs resulted in 
increased global [Ca2+]i and vasoconstriction, thus providing the first example of a 
PKA-dependent pathway underlying vascular smooth muscle contraction. Future 
studies should further examine the in vivo relevance of this pathway.
LTCC regulation by Gs/AC/PKA and Gq/PLC/PKC axes in vascular smooth 
muscle is mediated by AKAP5 (Figure 3) [85, 86]. The involvement of the scaffold 
in this regulation was initially speculated from total internal reflection fluorescence 
(TIRF) microscopy experiments that optically recorded the activity of single or 
clusters of LTCCs [87, 88]. From these experiments, it was clear that the activity and 
location of functional LTCCs were heterogeneous throughout the surface mem-
brane of vascular smooth muscle cells [81, 87, 89]. Whereas some LTCCs showed 
stochastic activity with low Ca2+ flux and duration of events, others had persistent 
activity characterized by increased Ca2+ flux and events with prolonged open time 
that were produced by the opening of two or more channels [81, 87, 89–91]. The 
Figure 3. 
Regulation of vascular smooth muscle excitability by voltage-gated Ca2+ channels. Ca2+ influx via L-type 
Ca2+ channel CaV1.2 is essential for vascular smooth muscle contraction [33]. Their activity is regulated 
by Gs/PKA and Gq/PKC signaling pathways upon activation of a specific GPCR by a given stimulus (e.g., 
angII or HG). The association of CaV1.2 with these signaling pathways is orchestrated by AKAP5 [86]. PKA 
(and perhaps PKC) augments L-type Ca2+ channel CaV1.2 activity by increasing CaV1.2 phosphorylation at 
serine 1928 (pS1928) [82, 85]. The phosphatase PP2B suppresses enhancement of L-type Ca2+ channel CaV1.2 
activity presumably by preventing/opposing channel phosphorylation in vascular smooth muscle cells (gray 
line). Two TTCC subtypes are expressed in vascular smooth muscle, with CaV3.1 contributing to contractile 
mechanisms and CaV3.2 forming a complex with RyR in the sarcoplasmic reticulum and BKCa channels 
in the surface membrane to foster relaxation [95, 100]. Although PKA has been shown to inhibit CaV3.2, 
whether this requires AKAP5 function is unclear (dotted red lines with perpendicular line at the end). It is 
also unclear whether AKAP5-anchored PKC and PKA regulate CaV3.1 channel activity (dotted light and 
dark red lines with star near CaV3.1). Finally, whether the GPCRs activated by angII and HG are targeted 
to specific complexes by AKAP5 is unclear (red dotted line with ?? symbols). The model was generated by 
taking in consideration studies cited and described above. GPCR = G-protein coupled receptors; angiotensin 
II = angII; high glucose = HG; AKAP5 = A kinase anchoring protein 5; protein kinase A= PKA; protein kinase 
C = PKC; protein phosphatase 2B; PP2B; phosphorylation at CaV1.2 serine 1928 = pS1928; K+ = potassium; 
Ca2+ = calcium; ryanodine receptors = RyR.
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location of functional LTCCs were heterogeneous throughout the surface mem-
brane of vascular smooth muscle cells [81, 87, 89]. Whereas some LTCCs showed 
stochastic activity with low Ca2+ flux and duration of events, others had persistent 
activity characterized by increased Ca2+ flux and events with prolonged open time 
that were produced by the opening of two or more channels [81, 87, 89–91]. The 
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serine 1928 (pS1928) [82, 85]. The phosphatase PP2B suppresses enhancement of L-type Ca2+ channel CaV1.2 
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line). Two TTCC subtypes are expressed in vascular smooth muscle, with CaV3.1 contributing to contractile 
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in the surface membrane to foster relaxation [95, 100]. Although PKA has been shown to inhibit CaV3.2, 
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stochastic and persistent activity of LTCCs was modulated by membrane poten-
tial [92]. However, the occurrence of LTCCs with persistent activity is limited to 
specific regions of the surface membrane and has been demonstrated to be highly 
dependent on PKC activity and AKAP5 expression [81, 86]. The activity of phos-
phatases, such as PP2B, that are targeted to the channel by AKAP5, counteracts 
anchored kinase activity and restricts persistent LTCC activity (Figure 3) [89]. 
Accordingly, in vascular smooth muscle in which PKC is inhibited or cells from mice 
with genetically depleted PKC or AKAP5, the frequency of persistent LTCC activ-
ity is minimal [86, 87, 93]. In addition, PP2B inhibition stimulates persistent LTCC 
events in cells from wild type but not AKAP5−/− mice, suggesting that removing this 
“brake” facilitates kinase-mediated potentiation of channel activity [86, 89]. These 
results suggest an important role for AKAP5-anchored PKC and PP2B activity in 
modulating basal persistent LTCC activity. The physiological significance of these 
findings is underscored by data indicating that persistent LTCC events account for 
50% of the total dihydropyridine-sensitive (e.g., LTCCs) Ca2+ influx at physiologi-
cal membrane potentials [92], which is critical for vascular smooth muscle contrac-
tility in health and disease [82, 84, 86, 93].
4.2 T-type Ca2+ channels
T-type Ca2+ channels are formed by pore-forming α1 subunits with similar 
topology as that of the LTCC α1c subunit, but with no known auxiliary subunits 
that modulate channel function [74]. TTCCs are activated at more hyperpolar-
ized potentials and show similar conductance with Ca2+ or Ba2+ as charge carriers. 
Vascular smooth muscle cells express several TTCC α1 subunits, including CaV3.1 
(α1G) and CaV3.2 (α1H) [9, 94–98]. Intriguingly, CaV3.1, which is found in murine 
vascular smooth muscle, seems to be replaced by CaV3.3 (α1I) in human cells [96], 
suggesting that expression of TTCC α1 subunits is species-dependent. TTCCs have 
been shown to contribute to vascular smooth muscle excitability in several vascular 
beds from different species [9, 98]. However, rigorous analysis revealed that differ-
ent CaV3.X subunits may have very divergent physiological responses. For instance, 
whereas CaV3.1 (CaV3.3) mediates low-pressure-induced constriction, CaV3.2 
contributes to the negative feedback regulation of vascular tone by stimulating the 
RyR/BKCa axis (Figure 3) [64, 95, 96]. TTCCs can also be regulated by signaling 
molecules. Indeed, the NO/PKG and AC/PKA axes both inhibit vascular TTCCs 
[99, 100], which may have key implications in vascular smooth muscle excitability. 
Whether these signaling molecules are organized and targeted by scaffold proteins 
such as AKAPs to areas near TTCCs to fine-tune their function is unclear and 
therefore the subject of future studies.
5. Conclusions
Vascular smooth muscle excitability is exquisitely controlled by a repertoire of 
ion channels, which in themselves, are regulated by several vasoactive agents. The 
precise regulation of ion channels in vascular smooth muscle cells is essential for the 
dynamic adjustment of vascular tone necessary to maintain adequate tissue perfu-
sion and blood pressure. Here, we have provided a brief overview of our current 
knowledge of key ion channels and their regulation by receptor-mediated signal-
ing pathways that are activated by various vasoactive agents to modulate vascular 
smooth muscle excitability and therefore vascular tone. We focused on several TRP 
channels, multiple K+ channel subtypes, and various classes of VGCCs. We empha-
sized ion channel regulation by signaling pathways associated with the Gs/AC/PKA, 
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NO/sGC/PKG, and Gq/PLC/PKC axes given their important role in modulating vas-
cular smooth muscle excitability. When possible, we identified key gaps in knowl-
edge, even in areas that have been extensively studied, which are fertile ground for 
further research. Because of the importance of all the ion channels and signaling 
pathways discussed above on vascular control, understanding how they are affected 
during pathological conditions is essential for the development of rational therapies 
to treat (micro)vascular diseases.
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Cerebral Vascular Tone Regulation: 
Integration and Impact of Disease
Brayden Halvorson and Jefferson Frisbee
Abstract
This chapter summarizes the current knowledge regarding the regulation of 
the tone of cerebral resistance arteries under conditions of normal health and 
with the development of chronic diseases (e.g., metabolic disease). The work 
integrates the myogenic (pressure-induced) regulation of vascular tone, the impact 
of elevated luminal flow or shear stresses, that of local tissue metabolic activity on 
vascular tone and the concept of neurovascular coupling (linking neuronal activity 
to the impacts on vascular diameter). In addition, this work summarizes some of 
the recent work on how diseases such as type 2 diabetes impact the mechanisms 
of cerebrovascular tone regulation. It is anticipated that the current review will 
provide the reader with an up-to-date understanding of how the cerebral resistance 
vessels respond to changes in their local environment and contribute to the regula-
tion of blood flow within the brain.
Keywords: cerebral, perfusion resistance, metabolic disease, vascular function, 
vascular disease risk
1. Introduction
The brain has a remarkably high metabolic rate and thus requires a highly dis-
proportional amount of blood flow. Although its only 2% of body weight, the brain 
takes up 15–20% of cardiac output [1], making it one of the most highly perfused 
organs in the human body. This high metabolic rate coupled with its limited capacity 
for energy storage [2] necessitates heavy reliance on oxidative metabolism and thus 
requires constant blood flow to maintain nutrient and oxygen supply, remove waste 
products, and maintain a state of cerebral metabolic homeostasis. Severe underper-
fusion can quickly result in unconsciousness [3] and if prolonged, death [4]; while 
chronic mild under perfusion is associated with cognitive decline [5]. In addition to 
its high perfusion and metabolic rate, the cerebral circulation faces a unique chal-
lenge of being enclosed in the skull. This rigid structure prevents the expansion of 
tissue and extracellular fluid. Swelling within the skull from vasogenic edema leads 
to an increase in intracranial pressure which in turn can lead to neurologic compli-
cations or in more extreme cases death [1]. The unique challenges of the cerebral 
circulation, including intolerance to ischemia and edema, coupled with the para-
mount importance of maintaining constant nutrient and oxygen supply to cerebral 
tissue creates a need for precise regulation of cerebral blood flow and therefore the 
presence of redundant intrinsic mechanisms for its regulation. The anatomy of the 
brain vasculature ensures multiple routes for blood and oxygen delivery potentially 
allowing for perfusion even in cases of a blocked blood vessel [6]; however, acute 
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1. Introduction
The brain has a remarkably high metabolic rate and thus requires a highly dis-
proportional amount of blood flow. Although its only 2% of body weight, the brain 
takes up 15–20% of cardiac output [1], making it one of the most highly perfused 
organs in the human body. This high metabolic rate coupled with its limited capacity 
for energy storage [2] necessitates heavy reliance on oxidative metabolism and thus 
requires constant blood flow to maintain nutrient and oxygen supply, remove waste 
products, and maintain a state of cerebral metabolic homeostasis. Severe underper-
fusion can quickly result in unconsciousness [3] and if prolonged, death [4]; while 
chronic mild under perfusion is associated with cognitive decline [5]. In addition to 
its high perfusion and metabolic rate, the cerebral circulation faces a unique chal-
lenge of being enclosed in the skull. This rigid structure prevents the expansion of 
tissue and extracellular fluid. Swelling within the skull from vasogenic edema leads 
to an increase in intracranial pressure which in turn can lead to neurologic compli-
cations or in more extreme cases death [1]. The unique challenges of the cerebral 
circulation, including intolerance to ischemia and edema, coupled with the para-
mount importance of maintaining constant nutrient and oxygen supply to cerebral 
tissue creates a need for precise regulation of cerebral blood flow and therefore the 
presence of redundant intrinsic mechanisms for its regulation. The anatomy of the 
brain vasculature ensures multiple routes for blood and oxygen delivery potentially 
allowing for perfusion even in cases of a blocked blood vessel [6]; however, acute 
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regulation of flow is done primary by altering the diameter of blood vessels, and 
thus the resistance to flow. The major mechanisms of local regulation of vascular 
tone intrinsic to the cerebral vasculature include myogenic, shear, and metabolic 
based regulation. Although each mechanism has a discrete effect on vascular tone 
the integration of the different contributors to determine an appropriate level of 
tone is much more difficult to discern, especially in the cerebral circulation. These 
complex interactions allow for highly accurate control of cerebral blood flow in addi-
tion to protecting vulnerable downstream capillaries from high pressures and flow 
rates that could otherwise lead to edema; but, they also introduce several potential 
areas for failure. The intimate interactions of the various mechanisms of regulation 
of flow mean that the failure of one mechanism has the potential to initiate a cascade 
of events that results in inappropriate regulation of flow. As such abnormal execu-
tion of vascular tone regulation may form the basis of vascular pathologies [7].
One of these pathologies with a significant vascular component associated 
with impaired cerebral vascular tone regulation is metabolic syndrome (MetS). 
The incidence and prevalence of MetS is growing in Western society [8–10] and 
is contributing to decreased quality of life and increased economic burden. Thus 
an understanding of how it alters the cerebral circulation is crucial. MetS is cat-
egorized by a collection of metabolic risk factors including obesity, hypertension, 
atherogenic dyslipidemia and impaired glycemic control creating a pro-oxidant 
pro-inflammatory environment that raises the risk of developing impaired vascular 
structures and function [11–14]. These impairments are particularly detrimental 
when they affect the cerebral circulation and lead to cerebrovascular pathologies 
such as stroke or transient ischemic attack (TIA) due to the detrimental conse-
quences associated with such events. However, cognitive impairments are not lim-
ited to individuals that have experienced an acute ischemic event since even in their 
absence MetS is strongly associated with impaired cognitive function and decreased 
quality of life [15–18]. Therefore preventing their occurrence by protecting the 
cerebrovasculature from functional and structural decline is paramount. This 
chapter will present a description of the local mechanisms involved in the regula-
tion of cerebral vascular tone, how they integrate with one another and how they 
can be compromised in disease. Although impairments to the regulation of cerebral 
vascular tone are not limited to conditions associated with MetS this discussion will 
focus on the impact of MetS and its associated risk factors.
2. Myogenic mechanism
The myogenic mechanism which was first described by Bayliss is an intrinsic 
property of the vascular smooth muscle to respond to changes in intravascular pres-
sure which is independent of other mechanisms of tone regulation including neural, 
metabolic, and hormonal influences [19]. The intrinsic nature of the myogenic 
response is supported by its existence in arteries and arterioles that have been 
sympathetically denervated and had their endothelium removed [20] thus leaving 
only the vessel itself to initiate and execute the response. The prototypical response 
of the vascular smooth muscle in response to an increase in intraluminal pressure 
is initial distension quickly followed by a constriction. The opposite can be said in 
situations of decreased intraluminal pressure; a fall in intraluminal pressure results 
in vessel collapse followed by dilation [21]. The myogenic response has several 
physiological roles including the establishment and maintenance of basal vascular 
tone (some degree of constriction) so that resistance may be increased or decreased 
by metabolic vasoconstrictors or vasodilators respectively, in order to regulate tissue 
perfusion. The establishment and maintenance of this partially constricted state 
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in a pressurized vessel is referred to as myogenic tone. Additionally, the myogenic 
tone has a role in flow and pressure regulation. It functions by constricting to drop 
the pressure that reaches the downstream capillaries and protect them from edema 
or vascular remodeling associated with hypertension in the capillaries [22–25]. 
Equally important as protecting from hypertension is the ability of the vasculature 
to promote flow during low pressure by dilating. This ability to alter diameter over 
a range of pressures is referred to as myogenic reactivity. Beyond the local implica-
tions for the regulation of vascular tone, resistance to flow also has implications for 
systemic blood pressure since mean arterial pressure is the product of total periph-
eral resistance and cardiac output. This relationship illustrates system-wide impli-
cations of accurate vascular tone regulation. While the myogenic response is present 
throughout the body in a variety of vessels (arterioles, veins, lymphatic vessels) [26] 
the aforementioned functions of the myogenic response are particularly important 
in the cerebral circulation due to the catastrophic outcomes associated with under 
or over perfusion including unconsciousness and edema respectively. It is therefore 
not surprising that the most prominent myogenic response is found in the cere-
bral circulation with arterioles (resistance vessels) having the most pronounced 
response [1]. It should also be noted that the large arteries feeding the brain have 
a greater contribution to regulating vascular resistance in the cerebral circulation 
compared to other vascular beds, again providing evidence for the importance of 
regulating tone in the cerebral circulation.
A phase model of arterial myogenic behavior is commonly used to describe the 
response over a range of pressure. In the first phase, there is an initial development 
of myogenic tone at approximately 40–60 mmHg with increasing pressure up to 
that point causing passive distension. There is then a phase of myogenic reactivity 
in the pressure range of 60–140 mmHg and finally a phase of forced dilation at 
transmural pressures greater than approximately 140 mmHg [27].
2.1 Myogenic tone
Myogenic tone develops at approximately 40–60 mmHg and is characterized 
by an increase in intracellular Ca2+, of about 200%, followed by a reduction in 
lumen diameter. This pressure causes cellular deformation, depolarization of the 
vascular smooth muscle cells (VSMC), and a significant increase in wall tension. 
Wall tension appears to be the controlled parameter in the myogenic response 
which is altered during an increase or decrease in transmural pressure. The myo-
genic response adjusts the diameter of the vessel in an attempt to restore or limit 
the change in basal wall tension through a negative feedback mechanism [28, 29]. 
The suggestion that wall tension is the controlled parameter is supported by its 
correlation with changes in cell calcium and myosin light-chain phosphorylation, 
a relationship that is not seen with vessel diameter [30, 31].
The mechanism of the myogenic response is attributed to stretch-activated ion 
channels: including L-type calcium channels, voltage-activated calcium channels 
and calcium activated potassium channels along with enzymatic mechanisms. 
Specifically, increased intraluminal pressure causes depolarization of the VSMC 
membrane and calcium influx by the opening of voltage-gated calcium channels 
(VGCCs), with the most prominent involvement being from CaV1.2. This influx 
of Ca2+ leads to increased myosin light-chain (MLC) phosphorylation which 
promotes increased actin/myosin interaction followed by cross-bridge cycling and 
cell shortening (vasoconstriction) [7, 24, 32–34]. The importance of Ca2+ influx 
in the generation of myogenic tone supported by its complete abolishment under 
Ca2+ free conditions [32, 35]; this is also a technique frequently used to study the 
passive mechanical characteristics of vessels to determine the degree of vascular 
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regulation of flow is done primary by altering the diameter of blood vessels, and 
thus the resistance to flow. The major mechanisms of local regulation of vascular 
tone intrinsic to the cerebral vasculature include myogenic, shear, and metabolic 
based regulation. Although each mechanism has a discrete effect on vascular tone 
the integration of the different contributors to determine an appropriate level of 
tone is much more difficult to discern, especially in the cerebral circulation. These 
complex interactions allow for highly accurate control of cerebral blood flow in addi-
tion to protecting vulnerable downstream capillaries from high pressures and flow 
rates that could otherwise lead to edema; but, they also introduce several potential 
areas for failure. The intimate interactions of the various mechanisms of regulation 
of flow mean that the failure of one mechanism has the potential to initiate a cascade 
of events that results in inappropriate regulation of flow. As such abnormal execu-
tion of vascular tone regulation may form the basis of vascular pathologies [7].
One of these pathologies with a significant vascular component associated 
with impaired cerebral vascular tone regulation is metabolic syndrome (MetS). 
The incidence and prevalence of MetS is growing in Western society [8–10] and 
is contributing to decreased quality of life and increased economic burden. Thus 
an understanding of how it alters the cerebral circulation is crucial. MetS is cat-
egorized by a collection of metabolic risk factors including obesity, hypertension, 
atherogenic dyslipidemia and impaired glycemic control creating a pro-oxidant 
pro-inflammatory environment that raises the risk of developing impaired vascular 
structures and function [11–14]. These impairments are particularly detrimental 
when they affect the cerebral circulation and lead to cerebrovascular pathologies 
such as stroke or transient ischemic attack (TIA) due to the detrimental conse-
quences associated with such events. However, cognitive impairments are not lim-
ited to individuals that have experienced an acute ischemic event since even in their 
absence MetS is strongly associated with impaired cognitive function and decreased 
quality of life [15–18]. Therefore preventing their occurrence by protecting the 
cerebrovasculature from functional and structural decline is paramount. This 
chapter will present a description of the local mechanisms involved in the regula-
tion of cerebral vascular tone, how they integrate with one another and how they 
can be compromised in disease. Although impairments to the regulation of cerebral 
vascular tone are not limited to conditions associated with MetS this discussion will 
focus on the impact of MetS and its associated risk factors.
2. Myogenic mechanism
The myogenic mechanism which was first described by Bayliss is an intrinsic 
property of the vascular smooth muscle to respond to changes in intravascular pres-
sure which is independent of other mechanisms of tone regulation including neural, 
metabolic, and hormonal influences [19]. The intrinsic nature of the myogenic 
response is supported by its existence in arteries and arterioles that have been 
sympathetically denervated and had their endothelium removed [20] thus leaving 
only the vessel itself to initiate and execute the response. The prototypical response 
of the vascular smooth muscle in response to an increase in intraluminal pressure 
is initial distension quickly followed by a constriction. The opposite can be said in 
situations of decreased intraluminal pressure; a fall in intraluminal pressure results 
in vessel collapse followed by dilation [21]. The myogenic response has several 
physiological roles including the establishment and maintenance of basal vascular 
tone (some degree of constriction) so that resistance may be increased or decreased 
by metabolic vasoconstrictors or vasodilators respectively, in order to regulate tissue 
perfusion. The establishment and maintenance of this partially constricted state 
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in a pressurized vessel is referred to as myogenic tone. Additionally, the myogenic 
tone has a role in flow and pressure regulation. It functions by constricting to drop 
the pressure that reaches the downstream capillaries and protect them from edema 
or vascular remodeling associated with hypertension in the capillaries [22–25]. 
Equally important as protecting from hypertension is the ability of the vasculature 
to promote flow during low pressure by dilating. This ability to alter diameter over 
a range of pressures is referred to as myogenic reactivity. Beyond the local implica-
tions for the regulation of vascular tone, resistance to flow also has implications for 
systemic blood pressure since mean arterial pressure is the product of total periph-
eral resistance and cardiac output. This relationship illustrates system-wide impli-
cations of accurate vascular tone regulation. While the myogenic response is present 
throughout the body in a variety of vessels (arterioles, veins, lymphatic vessels) [26] 
the aforementioned functions of the myogenic response are particularly important 
in the cerebral circulation due to the catastrophic outcomes associated with under 
or over perfusion including unconsciousness and edema respectively. It is therefore 
not surprising that the most prominent myogenic response is found in the cere-
bral circulation with arterioles (resistance vessels) having the most pronounced 
response [1]. It should also be noted that the large arteries feeding the brain have 
a greater contribution to regulating vascular resistance in the cerebral circulation 
compared to other vascular beds, again providing evidence for the importance of 
regulating tone in the cerebral circulation.
A phase model of arterial myogenic behavior is commonly used to describe the 
response over a range of pressure. In the first phase, there is an initial development 
of myogenic tone at approximately 40–60 mmHg with increasing pressure up to 
that point causing passive distension. There is then a phase of myogenic reactivity 
in the pressure range of 60–140 mmHg and finally a phase of forced dilation at 
transmural pressures greater than approximately 140 mmHg [27].
2.1 Myogenic tone
Myogenic tone develops at approximately 40–60 mmHg and is characterized 
by an increase in intracellular Ca2+, of about 200%, followed by a reduction in 
lumen diameter. This pressure causes cellular deformation, depolarization of the 
vascular smooth muscle cells (VSMC), and a significant increase in wall tension. 
Wall tension appears to be the controlled parameter in the myogenic response 
which is altered during an increase or decrease in transmural pressure. The myo-
genic response adjusts the diameter of the vessel in an attempt to restore or limit 
the change in basal wall tension through a negative feedback mechanism [28, 29]. 
The suggestion that wall tension is the controlled parameter is supported by its 
correlation with changes in cell calcium and myosin light-chain phosphorylation, 
a relationship that is not seen with vessel diameter [30, 31].
The mechanism of the myogenic response is attributed to stretch-activated ion 
channels: including L-type calcium channels, voltage-activated calcium channels 
and calcium activated potassium channels along with enzymatic mechanisms. 
Specifically, increased intraluminal pressure causes depolarization of the VSMC 
membrane and calcium influx by the opening of voltage-gated calcium channels 
(VGCCs), with the most prominent involvement being from CaV1.2. This influx 
of Ca2+ leads to increased myosin light-chain (MLC) phosphorylation which 
promotes increased actin/myosin interaction followed by cross-bridge cycling and 
cell shortening (vasoconstriction) [7, 24, 32–34]. The importance of Ca2+ influx 
in the generation of myogenic tone supported by its complete abolishment under 
Ca2+ free conditions [32, 35]; this is also a technique frequently used to study the 
passive mechanical characteristics of vessels to determine the degree of vascular 
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remodeling since the VMSC exhibit a passive response (no force production) its 
strain is only due to the applied stress applied and the composition of the vessel 
[36]. Under physiological conditions the magnitude of the constrictor response to 
increased intraluminal pressure is limited by calcium-activated potassium chan-
nels that carry hyperpolarizing current proportional to the intracellular calcium 
concentration [35]. This negative feedback mechanism is supported by enhanced 
myogenic constriction being observed following blockade of calcium-activated 
potassium channel by specific inhibitors of these channels [37–39]. Additionally, 
at this pressure of 40–60 mmHg there is an activation of enzymatic systems and 
a complex interaction between matrix metalloproteins, the extracellular matrix, 
integrins and the cytoskeleton [40–42] that contribute to the myogenic reactiv-
ity at higher intraluminal pressures within the range of 60–140 mmHg [27]. This 
myogenic tone phase can also be characterized as the lower limit of autoregulation, 
which has important physiological implications. Below this pressure blood flow 
becomes dependent on blood pressure since the vessel cannot further dilate and 
begins to collapse as the pressure drops below this point [43]. Having an appropriate 
lower limit becomes especially important in situations of cerebral ischemia to allow 
restoration of flow in the presence of hypotension.
2.2 Myogenic reactivity
In this range of intraluminal pressure of 60–140 mmHg where the myogenic tone 
has already been established increases in pressure generally result in mild constric-
tion and decreased pressure leads to mild dilation. Just as previously discussed for the 
generation of myogenic tone, increased pressure within this range leads to stretch, 
depolarization, and constriction of the vascular smooth muscle. However, in the 
myogenic reactivity phase, there is little change in vessel diameter across the range 
of pressures along with relatively small increases in Ca2+ (<20%) despite sizable 
increases in force production [27]. Multiple studies suggest an increased sensitivity 
to Ca2+ compared to the previous phase in the development of myogenic tone [20, 27, 
44–48]. Increased sensitivity to Ca2+ is achieved by inhibition of myosin light chain 
phosphatase (MLCP) which promotes the accumulation of phosphorylated LC20 
without an accompanying increase in calcium-induced myosin light chain kinase 
activity [49]. The presence of a contractile mechanism that does not require large 
variation of calcium, such as altering Ca2+ sensitivity requires less storage and trans-
membrane shuttling and is therefore advantageous in terms of conserving Ca2+ [35].
There are several proposed mechanisms that regulate Ca2+ sensitivity within this 
phase including, activation of protein kinase C (PKC), RhoA/Rho kinase pathways, 
and reactive oxygen species (ROS) [27, 35, 44, 46, 50]. The following studies provide 
evidence for the aforementioned mechanisms of enhanced Ca2+ sensitivity in this 
phase of the myogenic response through the utilization of specific inhibitors or trans-
genic animal models. Inhibition of PKC stops myogenic vasoconstriction in middle 
cerebral arteries with no impact on pressure-induced Ca2+ elevation [46]. Direct 
assessment of Ca2+ sensitivity by measuring the Ca2+-tone relationship has consis-
tency found decreased sensitivity during Rho kinase inhibition [20, 45]. ROK has also 
been reported to trigger smooth muscle depolarization during myogenic constriction 
and limit the extent of depolarization by opening delayed rectifier potassium channels 
[51, 52]. Arteries from transgenic animals missing NADPH oxidase function show an 
absence of myogenic activity [53], while mice deficient in superoxide dismutase, an 
endogenous antioxidant enzyme that catalyzes the breakdown of superoxide radical 
to H2O2, acquired enhanced myogenic reactivity [54]. Additional mechanisms that 
contribute to the myogenic reactivity phase independent of Ca2+ sensitivity include 
actin cytoskeleton reorganization and thin filament regulation [55, 56].
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2.3 Forced dilation
Although the prototypical response of increased intraluminal pressure is a 
constriction, at excessively high pressures, beyond the autoregulatory range of 
approximately 140 mmHg, forced dilation often occurs [57]. This process results 
in a loss of myogenic tone, and thus results in an increase in vessel diameter, rapid 
increase in wall tension and significant elevation in Ca2+ (>50%) [27]. Although 
the name implies a degree of passiveness in the process, forced dilation is likely an 
active vasodilation involving KCa channels, nitric oxide (NO) and or ROS, which 
are activated to protect the arterial wall from damage [44, 57]. If the pressure 
is reduced to within the myogenic reactivity range reestablishment of tone and 
 reduction in Ca2+ is observed.
3. Response to flow (shear stress)
An increase in flow leads to an increase in a frictional force known as shear that 
is detected by the endothelial cells lining the vessel lumen as blood moves through a 
vessel. As such, the magnitude of the shear force is proportional to blood flow. Shear 
catalyzes physiologically important responses in the cerebral vasculature such as 
encouraging reperfusion after ischemia, aiding in the hyperemic response to increased 
metabolic demand, and perhaps protection of downstream capillaries from edema 
and structural damage. Flow has been found to induce both constrictor and dilator 
pathways that act on the VSMC and result in a final level of tone taking into account 
the opposing processes. It is generally accepted that in the peripheral circulation flow 
leads to dilation; however, in the cerebral circulation the response is more contro-
versial with both constriction and dilation being reported. These opposing observa-
tions may be because of a variety of factors including the area of the brain studied, 
the preparation used or because of interactions with other mechanisms affecting 
cerebral vascular tone. Within the cerebral circulation, the vertebrobasilar systems 
appear to elicit flow-mediated dilation, as measured in rats and mice [58] and humans 
[59]. The increase in flow is sensed by the endothelium, which initiates a negative 
feedback mechanism in an attempt to decrease the shear stress by dilating. Shear-
induced dilation is largely endothelium-dependent and is at least partially mediated 
by NO [60]. The production of NO is controlled by the enzyme nitric oxide synthase 
(NOS), particularly endothelial NOS (eNOS), which catalyzes the formation of NO 
from L-arginine and is itself dependent on phosphorylation by Akt [61, 62]. The NO 
formed by eNOS then diffuses into the vascular smooth muscle where it activates 
soluble guanylyl cyclase (sGC) and increases cyclic guanine monophosphate (cGMP) 
and activating protein kinase G [63, 64]. Activation of protein kinase G opens large-
conductance Ca2+-activated K+ (BKCa) channels reducing intracellular Ca2+ which 
leads to relaxation of the vascular smooth muscle and thus vasodilation [65]. In addi-
tion to NO, eNOS can also lead to the formation of H2O2 which may also mediate flow-
induced dilation [18]. During enzymatic cycling, eNOS produces oxygen radicals [66, 
67] which, in the presence of sufficient antioxidants, are converted into H2O2 that may 
then, like NO, activate sGC and lead to dilation [68]. Other endothelium-dependent 
dilators such as prostaglandins do not appear to be involved in shear-induced dilation 
since the COX inhibitor indomethacin had no effect on the response to flow [60].
Constriction of cerebral vessels has also been reported in cats [69], rats [70] and 
human isolated cerebral arteries [71]. Constriction appears to predominate within 
the carotid circulatory area [58] especially when studies using ex vivo isolated 
vessels. In contrast to the dilator response, flow-induced constriction occurs 
independent of the endothelium [72, 73]. Although the mechanics for constriction 
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remodeling since the VMSC exhibit a passive response (no force production) its 
strain is only due to the applied stress applied and the composition of the vessel 
[36]. Under physiological conditions the magnitude of the constrictor response to 
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nels that carry hyperpolarizing current proportional to the intracellular calcium 
concentration [35]. This negative feedback mechanism is supported by enhanced 
myogenic constriction being observed following blockade of calcium-activated 
potassium channel by specific inhibitors of these channels [37–39]. Additionally, 
at this pressure of 40–60 mmHg there is an activation of enzymatic systems and 
a complex interaction between matrix metalloproteins, the extracellular matrix, 
integrins and the cytoskeleton [40–42] that contribute to the myogenic reactiv-
ity at higher intraluminal pressures within the range of 60–140 mmHg [27]. This 
myogenic tone phase can also be characterized as the lower limit of autoregulation, 
which has important physiological implications. Below this pressure blood flow 
becomes dependent on blood pressure since the vessel cannot further dilate and 
begins to collapse as the pressure drops below this point [43]. Having an appropriate 
lower limit becomes especially important in situations of cerebral ischemia to allow 
restoration of flow in the presence of hypotension.
2.2 Myogenic reactivity
In this range of intraluminal pressure of 60–140 mmHg where the myogenic tone 
has already been established increases in pressure generally result in mild constric-
tion and decreased pressure leads to mild dilation. Just as previously discussed for the 
generation of myogenic tone, increased pressure within this range leads to stretch, 
depolarization, and constriction of the vascular smooth muscle. However, in the 
myogenic reactivity phase, there is little change in vessel diameter across the range 
of pressures along with relatively small increases in Ca2+ (<20%) despite sizable 
increases in force production [27]. Multiple studies suggest an increased sensitivity 
to Ca2+ compared to the previous phase in the development of myogenic tone [20, 27, 
44–48]. Increased sensitivity to Ca2+ is achieved by inhibition of myosin light chain 
phosphatase (MLCP) which promotes the accumulation of phosphorylated LC20 
without an accompanying increase in calcium-induced myosin light chain kinase 
activity [49]. The presence of a contractile mechanism that does not require large 
variation of calcium, such as altering Ca2+ sensitivity requires less storage and trans-
membrane shuttling and is therefore advantageous in terms of conserving Ca2+ [35].
There are several proposed mechanisms that regulate Ca2+ sensitivity within this 
phase including, activation of protein kinase C (PKC), RhoA/Rho kinase pathways, 
and reactive oxygen species (ROS) [27, 35, 44, 46, 50]. The following studies provide 
evidence for the aforementioned mechanisms of enhanced Ca2+ sensitivity in this 
phase of the myogenic response through the utilization of specific inhibitors or trans-
genic animal models. Inhibition of PKC stops myogenic vasoconstriction in middle 
cerebral arteries with no impact on pressure-induced Ca2+ elevation [46]. Direct 
assessment of Ca2+ sensitivity by measuring the Ca2+-tone relationship has consis-
tency found decreased sensitivity during Rho kinase inhibition [20, 45]. ROK has also 
been reported to trigger smooth muscle depolarization during myogenic constriction 
and limit the extent of depolarization by opening delayed rectifier potassium channels 
[51, 52]. Arteries from transgenic animals missing NADPH oxidase function show an 
absence of myogenic activity [53], while mice deficient in superoxide dismutase, an 
endogenous antioxidant enzyme that catalyzes the breakdown of superoxide radical 
to H2O2, acquired enhanced myogenic reactivity [54]. Additional mechanisms that 
contribute to the myogenic reactivity phase independent of Ca2+ sensitivity include 
actin cytoskeleton reorganization and thin filament regulation [55, 56].
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2.3 Forced dilation
Although the prototypical response of increased intraluminal pressure is a 
constriction, at excessively high pressures, beyond the autoregulatory range of 
approximately 140 mmHg, forced dilation often occurs [57]. This process results 
in a loss of myogenic tone, and thus results in an increase in vessel diameter, rapid 
increase in wall tension and significant elevation in Ca2+ (>50%) [27]. Although 
the name implies a degree of passiveness in the process, forced dilation is likely an 
active vasodilation involving KCa channels, nitric oxide (NO) and or ROS, which 
are activated to protect the arterial wall from damage [44, 57]. If the pressure 
is reduced to within the myogenic reactivity range reestablishment of tone and 
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An increase in flow leads to an increase in a frictional force known as shear that 
is detected by the endothelial cells lining the vessel lumen as blood moves through a 
vessel. As such, the magnitude of the shear force is proportional to blood flow. Shear 
catalyzes physiologically important responses in the cerebral vasculature such as 
encouraging reperfusion after ischemia, aiding in the hyperemic response to increased 
metabolic demand, and perhaps protection of downstream capillaries from edema 
and structural damage. Flow has been found to induce both constrictor and dilator 
pathways that act on the VSMC and result in a final level of tone taking into account 
the opposing processes. It is generally accepted that in the peripheral circulation flow 
leads to dilation; however, in the cerebral circulation the response is more contro-
versial with both constriction and dilation being reported. These opposing observa-
tions may be because of a variety of factors including the area of the brain studied, 
the preparation used or because of interactions with other mechanisms affecting 
cerebral vascular tone. Within the cerebral circulation, the vertebrobasilar systems 
appear to elicit flow-mediated dilation, as measured in rats and mice [58] and humans 
[59]. The increase in flow is sensed by the endothelium, which initiates a negative 
feedback mechanism in an attempt to decrease the shear stress by dilating. Shear-
induced dilation is largely endothelium-dependent and is at least partially mediated 
by NO [60]. The production of NO is controlled by the enzyme nitric oxide synthase 
(NOS), particularly endothelial NOS (eNOS), which catalyzes the formation of NO 
from L-arginine and is itself dependent on phosphorylation by Akt [61, 62]. The NO 
formed by eNOS then diffuses into the vascular smooth muscle where it activates 
soluble guanylyl cyclase (sGC) and increases cyclic guanine monophosphate (cGMP) 
and activating protein kinase G [63, 64]. Activation of protein kinase G opens large-
conductance Ca2+-activated K+ (BKCa) channels reducing intracellular Ca2+ which 
leads to relaxation of the vascular smooth muscle and thus vasodilation [65]. In addi-
tion to NO, eNOS can also lead to the formation of H2O2 which may also mediate flow-
induced dilation [18]. During enzymatic cycling, eNOS produces oxygen radicals [66, 
67] which, in the presence of sufficient antioxidants, are converted into H2O2 that may 
then, like NO, activate sGC and lead to dilation [68]. Other endothelium-dependent 
dilators such as prostaglandins do not appear to be involved in shear-induced dilation 
since the COX inhibitor indomethacin had no effect on the response to flow [60].
Constriction of cerebral vessels has also been reported in cats [69], rats [70] and 
human isolated cerebral arteries [71]. Constriction appears to predominate within 
the carotid circulatory area [58] especially when studies using ex vivo isolated 
vessels. In contrast to the dilator response, flow-induced constriction occurs 
independent of the endothelium [72, 73]. Although the mechanics for constriction 
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in response to increased flow is not fully understood it appears to be mediated 
in part by a combination of integrin signaling, free radicals, and tyrosine kinase. 
Giving integrin-binding peptides, scavenging ROS by superoxide dismutase (SOD) 
or inhibiting tyrosine [69] all significantly reduced or eliminated constriction in 
response to flow. Just as in flow-induced dilation shear stress appears to be the 
initiating parameter in flow induced constriction whose force can be transduced by 
integrin signaling [69]. Additionally, Koller and Toth found that flow-induced con-
striction of cerebral vessels were blocked by inhibiting the synthesis of 20-HETE, 
thromboxane A2 receptor, COX activity, and scavenging ROS. From that, they 
proposed that increase flow activates an AA cascade with metabolism by CYP450 
4A enzymes resulting in the production of 20-HETE and ROS which contribute to 
the constriction via thromboxane A2/prostaglandin H2 receptors [71].
The differences in observed responses may also be dependent on whether the 
study was conducted in vivo or ex vivo. Ex vivo studies typically use a physiologic 
salt solution that has a much lower viscosity than blood and may be inadequate 
to stimulate the endothelium to produce endothelium-dependent dilation [74]. 
Consequently, the ex vivo responses to intraluminal shear have been shown to be 
endothelium-independent [69, 72]. Furthermore, ex vivo study generally lack pulsa-
tile flow pumps but those that have been able to employ peristaltic or piston pump 
have indicated a role for shear-mediated regulation [68, 75, 76]. In contrast, in vivo 
study has produced more consistent shear-mediated dilation [62, 77]. Raignault 
et al. showed in a mouse model that the cerebrovascular endothelium optimally 
integrates shear stress to eNOS-mediated dilation under physiological pulse pres-
sures, a phenomenon that was not seen in static flow conditions [76]. It appears that 
cerebral arteries are more responsive to a pulsatile environment with a viscose fluid 
(blood) as is experienced in vivo and consequently able to dilate in response to shear 
stress through endothelium-dependent production of NO [68, 76, 78].
Although flow induced constriction is not usually seen in vivo at high flow rates 
it may play a protective role in the cerebral circulation. Just as low flow situa-
tions are dangerous, especially in the brain, so too are instances of extreme flow; 
therefore it is important to have multiple regulatory mechanisms that are able to 
attenuate an increase in flow as a protective mechanism for the cerebral circulation 
from high volumes [1, 79, 80]. It is advantageous for the response to flow to adapt 
in accordance with other inputs on the regulation of vascular tone. This may be the 
reason why characterizing the response to flow in the cerebral circulation has been 
variable. One variable that may alter the response to flow is the absolute rate of flow. 
In isolated branches of MCA from rats vessels dilated with flow up to 10 μL/min but 
their diameter constricted back to baseline at higher levels of flow [81]. Shimoda 
et al. also found a biphasic flow-dependent response in anterior and middle cerebral 
arteries of neonatal pigs; flow rates between 0.077 and 0.212 mL/min constricted 
vessels while dilation occurred at higher flow rates up to 1.6 mL/min [82].
3.1 Flow and pressure
In a physiological setting multiple inputs are being processed by the cerebral 
vasculature leading to the generation of a certain level of tone. Pressure and shear 
stress exerted by flowing blood are two mechanical stimuli that have been described 
to play a major role in the regulation of vascular tone [83, 84]. It is therefore impor-
tant to consider their interaction when determining the resultant effect on vascular 
tone. At high pressures (around >80 mmHg) cerebral vessels tend to constrict in 
response to flow [72, 85–87]. This biphasic response is further supported by find-
ings from Garcia-Roldan and Bevan in isolated rabbit pial arterioles with flow rates 
from 0 to 20 μL/min at 90 mmHg but did not with the same flow at 60 mmHg [72]. 
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It is interesting that the tipping points for “high” and “low” pressures observed in 
previous studies are around 80 mmHg since, in resistance arterioles such as the MCA 
this pressure is commonly measured under physiological conditions. If 80 mmHg is 
indeed the point where higher pressures lead to constriction and lower to dilation in 
response to shear the resistance arterioles that are resting around this pressure would 
have the opportunity to tightly regulate the response to flow and shear thus allowing 
for precise control of cerebral blood flow. Please see Figure 1 for a schematic repre-
sentation of how flow and intravascular pressure can impact cerebral vascular tone.
4. Metabolic control
The mechanical stimuli of pressure and flow are generally thought to be important 
in setting the basal vascular tone so that metabolic influences are able to cause dilation 
or constriction depending on the needs of the cerebral tissue [24]. Metabolic control 
of vascular resistance is of particular importance in the cerebral circulation since 
cerebral tissue is extremely intolerant to ischemia [88]. As such, the cerebral circula-
tion has a precise and highly localized coupling between the metabolic requirements 
of cerebral tissue and the magnitude of blood flow by controlling vascular resistance. 
There are numerous vasoactive metabolites that contribute to the control of cerebral 
vascular tone including adenosine, CO2, H+, O2 and K+. Increasing concentrations of 
adenosine, CO2, H+, and K+ and decreased concentration of O2 result in relaxation of 
VSM and dilation of cerebral resistance vessels. Each metabolite is associated with a 
cascade of events that ultimately either alters intracellular Ca2+ concentration or Ca2+ 
sensitivity of the VSM and results in a change in vessel diameter. Although the effects 
of each metabolite have been well characterized the relative importance of each along 
with its interaction with each other and other parameters of tone remains an area of 
further investigation. The discussion below is summarized in Figure 1.
Figure 1. 
A schematic representation of how intravascular pressure (myogenic), increased lumen flow rates (shear), 
tissue metabolism and neurovascular coupling can impact cerebral vascular tone regulation.
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in response to increased flow is not fully understood it appears to be mediated 
in part by a combination of integrin signaling, free radicals, and tyrosine kinase. 
Giving integrin-binding peptides, scavenging ROS by superoxide dismutase (SOD) 
or inhibiting tyrosine [69] all significantly reduced or eliminated constriction in 
response to flow. Just as in flow-induced dilation shear stress appears to be the 
initiating parameter in flow induced constriction whose force can be transduced by 
integrin signaling [69]. Additionally, Koller and Toth found that flow-induced con-
striction of cerebral vessels were blocked by inhibiting the synthesis of 20-HETE, 
thromboxane A2 receptor, COX activity, and scavenging ROS. From that, they 
proposed that increase flow activates an AA cascade with metabolism by CYP450 
4A enzymes resulting in the production of 20-HETE and ROS which contribute to 
the constriction via thromboxane A2/prostaglandin H2 receptors [71].
The differences in observed responses may also be dependent on whether the 
study was conducted in vivo or ex vivo. Ex vivo studies typically use a physiologic 
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It is interesting that the tipping points for “high” and “low” pressures observed in 
previous studies are around 80 mmHg since, in resistance arterioles such as the MCA 
this pressure is commonly measured under physiological conditions. If 80 mmHg is 
indeed the point where higher pressures lead to constriction and lower to dilation in 
response to shear the resistance arterioles that are resting around this pressure would 
have the opportunity to tightly regulate the response to flow and shear thus allowing 
for precise control of cerebral blood flow. Please see Figure 1 for a schematic repre-
sentation of how flow and intravascular pressure can impact cerebral vascular tone.
4. Metabolic control
The mechanical stimuli of pressure and flow are generally thought to be important 
in setting the basal vascular tone so that metabolic influences are able to cause dilation 
or constriction depending on the needs of the cerebral tissue [24]. Metabolic control 
of vascular resistance is of particular importance in the cerebral circulation since 
cerebral tissue is extremely intolerant to ischemia [88]. As such, the cerebral circula-
tion has a precise and highly localized coupling between the metabolic requirements 
of cerebral tissue and the magnitude of blood flow by controlling vascular resistance. 
There are numerous vasoactive metabolites that contribute to the control of cerebral 
vascular tone including adenosine, CO2, H+, O2 and K+. Increasing concentrations of 
adenosine, CO2, H+, and K+ and decreased concentration of O2 result in relaxation of 
VSM and dilation of cerebral resistance vessels. Each metabolite is associated with a 
cascade of events that ultimately either alters intracellular Ca2+ concentration or Ca2+ 
sensitivity of the VSM and results in a change in vessel diameter. Although the effects 
of each metabolite have been well characterized the relative importance of each along 
with its interaction with each other and other parameters of tone remains an area of 
further investigation. The discussion below is summarized in Figure 1.
Figure 1. 
A schematic representation of how intravascular pressure (myogenic), increased lumen flow rates (shear), 
tissue metabolism and neurovascular coupling can impact cerebral vascular tone regulation.
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4.1 Adenosine
Adenosine has been proposed as being the primary metabolite controlling 
metabolic regulation of cerebral vascular tone. It is a naturally occurring nucleoside 
produced as a byproduct of ATP metabolism; thus, its accumulation signals a need for 
increased blood flow to match the metabolic activity. This relationship with metabo-
lism has widely implicated adenosine in local regulation of cerebral vascular tone 
during functional hyperemia, ischemia, or whenever PO2 becomes limited [89–91]. 
Adenosine has direct effects on the vasculature [92, 93] that can both vasodilate 
and hyperpolarize VSM and is therefore considered an EDHF [94]. There are four 
distinct subtypes of adenosine receptors; however, the A2A receptor appears to be of 
high importance in mediating vasodilation [95–97]. The A2A receptor is a purinergic 
P1 receptor that has been confirmed to be present in cerebral microvessels [98–101] 
on the VSM cells [102, 103]. It causes dilation in a concentration-dependent manner 
[101, 104] once bound to the A2A receptor by activation of adenylate cyclase [105] and 
therefore cAMP [106–108] which reduces cytosolic calcium and leads to vasodilation. 
The opening of KATP channels also occurs secondary to the increase in cAMP levels as a 
result of adenosine binding to its receptors on the cell membrane [109–112]. The con-
tribution of opening KATP channels to dilation is likely substantial since during block-
ade of KATP channels with glibenclamide, adenosine-induced dilation was reduced by 
approximately 50% [113]. Although A2A receptors are generally considered the most 
important mediators of the effects of adenosine on vascular tone the A2B receptors 
are also proposed to cause dilation through similar mechanisms as A2A in addition to 
coupling to Gq proteins to produce Ca2+ mobilization by activation of phospholipase C 
and mitogen-activated protein kinase activation [98, 114, 115]. In addition to dilat-
ing the cerebral vasculature adenosine may also block vasoconstrictive signals in the 
parenchyma as evidenced by in vitro data from Gordon et al. [116]. When adenosine 
receptors are blocked with theophylline dilation was attenuated to arterial hypoxia 
[117]. Similarly the competitive adenosine receptor antagonist aminophylline causes a 
20–30% decrease in CBF and cerebral oxygen delivery in normoxia [118].
4.2 PCO2
Similar to many of the other metabolites discussed CO2 tends to increase under 
conditions of increased metabolism without adequate flow to eliminate it from the 
area of production and thus its accumulation leads to dilation of the vasculature. High 
sensitivity to PCO2 is unique to the cerebral circulation [119] causing approximately 
3–6% increase and 1–3% decrease in flow per mmHg change in PaCO2 above or below 
eupnoeic PaCO2 respectively. This high sensitivity is seen throughout the arterial side 
of the vascular network including the large arteries in the neck [120] and large intra-
cranial arteries [121–123] to the smallest pial arterioles [124] and parenchymal vessels 
[125–128]. There are likely several redundant mechanistic contributors to the sensi-
tivity of the vasculature to PCO2 which may contribute to the debate as to whether 
the dilation is triggered by increased PCO2 or rather the accompanying increase H+ 
concentration from the carbonic anhydrase reaction. There is strong support that the 
change in PCO2 mediates at least in part alterations in cerebral vascular tone locally 
by changes in perivascular pH [107, 129–131] as evidenced by acidic and alkaline 
perfusate administered through an intracranial window. Experiments that have been 
able to alter pH and PCO2 independently have provided evidence of the dependence 
of altered pH to initiate a change in cerebral vascular tone [74]. In a cat pial arteriole 
cranial window preparation, lowering pH along with hypercapnia resulted in no 
difference in the magnitude of vasodilation when compared to acidic isocapnia [132]. 
Interestingly, vessel tone was unaltered in response to intraluminal CO2 change, 
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suggesting that a change in superfusate pH is necessary to evoke a change in cerebral 
vascular tone [107, 133]. This is supported by the findings of unchanged CBF in 
humans [107] and animals [133] in response to changes in arterial pH, and highly 
localized pial arteriolar diameter changes in response to the application of acidic/
basic solution into the perivascular space [131]. Additionally, when pH is maintained 
as seen in an experiment with artificial CSF pretreated with sodium bicarbonate, pial 
vessel dilation is eliminated in response to intraluminal hypercapnia [107, 134] further 
supporting that a change in superfusate pH is necessary to alter the cerebral vascular 
tone. In addition to its link with CO2 and H+ through the carbonic anhydrase reaction, 
there is some evidence that bicarbonate ion may independently influence vascular 
tone. Having the ability to sense and react to multiple parameters associated with 
acidosis allows for control of tone in response to not only the pH but also the cause 
of the disturbance (accumulation of CO2 for instance). In isolated rat basilar arter-
ies reduced [HCO3−]o has been shown to directly increase cerebral vascular tone 
(with pH maintained at 7.4 and CO2 kept constant at 5%) through the binding of 
receptor protein tyrosine phosphatase through an endothelium-dependent response 
[135]. HCO3− may, therefore, stimulate soluble adenylate cyclase activity through 
a pH-independent mechanism [136]. If this is correct then the modest increase 
in [HCO3−] during hypercapnia may aid in the dilation response to CO2 but the 
opposing vasocontractile response to decreases in [HCO3−]o may limits the vasore-
laxation caused by a reduction in pH [135]. Limiting vasorelaxation during acidosis is 
important to lessen the increase in capillary pressure associated with vasorelaxation of 
upstream arterioles. Hyper-relaxation may overload the capillaries leading to edema 
and damage thereby worsening the consequences of local inadequate perfusion.
4.3 PO2
The effects of oxygen are unique in that its availability is required for aerobic 
metabolism rather than a byproduct like some of the metabolic factors discussed. 
Therefore it is not surprising that its abundance leads to vasoconstriction and its 
relative shortage leads to dilation. Although its availability is tightly linked to that of 
PCO2 and H+ and other metabolic byproducts in a physiological setting, studies have 
been able to discern its independent effect in the presence of otherwise constant con-
ditions. Data from isolated arteries/arterioles suggest there is in fact an oxygen sensor 
independent of other vasoactive metabolic byproducts within the vascular wall 
itself [137–142]. Once the change in oxygen is sensed there are various mediators of 
hypoxic dilation including endothelial-derived NO [138, 141], prostanoids [137, 140, 
141, 143], 20-HETE [141] and EDHF [139]; however, the contribution of each factor 
appears to be dependent on the severity of hypoxia [141]. In skeletal muscle, dilation 
from mild hypoxia (15% O2) was mostly NO-dependent, while moderate (10% O2) 
was mediated by a combination of increased PGI2 and decreased 20-HETE, and 
severe (0% O2) was almost entirely accounted for by an increase in PGI2 [141]. In all 
cases, there appears to be significant involvement by the endothelium to mediate the 
dilation, which is further supported by a reduction in hypoxic dilation when isolated 
vessels were exposed to indomethacin (an inhibitor of AA metabolism and thus the 
production of PGI2) [137, 144, 145] and to a lesser degree by L-NAME (an inhibitor 
of NO production from NOS) [145]. Therefore, PGI2 is likely a substantial contribu-
tor to hypoxic dilation with a lesser but likely still significant role for NO. Human 
studies measuring CBF with pcMRI, instead of isolated vessel diameter as in the 
aforementioned studies, with and without administration of L-NAME suggest that 
hypoxic dilation is highly dependent on NO, with no change from baseline observed 
in hypoxia when L-NAME was administered [146]. These differences may be 
because of a species-specific response or differences in ex vivo and in vivo conditions. 
Basic and Clinical Understanding of Microcirculation
28
4.1 Adenosine
Adenosine has been proposed as being the primary metabolite controlling 
metabolic regulation of cerebral vascular tone. It is a naturally occurring nucleoside 
produced as a byproduct of ATP metabolism; thus, its accumulation signals a need for 
increased blood flow to match the metabolic activity. This relationship with metabo-
lism has widely implicated adenosine in local regulation of cerebral vascular tone 
during functional hyperemia, ischemia, or whenever PO2 becomes limited [89–91]. 
Adenosine has direct effects on the vasculature [92, 93] that can both vasodilate 
and hyperpolarize VSM and is therefore considered an EDHF [94]. There are four 
distinct subtypes of adenosine receptors; however, the A2A receptor appears to be of 
high importance in mediating vasodilation [95–97]. The A2A receptor is a purinergic 
P1 receptor that has been confirmed to be present in cerebral microvessels [98–101] 
on the VSM cells [102, 103]. It causes dilation in a concentration-dependent manner 
[101, 104] once bound to the A2A receptor by activation of adenylate cyclase [105] and 
therefore cAMP [106–108] which reduces cytosolic calcium and leads to vasodilation. 
The opening of KATP channels also occurs secondary to the increase in cAMP levels as a 
result of adenosine binding to its receptors on the cell membrane [109–112]. The con-
tribution of opening KATP channels to dilation is likely substantial since during block-
ade of KATP channels with glibenclamide, adenosine-induced dilation was reduced by 
approximately 50% [113]. Although A2A receptors are generally considered the most 
important mediators of the effects of adenosine on vascular tone the A2B receptors 
are also proposed to cause dilation through similar mechanisms as A2A in addition to 
coupling to Gq proteins to produce Ca2+ mobilization by activation of phospholipase C 
and mitogen-activated protein kinase activation [98, 114, 115]. In addition to dilat-
ing the cerebral vasculature adenosine may also block vasoconstrictive signals in the 
parenchyma as evidenced by in vitro data from Gordon et al. [116]. When adenosine 
receptors are blocked with theophylline dilation was attenuated to arterial hypoxia 
[117]. Similarly the competitive adenosine receptor antagonist aminophylline causes a 
20–30% decrease in CBF and cerebral oxygen delivery in normoxia [118].
4.2 PCO2
Similar to many of the other metabolites discussed CO2 tends to increase under 
conditions of increased metabolism without adequate flow to eliminate it from the 
area of production and thus its accumulation leads to dilation of the vasculature. High 
sensitivity to PCO2 is unique to the cerebral circulation [119] causing approximately 
3–6% increase and 1–3% decrease in flow per mmHg change in PaCO2 above or below 
eupnoeic PaCO2 respectively. This high sensitivity is seen throughout the arterial side 
of the vascular network including the large arteries in the neck [120] and large intra-
cranial arteries [121–123] to the smallest pial arterioles [124] and parenchymal vessels 
[125–128]. There are likely several redundant mechanistic contributors to the sensi-
tivity of the vasculature to PCO2 which may contribute to the debate as to whether 
the dilation is triggered by increased PCO2 or rather the accompanying increase H+ 
concentration from the carbonic anhydrase reaction. There is strong support that the 
change in PCO2 mediates at least in part alterations in cerebral vascular tone locally 
by changes in perivascular pH [107, 129–131] as evidenced by acidic and alkaline 
perfusate administered through an intracranial window. Experiments that have been 
able to alter pH and PCO2 independently have provided evidence of the dependence 
of altered pH to initiate a change in cerebral vascular tone [74]. In a cat pial arteriole 
cranial window preparation, lowering pH along with hypercapnia resulted in no 
difference in the magnitude of vasodilation when compared to acidic isocapnia [132]. 
Interestingly, vessel tone was unaltered in response to intraluminal CO2 change, 
29
Cerebral Vascular Tone Regulation: Integration and Impact of Disease
DOI: http://dx.doi.org/10.5772/intechopen.90404
suggesting that a change in superfusate pH is necessary to evoke a change in cerebral 
vascular tone [107, 133]. This is supported by the findings of unchanged CBF in 
humans [107] and animals [133] in response to changes in arterial pH, and highly 
localized pial arteriolar diameter changes in response to the application of acidic/
basic solution into the perivascular space [131]. Additionally, when pH is maintained 
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relative shortage leads to dilation. Although its availability is tightly linked to that of 
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appears to be dependent on the severity of hypoxia [141]. In skeletal muscle, dilation 
from mild hypoxia (15% O2) was mostly NO-dependent, while moderate (10% O2) 
was mediated by a combination of increased PGI2 and decreased 20-HETE, and 
severe (0% O2) was almost entirely accounted for by an increase in PGI2 [141]. In all 
cases, there appears to be significant involvement by the endothelium to mediate the 
dilation, which is further supported by a reduction in hypoxic dilation when isolated 
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production of PGI2) [137, 144, 145] and to a lesser degree by L-NAME (an inhibitor 
of NO production from NOS) [145]. Therefore, PGI2 is likely a substantial contribu-
tor to hypoxic dilation with a lesser but likely still significant role for NO. Human 
studies measuring CBF with pcMRI, instead of isolated vessel diameter as in the 
aforementioned studies, with and without administration of L-NAME suggest that 
hypoxic dilation is highly dependent on NO, with no change from baseline observed 
in hypoxia when L-NAME was administered [146]. These differences may be 
because of a species-specific response or differences in ex vivo and in vivo conditions. 
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Additional mechanisms of hypoxic dilation include adenosine whose action has 
previously been discussed. In hyperoxic conditions constriction is favored, mediated 
by a greater conversion of AA to 20-HETE as opposed to dilators such as PGI2 [147].
4.4 Potassium and neurovascular coupling
Although K+ is not directly a byproduct of a metabolite pathway it tends 
to increase in concentration when the frequency of neuronal depolarization is 
increased, and is therefore indicative of increased metabolism. K+ channels are 
present in cerebrovascular smooth muscle cells and are important regulators of tone 
because of their ability to alter membrane potential [148, 149]. Although K+ channels 
are present through the peripheral vasculature, the cerebral circulation has a unique 
anatomical feature that allows for intimate interaction of astrocytic endfeet and 
cerebral vessels. This tight interaction between the astrocytic endfeet and vascu-
lature allows for precise localized changes in blood flow to match the site-specific 
neural activity in the brain [150, 151]. K+ can therefore be thought of as a direct link 
between neuronal activity and blood flow. This pairing of neuronal metabolism with 
appropriate blood flow and is termed neurovascular coupling (NVC). NVC forms the 
mechanistic basis for neuroimaging techniques that are able to map changes in neu-
ronal activity based on vascular responses such as changes in blood flow or oxygen 
saturation [152]. As such, an understanding of NVC is not only crucial to understand 
the regulation of cerebral vascular tone but is also needed to interpret these neuroim-
aging techniques including functional magnetic resonance imaging (fMRI), positron 
emission tomography (PET), and near-infrared spectroscopy [153].
NVC is dependent on the interactions of the neurovascular unit which is made 
up of three major components: the vascular smooth muscle, neuron, and astrocyte 
glial cell. Somewhat surprisingly, the initiation site of neurovascular coupling is 
at the level of capillaries which then leads to changes upstream; however, once the 
close anatomical locations of neurons to the capillaries (8–20 μm) are considered 
this becomes a logical point of initiation [154]. Not only does NVC rely on interac-
tions apart from the vasculature but it also requires several structural components 
to facilitate cell-to-cell interactions of these different cell types. These components 
include gap junctions [155, 156], anchoring proteins [157] and specialized ion 
channels [158] expressed on cell–cell interface membranes. Neurons initiate NVC 
by generating direct signals that act on the vasculature and indirect signals that are 
transmitted through astrocytes and lead to increases in intracellular Ca2+ within 
the astrocyte. This is achieved by the glutamatergic synaptic activity initiating 
post-synaptic N-methyl-D-receptors (NMDA) and a-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptors. The increase in intracellular Ca2+ 
activates Ca2+-dependent enzymes to produce vasodilators. Some of the enzymes 
activated include neuronal NOS (nNOS) and cyclooxygenase 2 (COX-2) [159, 160]. 
Glutamate also acts on metabotropic glutamate receptors in astrocytes increasing 
Ca2+ in these cells and leading to the production of vasoactive metabolites including 
adenosine, ATP, and K+ that act of the VSMCs [161].
Astrocytes are anatomically well positioned to transmit signals from neurons 
to the vasculature because of their close proximity to the capillaries; however, in 
a vascular network both the downstream and upstream vasculature must work 
in concert in order to effectively regulate blood flow delivery. It appears that 
endothelial cells provide the crucial role of retrograde propagation of the vasomo-
tor response allowing for coordination between up and downstream vasculature. 
Endothelial cells can produce numerous metabolites including NO, prostanoids, 
and endothelin to alter VSMCs constriction. Endothelial intermediate K+ channels 
(KIR) channels and small conductance K+ channels (KSK) have been implicated as a 
31
Cerebral Vascular Tone Regulation: Integration and Impact of Disease
DOI: http://dx.doi.org/10.5772/intechopen.90404
mechanistic contributor to the propagation of the vasodilatory signal upstream for 
a synchronized hemodynamic response between the capillaries and arterioles via 
myoendothelial gap junctions [162]. Secondary to the movement of hyperpolar-
izing current through gap junctions, K+ efflux from KIR and KSK channels generates 
what has been described as a “K+ cloud” [163] that also hyperpolarizes neighboring 
VSMC through both the inducible Na+-K+ electrogenic pump and stimulation of 
inward rectifying potassium channels in the VSMC of cerebral arteries and arteri-
oles. In both cases, there is a net efflux of K+ from VSMC [164–167] in conjunction 
with closed voltage-gated calcium channels and therefore results in the relaxation 
of the VSMC. The importance of K+ channels in dilating the cerebral vasculature 
is supported by reduced K+ conductance, depolarization and ultimately constric-
tion seen in experimental inhibition of the channels [163]. For example, 6–10 mM 
K+ applied to capillaries generated a hyperpolarizing response in endothelial cells 
which was transmitted upstream to penetrating arterioles hyperpolarizing and 
relaxing VSMCs [168]. This propagation of the vasodilation signal was blocked with 
inhibition of KIR with barium or endothelial deletion of KIR1.2 channels, support-
ing its role transmitting the hyperpolarizing current. Interestingly the capillaries 
themselves did not dilate to K+ suggesting they act as a sensor detecting the signal 
for the upstream arterioles to be the effector of the response [161].
Although in a physiological setting K+ tends to lead to vasodilation, the response 
to K+ may be dependent on the [K+]. In isolated cerebral arterioles low (<7 mM) and 
moderate (8–15 mM) increases in [K+] result in endothelium-independent dilations 
and sustained dilation respectively through mechanisms previously discussed [165]. 
Higher K+ concentrations cause constriction; however, under normal physiologi-
cal conditions this concentration is not reached and is only seen under pathological 
processes such as spreading depression and stroke [169, 170]. This response seen 
in isolated vessel has also been confirmed in vivo [151]. There is a combination of 
mechanisms at work in response to K+ that may explain the opposing responses to 
different concentrations. Alone an increase in [K+]o actually tends to depolarize 
neighboring VSMC resulting in constriction; this response predominates at high [K+]. 
At low concentrations, the minor increase in [K+]o would by itself lead to constriction 
but it also stimulates both KIR channels [150, 171–174] and Na+/K+ ATPase [175–177] 
promoting K+ efflux as previously described. This description of the electrophysiology 
at work in the VSMC is supported by Em measurement in VSMCs when a solution con-
taining [K+] (<20 mM) is applied and produces VSM hyperpolarization, whereas at 
higher K+ concentrations depolarization predominates [166, 172, 178]. Ultimately the 
signals generated by neurons, astrocytes, and endothelial cells must be received and 
integrated into a final level of tone by the VSMCs. A schematic representation of the 
impact of neurovascular coupling on cerebral vascular tone is presented in Figure 1.
5. Effect of diseased states
Each component implicated in the regulation of tone has a multitude of signals 
being produce that is intended to affect a vasomotor response from the VSMCs. Signals 
from myogenic, shear, metabolic, and neurovascular influences may be additive or 
opposing in their effect on VSMCs and further combine with one another creating 
intricate and precise regulation of cerebral vascular tone. It is this intricacy however, 
that also introduces many possible steps in the pathway for an abnormal response to 
occur. As such changes to the regulation of tone may form the basis of several patholo-
gies including MetS. The contributing risk factors associated with MetS alter the local 
regulation of cerebral vascular tone by inducing changes in both the structure and 
function of the vessels. These risk factors include hypertension, T2DM, and obesity 
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in concert in order to effectively regulate blood flow delivery. It appears that 
endothelial cells provide the crucial role of retrograde propagation of the vasomo-
tor response allowing for coordination between up and downstream vasculature. 
Endothelial cells can produce numerous metabolites including NO, prostanoids, 
and endothelin to alter VSMCs constriction. Endothelial intermediate K+ channels 
(KIR) channels and small conductance K+ channels (KSK) have been implicated as a 
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mechanistic contributor to the propagation of the vasodilatory signal upstream for 
a synchronized hemodynamic response between the capillaries and arterioles via 
myoendothelial gap junctions [162]. Secondary to the movement of hyperpolar-
izing current through gap junctions, K+ efflux from KIR and KSK channels generates 
what has been described as a “K+ cloud” [163] that also hyperpolarizes neighboring 
VSMC through both the inducible Na+-K+ electrogenic pump and stimulation of 
inward rectifying potassium channels in the VSMC of cerebral arteries and arteri-
oles. In both cases, there is a net efflux of K+ from VSMC [164–167] in conjunction 
with closed voltage-gated calcium channels and therefore results in the relaxation 
of the VSMC. The importance of K+ channels in dilating the cerebral vasculature 
is supported by reduced K+ conductance, depolarization and ultimately constric-
tion seen in experimental inhibition of the channels [163]. For example, 6–10 mM 
K+ applied to capillaries generated a hyperpolarizing response in endothelial cells 
which was transmitted upstream to penetrating arterioles hyperpolarizing and 
relaxing VSMCs [168]. This propagation of the vasodilation signal was blocked with 
inhibition of KIR with barium or endothelial deletion of KIR1.2 channels, support-
ing its role transmitting the hyperpolarizing current. Interestingly the capillaries 
themselves did not dilate to K+ suggesting they act as a sensor detecting the signal 
for the upstream arterioles to be the effector of the response [161].
Although in a physiological setting K+ tends to lead to vasodilation, the response 
to K+ may be dependent on the [K+]. In isolated cerebral arterioles low (<7 mM) and 
moderate (8–15 mM) increases in [K+] result in endothelium-independent dilations 
and sustained dilation respectively through mechanisms previously discussed [165]. 
Higher K+ concentrations cause constriction; however, under normal physiologi-
cal conditions this concentration is not reached and is only seen under pathological 
processes such as spreading depression and stroke [169, 170]. This response seen 
in isolated vessel has also been confirmed in vivo [151]. There is a combination of 
mechanisms at work in response to K+ that may explain the opposing responses to 
different concentrations. Alone an increase in [K+]o actually tends to depolarize 
neighboring VSMC resulting in constriction; this response predominates at high [K+]. 
At low concentrations, the minor increase in [K+]o would by itself lead to constriction 
but it also stimulates both KIR channels [150, 171–174] and Na+/K+ ATPase [175–177] 
promoting K+ efflux as previously described. This description of the electrophysiology 
at work in the VSMC is supported by Em measurement in VSMCs when a solution con-
taining [K+] (<20 mM) is applied and produces VSM hyperpolarization, whereas at 
higher K+ concentrations depolarization predominates [166, 172, 178]. Ultimately the 
signals generated by neurons, astrocytes, and endothelial cells must be received and 
integrated into a final level of tone by the VSMCs. A schematic representation of the 
impact of neurovascular coupling on cerebral vascular tone is presented in Figure 1.
5. Effect of diseased states
Each component implicated in the regulation of tone has a multitude of signals 
being produce that is intended to affect a vasomotor response from the VSMCs. Signals 
from myogenic, shear, metabolic, and neurovascular influences may be additive or 
opposing in their effect on VSMCs and further combine with one another creating 
intricate and precise regulation of cerebral vascular tone. It is this intricacy however, 
that also introduces many possible steps in the pathway for an abnormal response to 
occur. As such changes to the regulation of tone may form the basis of several patholo-
gies including MetS. The contributing risk factors associated with MetS alter the local 
regulation of cerebral vascular tone by inducing changes in both the structure and 
function of the vessels. These risk factors include hypertension, T2DM, and obesity 
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which promote a pro-inflammatory pro-oxidant state. Functionally, MetS is highly 
linked to increased smooth muscle activation and endothelial dysfunction which has 
important implications for the ability of a vessel to dilate in response to a multitude 
of stimuli previously discussed including hypotension, shear, hypoxia, and other 
metabolic stimuli. Increased myogenic properties are consistently overserved in MetS 
in multiple vascular beds [179, 180] including in the cerebral circulation [181–183]. 
This increase in constriction may be due to both a decrease in buffering capacity from 
endothelial dysfunction and alterations in the vascular smooth muscle itself [183, 184]. 
Endothelial dysfunction also has implication for shear-induced dilation since it is highly 
dependent on NO bioavailability which has consistently been shown to be reduced in 
MetS. The chronic inflammatory state seen in MetS likely contributes to the reduction 
in NO bioavailability due to increased scavenging to the produced NO by reactive 
oxygen species since this reduction in NO bioavailability is consistently reported to 
evolve in parallel with oxidant stress and the development of a chronic inflammatory 
state [185, 186]. This is supported by improved dilatory reactivity of MCA with the 
pretreatment of the cell-permeable superoxide dismutase mimetic TEMPOL in a model 
of T2DM [145]. Interestingly some studies have actually shown an increase in eNOS 
expression which may be an attempt to compensate for the increased scavenging; 
however, they too continue to find reduced dilator reactivity [187].
Aside from reduced NO bioavailability, a shift in arachidonic acid metabolism 
toward constrictors and away from dilators that are highly responsible for hypoxic 
dilation has been demonstrated [145]. Thus not only does endothelial dysfunction 
seen in MetS increase cerebrovascular resistance by decreased dilator metabolite 
production it may also promote the production of constrictors that exacerbate the 
impaired dilation capacity of cerebral vessels [184, 188]. A change in sensitivity to 
various metabolites in addition to their differential production may also contribute 
to differential vasomotor responses. For example, studies using SNP, an exogenous 
NO donor, while blocking endogenous NO production by eNOS using L-NAME, 
found smaller relaxation of the MCA in spontaneously hypertensive rats which was 
attributed to a decreased expression of soluble guanylate cyclase [189–192]. In a 
model of T2DM decreased sensitivity of MCA to the PGI2 analog iloprost was also 
found suggesting that both decrease production and sensitivity of dilators may be 
contributing to the impaired dilation of the cerebral circulation in MetS [145].
Impaired dilation in response to exogenous dilator metabolites may also be due to 
vascular remodeling. Structural changes are an important consideration since even 
if the smooth muscle of a cerebral vessel is able to relax due to metabolic influences 
resulting in hyperpolarization, remodeling may prevent an increase in lumen diameter 
which is ultimately the major contributor to acute changes in resistance and thus the 
regulator of flow. Hypertension is largely implicated in the thickening of the vascular 
smooth muscle as well as increasing the ratio of collagen to elastin in the vessel. High 
intraluminal pressure increases the shear stress exerted on the vascular endothelium 
which normally could be restored to baseline by NO-induced vasodilation [193–195]; 
however, in a disease state with impaired NO production, there is a reduced ability to 
dilate resulting in endothelial damage and upregulation of atherogenic genes [193–195]. 
As a means of protection from chronic increased shear stress and wall tension that may 
lead to downstream edema cerebral vessels tend to hypertrophy with chronic hyperten-
sion, but this protective hypertrophy is also detrimental [188]. Since wall tension is 
equal to intraluminal pressure X radius and wall stress is wall tension/wall thickness, 
hypertension-induced hypertrophy and inward remodeling resulting in a decrease in 
radius and increase wall thickness can normalize both the wall tension and wall stress 
[188]. Although this remodeling may be protective in regards to increases in pressures 
and protecting the downstream capillaries from edema it increases the cerebrovascular 
resistance and limits the dilation reserve during hypotension and therefore presents 
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itself as a right-shift in the autoregulatory range [196, 197]. The development of myo-
genic tone at higher pressure implies an increased lower limit of autoregulation. This 
predisposes cerebral tissue to reduced blood flow during hypotension. When pressure 
drops below the lower limit flow becomes dependent on the passive diameter of the 
vessel. Not only does an impaired lower limit predispose hypertensive individuals to 
ischemia but the reduced passive diameter from vascular remodeling further compro-
mises flow to cerebral tissue resulting in hypoxic areas [43].
In addition to hypertrophy and inward remodeling, there is substantial arterial 
stiffening commonly seen in MetS. The pro-oxidant stress of ROS may interact 
with components of the perivascular matrix and initiate collagen cross-linking and 
deposition as well as the breakdown of elastin making the vessel less distensible 
[198]. This is measured by a left shift in the stress-strain curve of isolated cerebral 
vessels under passive conditions achieved by using a Ca2+ free solution preventing 
the development of tone [183]. The stiffening vessel from increased collagen to 
elastin ratio is made worse by the thickening of vessel walls previously discussed. 
In a model of T2DM with hypertension significant collagen deposition in addition 
to medial hypertrophy increasing the wall the lumen ratio and stiffness of the rats 
MCA [199] was demonstrated while T2DM in the absence of hypertension does 
not appear to induce structural changes to the cerebral vasculature [145]. This 
along with data that suggests the increase in arterial stiffness seems to follow a time 
course similar to that of the onset of hypertension suggests a strong relationship 
between hypertension and vascular remodeling [200]. Chronic uncontrolled hyper-
glycemia and inflammation do tend to lead to the development of hypertension and 
thus contribute to changes in the composition of cerebral vessels and it is likely the 
combination of both seen in MetS increases the degree to which remodeling occurs. 
A summary of the impact of disease states on the regulation of cerebral vascular 
tone is presented in Figure 2.
Figure 2. 
A schematic representation of how the presence of metabolic syndrome and the major constituent pathologies 
can impact the integrated regulation of cerebral vascular tone.
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which promote a pro-inflammatory pro-oxidant state. Functionally, MetS is highly 
linked to increased smooth muscle activation and endothelial dysfunction which has 
important implications for the ability of a vessel to dilate in response to a multitude 
of stimuli previously discussed including hypotension, shear, hypoxia, and other 
metabolic stimuli. Increased myogenic properties are consistently overserved in MetS 
in multiple vascular beds [179, 180] including in the cerebral circulation [181–183]. 
This increase in constriction may be due to both a decrease in buffering capacity from 
endothelial dysfunction and alterations in the vascular smooth muscle itself [183, 184]. 
Endothelial dysfunction also has implication for shear-induced dilation since it is highly 
dependent on NO bioavailability which has consistently been shown to be reduced in 
MetS. The chronic inflammatory state seen in MetS likely contributes to the reduction 
in NO bioavailability due to increased scavenging to the produced NO by reactive 
oxygen species since this reduction in NO bioavailability is consistently reported to 
evolve in parallel with oxidant stress and the development of a chronic inflammatory 
state [185, 186]. This is supported by improved dilatory reactivity of MCA with the 
pretreatment of the cell-permeable superoxide dismutase mimetic TEMPOL in a model 
of T2DM [145]. Interestingly some studies have actually shown an increase in eNOS 
expression which may be an attempt to compensate for the increased scavenging; 
however, they too continue to find reduced dilator reactivity [187].
Aside from reduced NO bioavailability, a shift in arachidonic acid metabolism 
toward constrictors and away from dilators that are highly responsible for hypoxic 
dilation has been demonstrated [145]. Thus not only does endothelial dysfunction 
seen in MetS increase cerebrovascular resistance by decreased dilator metabolite 
production it may also promote the production of constrictors that exacerbate the 
impaired dilation capacity of cerebral vessels [184, 188]. A change in sensitivity to 
various metabolites in addition to their differential production may also contribute 
to differential vasomotor responses. For example, studies using SNP, an exogenous 
NO donor, while blocking endogenous NO production by eNOS using L-NAME, 
found smaller relaxation of the MCA in spontaneously hypertensive rats which was 
attributed to a decreased expression of soluble guanylate cyclase [189–192]. In a 
model of T2DM decreased sensitivity of MCA to the PGI2 analog iloprost was also 
found suggesting that both decrease production and sensitivity of dilators may be 
contributing to the impaired dilation of the cerebral circulation in MetS [145].
Impaired dilation in response to exogenous dilator metabolites may also be due to 
vascular remodeling. Structural changes are an important consideration since even 
if the smooth muscle of a cerebral vessel is able to relax due to metabolic influences 
resulting in hyperpolarization, remodeling may prevent an increase in lumen diameter 
which is ultimately the major contributor to acute changes in resistance and thus the 
regulator of flow. Hypertension is largely implicated in the thickening of the vascular 
smooth muscle as well as increasing the ratio of collagen to elastin in the vessel. High 
intraluminal pressure increases the shear stress exerted on the vascular endothelium 
which normally could be restored to baseline by NO-induced vasodilation [193–195]; 
however, in a disease state with impaired NO production, there is a reduced ability to 
dilate resulting in endothelial damage and upregulation of atherogenic genes [193–195]. 
As a means of protection from chronic increased shear stress and wall tension that may 
lead to downstream edema cerebral vessels tend to hypertrophy with chronic hyperten-
sion, but this protective hypertrophy is also detrimental [188]. Since wall tension is 
equal to intraluminal pressure X radius and wall stress is wall tension/wall thickness, 
hypertension-induced hypertrophy and inward remodeling resulting in a decrease in 
radius and increase wall thickness can normalize both the wall tension and wall stress 
[188]. Although this remodeling may be protective in regards to increases in pressures 
and protecting the downstream capillaries from edema it increases the cerebrovascular 
resistance and limits the dilation reserve during hypotension and therefore presents 
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itself as a right-shift in the autoregulatory range [196, 197]. The development of myo-
genic tone at higher pressure implies an increased lower limit of autoregulation. This 
predisposes cerebral tissue to reduced blood flow during hypotension. When pressure 
drops below the lower limit flow becomes dependent on the passive diameter of the 
vessel. Not only does an impaired lower limit predispose hypertensive individuals to 
ischemia but the reduced passive diameter from vascular remodeling further compro-
mises flow to cerebral tissue resulting in hypoxic areas [43].
In addition to hypertrophy and inward remodeling, there is substantial arterial 
stiffening commonly seen in MetS. The pro-oxidant stress of ROS may interact 
with components of the perivascular matrix and initiate collagen cross-linking and 
deposition as well as the breakdown of elastin making the vessel less distensible 
[198]. This is measured by a left shift in the stress-strain curve of isolated cerebral 
vessels under passive conditions achieved by using a Ca2+ free solution preventing 
the development of tone [183]. The stiffening vessel from increased collagen to 
elastin ratio is made worse by the thickening of vessel walls previously discussed. 
In a model of T2DM with hypertension significant collagen deposition in addition 
to medial hypertrophy increasing the wall the lumen ratio and stiffness of the rats 
MCA [199] was demonstrated while T2DM in the absence of hypertension does 
not appear to induce structural changes to the cerebral vasculature [145]. This 
along with data that suggests the increase in arterial stiffness seems to follow a time 
course similar to that of the onset of hypertension suggests a strong relationship 
between hypertension and vascular remodeling [200]. Chronic uncontrolled hyper-
glycemia and inflammation do tend to lead to the development of hypertension and 
thus contribute to changes in the composition of cerebral vessels and it is likely the 
combination of both seen in MetS increases the degree to which remodeling occurs. 
A summary of the impact of disease states on the regulation of cerebral vascular 
tone is presented in Figure 2.
Figure 2. 
A schematic representation of how the presence of metabolic syndrome and the major constituent pathologies 
can impact the integrated regulation of cerebral vascular tone.
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6. Conclusions
In conclusion, the regulation of vascular tone involves a complex set of pathways 
with myogenic, shear, and metabolic control. The mechanical influences of pressure 
and flow serve as a stimulus for the myogenic and shear responses to set a basal level 
of tone over a wide range so that metabolic factors have room to produce vasoactive 
responses on the vasculature. Due to the paramount importance of precise cerebral 
blood flow control these mechanisms are particularly pronounced and redundant in 
the cerebral circulation allowing for greater protection against insufficient perfu-
sion or edema and capillary damage in situations of hypotension and hypertension 
respectively. However, due to the complexity of these homeostatic blood flow 
mechanisms there is the potential for the development of a pathological state. MetS 
presents a constellation of cardiovascular risk factors that are highly linked to the 
development of such cerebrovascular pathologies increasing the risk of stroke, TIA, 
and vascular dementia. The risk factors associated with MetS result in vascular 
remodeling which decreases the lumen size and increases stiffness and when paired 
with endothelial dysfunction and increased activation of the vascular smooth 
muscle it promotes increased cerebrovascular resistance. This right shifts the 
autoregulatory zone of myogenic regulation allowing for enhanced protection from 
hypertension but leaves cerebral tissue vulnerable to underperfusion. Controlling 
these risk factors and well as implementing targeted therapeutic strategies aimed 
at ameliorating the regulation of cerebrovascular tone has the potential to restore 
function in the cerebral circulation and improve current negative outcomes associ-
ated with MetS and cerebrovascular dysfunction.
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Primary Cilia are Sensory Hubs for 
Nitric Oxide Signaling
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Abstract
Primary cilia are sensory organelles present on the surface of most polarized 
cells. Primary cilia have been demonstrated to play many sensory cell roles, includ-
ing mechanosensory and chemosensory functions. We demonstrated previously 
that primary cilia of vascular endothelial cells will bend in response to fluid shear 
stress, which leads to the biochemical production and release of nitric oxide. This 
process is impaired in endothelial cells that lack primary cilia function or structure. 
In this chapter, we will provide an overview of ciliogenesis and the differences 
between primary cilia and multicilia, as well as an overview of our published work 
on primary cilia and nitric oxide, and a brief perspective on their implications in 
health and disease.
Keywords: primary cilia, nitric oxide, signaling, fluid shear stress,  
mechanosensory transduction
1. Introduction
Cilia are found in nearly every cell in the animal body, where they function as 
highly specialized sensory organelles. Ciliary malfunction, therefore, tends to result 
in severe abnormalities, which are often multisystemic. These abnormalities are 
known as ciliopathies, and as our understanding of cilia form and function continues 
to grow, so too does the list of known ciliopathies. It is now known that mutations 
in over 40 genes can alter cilia structure or function, and this list continues to grow; 
over 1000 polypeptides in the ciliary proteome have yet to be researched [1, 2].
The field of cilia research gained interest after the discovery that cilia play a role 
in the pathogenesis of Polycystic Kidney Disease (PKD) as fluid mechanosensors 
within the kidney. In addition to renal dysfunction, the cardiovascular system 
is also affected by PKD, which has prompted further research into the role that 
primary cilia play within this system. In kidney tubule epithelia, primary cilia acti-
vation leads to a calcium influx, and it has been proposed that this may also occur 
in vascular endothelial cells. In their study, Nauli et al. showed that vascular cilia 
play a similar function in sensing fluid shear stress, and there was a corresponding 
increase in calcium levels correlated with nitric oxide (NO) release. This is thought 
to contribute to blood pressure control directly. Testing this hypothesis, Nauli et al. 
showed that cilia mutant cell lines had little to no calcium influx, as well as a lack of 
NO release while under fluid shear stress [1, 3, 4].
Nitric oxide is a signaling molecule that plays many important functional roles 
in almost every organ system in the body. Various pathologies are associated with 
wayward NO production and altered bioavailability levels caused by abnormal 
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known as ciliopathies, and as our understanding of cilia form and function continues 
to grow, so too does the list of known ciliopathies. It is now known that mutations 
in over 40 genes can alter cilia structure or function, and this list continues to grow; 
over 1000 polypeptides in the ciliary proteome have yet to be researched [1, 2].
The field of cilia research gained interest after the discovery that cilia play a role 
in the pathogenesis of Polycystic Kidney Disease (PKD) as fluid mechanosensors 
within the kidney. In addition to renal dysfunction, the cardiovascular system 
is also affected by PKD, which has prompted further research into the role that 
primary cilia play within this system. In kidney tubule epithelia, primary cilia acti-
vation leads to a calcium influx, and it has been proposed that this may also occur 
in vascular endothelial cells. In their study, Nauli et al. showed that vascular cilia 
play a similar function in sensing fluid shear stress, and there was a corresponding 
increase in calcium levels correlated with nitric oxide (NO) release. This is thought 
to contribute to blood pressure control directly. Testing this hypothesis, Nauli et al. 
showed that cilia mutant cell lines had little to no calcium influx, as well as a lack of 
NO release while under fluid shear stress [1, 3, 4].
Nitric oxide is a signaling molecule that plays many important functional roles 
in almost every organ system in the body. Various pathologies are associated with 
wayward NO production and altered bioavailability levels caused by abnormal 
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signaling cascades, which are often the result of abnormal cilia-regulated signaling 
pathways. There is a documented connection between cilia and NO in the vascula-
ture, as well as an overlap between signaling pathways in other pathologies. It has 
been postulated that there is a connection between primary cilia and NO outside of 
the vasculature, but literature on the subject is scarce [1].
This chapter aims to explain cilia type, structure, and function, as well as 
ciliogenesis, nitric oxide signaling, and finally the interplay between nitric oxide 
and primary cilia.
2. Cilia type and structure
To understand what makes primary cilia unique, it is important to understand 
the differences between cilia form and function. Cilia are dynamic sensory organ-
elles present in nearly every cell in every animal, as well as most protozoa. There 
are two classes of cilia; motile, which possess the dynein motor complexes needed 
to move, and nonmotile. Motile and nonmotile cilia both contain a 25 μm diameter 
cytoskeletal scaffold known as the axoneme [5]. The axoneme is comprised of 
hundreds of proteins and houses nine peripheral microtubule doublets. These 
doublets are made up of A and B tubules, and they either surround a central pair of 
microtubules (9 + 2 pattern), or do not (9 + 0 pattern) [5]. Some motile cilia contain 
a 9 + 2 pattern and exist in clusters on cells called multiciliated cells (MCCs) [6]. 
There is also a class of motile cilia that have a 9 + 0 structure and exist as solitary 
monocilia on cell surfaces. The presence or absence of the central pair leads to 
significant functional differences in the cilia. The 9 + 2 structure commonly moves 
in a wave-like motion to move fluid, and an example of this are the ependymal cilia. 
The 9 + 2 patterned cilia also move cerebral spinal fluid, while the 9 + 0 structured 
most commonly moves in a rotary or corkscrew motion, as seen in flagella, which 
is useful for propulsion [7, 8]. There is some debate on whether sperm tail flagella 
should be classified as motile monocilia; regardless, they also possess a similar 
axonemal structure [5, 6, 9–11]. Nonmotile cilia, known as primary cilia, have a 
9 + 0 structure and exist as monocilia on the surface of cells. As primary cilia can be 
found on vascular endothelial cells, they will be the focus of this review, but a brief 
overview of multicilia and their motion will also be covered.
2.1 Ciliogenesis
Cilia formation is known as ciliogenesis. Ciliogenesis is correlated with cell divi-
sion and occurs at the G1/G0 phase of the cell cycle. Reabsorption or disassembly of 
the cilium starts after cell cycle re-entry. In the first step of ciliogenesis, the centro-
some travels to the cell surface, whereupon a basal body is formed by the mother 
centriole, and it nucleates the ciliary axoneme at the G1/G0 phase of the cell cycle 
[12]. This first process is regulated by distal appendage proteins, such as centro-
somal protein 164 [13]. During the second step, the cilium elongates; this process 
is regulated by nuclear distribution gene E homolog 1 (Nde1), up until the cilium is 
matured [14]. The third step is cilia resorption, followed by axonemal shortening 
during cell cycle reentry. This third process is controlled by the Aurora A-HDAC6, 
Nek2-Kif24, and Plk1-Kif2A pathways [15]. In the fourth step, the basal body is 
released from the cilia, which frees the centrioles that act as microtubule organizing 
centers (MTOC) or spindle poles for mitosis [12].
Immotile cilia formation is impacted by the coordination of the assembly and 
disassembly equilibrium, the IFT system, and membrane trafficking. When the 
axoneme nucleates from the basal body, it contains a microtubule bundle contained 
51
Primary Cilia are Sensory Hubs for Nitric Oxide Signaling
DOI: http://dx.doi.org/10.5772/intechopen.89680
within the ciliary membrane [16]. Enclosed within are certain signaling molecules 
and ion channels. Because cilia lack the machinery needed to synthesize ciliary 
proteins, proteins synthesized by the cell’s Golgi apparatus must be transported 
through a ciliary ‘gate’ and transition zone near the cilium base [17]. The transition 
zone, recognizable by a change from triplet to doublet microtubules, is located at 
the distal end of the basal body (Figure 1) [18]. Basal body docking with the plasma 
membrane can be either permanent, in the case of unicellular organisms, or tempo-
rary, in the case of metazoans [5].
Transition fibers, which are present in unicellular organisms, or distal and subdis-
tal appendages, which are present in mammals, are attached to microtubules within 
the transition zone [19]. Transition fibers function as docking sites for intraflagellar 
transport (IFT) proteins [20]. IFT transports cargo in a bidirectional manner along 
the length of cilia, and is mediated by kinesin-2 (anterograde) and cytoplasmic 
dynein-2 motors (retrograde) attached to multisubunit protein complexes known as 
IFT particles [21, 22]. Y-linkers exist at the distal end of the transition zone and secure 
the doublet microtubules to the ciliary membrane in most organisms [19].
2.2 Multicilia
In vertebrates, MCCs are present in a wide variety of different tissue types. 
In mammals, ependymal MCCs line brain ventricles and the airway epithelium. 
Multicilia are produced by specialized cells for highly specialized functions. MCCs 
are typically defined as having more than two cilia on their surface, although this 
occurrence is not well documented or understood. Recently, MCCs have been 
observed in unicellular eukaryotes and protists, as well as many metazoans, and 
even in certain plant sperms [23–25]. MCCs result in the production of motile 
axonemes, with the only notable exception being mammalian olfactory cilia. These 
olfactory MCCs lack dynein arms and are considered immotile despite having a 9 + 2 
Figure 1. 
Primary cilia structure. The axonemes of primary cilia are anchored from the basal body and encapsulated 
within the ciliary membrane. The ciliary membrane is one continuous extension of the plasma membrane. The 
basal body is composed of the mother and the daughter centrioles, as well as some transition fibers that anchor 
the basal body to the cell membrane. The ciliary membrane houses specific membrane and protein receptors, 
all of which facilitate proper cilia signaling (left panel). Primary cilia that are found on vascular endothelial 
cells are identifiable by an immunofluorescence technique with antibody against acetylated α-tubulin (green) 
labeling primary cilia, and pericentrin (red) labeling the centriole or basal body. The nucleus is counterstained 
with DAPI (blue) to label DNA (right panel). Left panel is adopted from Ref. [1].
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ture, as well as an overlap between signaling pathways in other pathologies. It has 
been postulated that there is a connection between primary cilia and NO outside of 
the vasculature, but literature on the subject is scarce [1].
This chapter aims to explain cilia type, structure, and function, as well as 
ciliogenesis, nitric oxide signaling, and finally the interplay between nitric oxide 
and primary cilia.
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To understand what makes primary cilia unique, it is important to understand 
the differences between cilia form and function. Cilia are dynamic sensory organ-
elles present in nearly every cell in every animal, as well as most protozoa. There 
are two classes of cilia; motile, which possess the dynein motor complexes needed 
to move, and nonmotile. Motile and nonmotile cilia both contain a 25 μm diameter 
cytoskeletal scaffold known as the axoneme [5]. The axoneme is comprised of 
hundreds of proteins and houses nine peripheral microtubule doublets. These 
doublets are made up of A and B tubules, and they either surround a central pair of 
microtubules (9 + 2 pattern), or do not (9 + 0 pattern) [5]. Some motile cilia contain 
a 9 + 2 pattern and exist in clusters on cells called multiciliated cells (MCCs) [6]. 
There is also a class of motile cilia that have a 9 + 0 structure and exist as solitary 
monocilia on cell surfaces. The presence or absence of the central pair leads to 
significant functional differences in the cilia. The 9 + 2 structure commonly moves 
in a wave-like motion to move fluid, and an example of this are the ependymal cilia. 
The 9 + 2 patterned cilia also move cerebral spinal fluid, while the 9 + 0 structured 
most commonly moves in a rotary or corkscrew motion, as seen in flagella, which 
is useful for propulsion [7, 8]. There is some debate on whether sperm tail flagella 
should be classified as motile monocilia; regardless, they also possess a similar 
axonemal structure [5, 6, 9–11]. Nonmotile cilia, known as primary cilia, have a 
9 + 0 structure and exist as monocilia on the surface of cells. As primary cilia can be 
found on vascular endothelial cells, they will be the focus of this review, but a brief 
overview of multicilia and their motion will also be covered.
2.1 Ciliogenesis
Cilia formation is known as ciliogenesis. Ciliogenesis is correlated with cell divi-
sion and occurs at the G1/G0 phase of the cell cycle. Reabsorption or disassembly of 
the cilium starts after cell cycle re-entry. In the first step of ciliogenesis, the centro-
some travels to the cell surface, whereupon a basal body is formed by the mother 
centriole, and it nucleates the ciliary axoneme at the G1/G0 phase of the cell cycle 
[12]. This first process is regulated by distal appendage proteins, such as centro-
somal protein 164 [13]. During the second step, the cilium elongates; this process 
is regulated by nuclear distribution gene E homolog 1 (Nde1), up until the cilium is 
matured [14]. The third step is cilia resorption, followed by axonemal shortening 
during cell cycle reentry. This third process is controlled by the Aurora A-HDAC6, 
Nek2-Kif24, and Plk1-Kif2A pathways [15]. In the fourth step, the basal body is 
released from the cilia, which frees the centrioles that act as microtubule organizing 
centers (MTOC) or spindle poles for mitosis [12].
Immotile cilia formation is impacted by the coordination of the assembly and 
disassembly equilibrium, the IFT system, and membrane trafficking. When the 
axoneme nucleates from the basal body, it contains a microtubule bundle contained 
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within the ciliary membrane [16]. Enclosed within are certain signaling molecules 
and ion channels. Because cilia lack the machinery needed to synthesize ciliary 
proteins, proteins synthesized by the cell’s Golgi apparatus must be transported 
through a ciliary ‘gate’ and transition zone near the cilium base [17]. The transition 
zone, recognizable by a change from triplet to doublet microtubules, is located at 
the distal end of the basal body (Figure 1) [18]. Basal body docking with the plasma 
membrane can be either permanent, in the case of unicellular organisms, or tempo-
rary, in the case of metazoans [5].
Transition fibers, which are present in unicellular organisms, or distal and subdis-
tal appendages, which are present in mammals, are attached to microtubules within 
the transition zone [19]. Transition fibers function as docking sites for intraflagellar 
transport (IFT) proteins [20]. IFT transports cargo in a bidirectional manner along 
the length of cilia, and is mediated by kinesin-2 (anterograde) and cytoplasmic 
dynein-2 motors (retrograde) attached to multisubunit protein complexes known as 
IFT particles [21, 22]. Y-linkers exist at the distal end of the transition zone and secure 
the doublet microtubules to the ciliary membrane in most organisms [19].
2.2 Multicilia
In vertebrates, MCCs are present in a wide variety of different tissue types. 
In mammals, ependymal MCCs line brain ventricles and the airway epithelium. 
Multicilia are produced by specialized cells for highly specialized functions. MCCs 
are typically defined as having more than two cilia on their surface, although this 
occurrence is not well documented or understood. Recently, MCCs have been 
observed in unicellular eukaryotes and protists, as well as many metazoans, and 
even in certain plant sperms [23–25]. MCCs result in the production of motile 
axonemes, with the only notable exception being mammalian olfactory cilia. These 
olfactory MCCs lack dynein arms and are considered immotile despite having a 9 + 2 
Figure 1. 
Primary cilia structure. The axonemes of primary cilia are anchored from the basal body and encapsulated 
within the ciliary membrane. The ciliary membrane is one continuous extension of the plasma membrane. The 
basal body is composed of the mother and the daughter centrioles, as well as some transition fibers that anchor 
the basal body to the cell membrane. The ciliary membrane houses specific membrane and protein receptors, 
all of which facilitate proper cilia signaling (left panel). Primary cilia that are found on vascular endothelial 
cells are identifiable by an immunofluorescence technique with antibody against acetylated α-tubulin (green) 
labeling primary cilia, and pericentrin (red) labeling the centriole or basal body. The nucleus is counterstained 
with DAPI (blue) to label DNA (right panel). Left panel is adopted from Ref. [1].
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structure. This occurrence is indicative of MCCs being a solution to the need for local 
fluid flow, possibly due to their ability for hydrodynamic coupling [6, 26, 27].
Multicilia carry out their functions by beating, and the basic machinery and 
organization of cilia beating seems well conserved between eukaryotes, as well 
as between single motile cilium and multicilia. Some parameters, such as beat 
frequency, are under cellular control and are varied among cell types. In addition, 
only motile cilia and sperm flagella contain the dynein machinery needed to power 
axonemal beating during ATP hydrolysis [5, 28]. The ciliary beat cycle has two 
phases: the effective stroke, and the recovery stroke. The effective stroke is the 
initially bending from its upright position, while the recovery stroke sees it return to 
its original, unbent position [6, 29]. Ciliary motility is controlled by outer and inner 
axonemal dynein arms, which slide adjacent doublets in respect to one another. The 
sliding is mediated by protein bridges between doublets, and by the basal anchoring 
of the axoneme. As a result, cilia bend [6, 29].
The phenomenon metachrony occurs when cilia are organized in such a way that 
each cilium, in a two-dimensional array, will beat at the same frequency, but in a 
phase shifted manner. As a result, a traveling wave of ciliary action moves across 
the array, which propels fluids in a current. Even if each cilium in an array start off 
in synch, hydrodynamic forces between each cilium will nudge them back towards 
metachrony, possibly because in a metachronal array, the work each cilium must do 
is reduced, and more fluid is displaced. Because of this, multiciliation is thought to 
be a more evolutionarily efficient way to generate fluid flow [6, 30–32].
2.3 Primary cilia
Nearly all human cells house a single nonmotile cilium on their surface, and 
these primary cilia serve sensory and signaling purposes. The role of primary cilia 
function and formation on animal health and pathophysiology has only recently 
been brought to researcher’s attentions and is even now not fully understood. A 
wealth of new information about the primary cilia has been discovered within the 
last few decades, shedding some light on the function of the previously thought 
vestigial organelle [33].
Primary cilia are part of various signaling pathways in vertebrates, and usually 
lack a microtubule central pair (9 + 0 axoneme), as well as the structures associated 
with the central doublet pair, such as the inner and outer dynein arms required for 
ciliary movement [34, 35]. Primary cilia can be found in, but are not limited to; 
endothelia, epithelia, and neurons. Although found in nearly every mammalian 
cell, notable exceptions include the intercalated cells of the kidney collecting ducts, 
red blood cells, hepatocytes, and MCCs [34].
Primary cilia function mainly as sensory hubs and are host to many different 
groups of mechanosensory proteins, chemosensory receptors, and ion channels. 
These translate extracellular stimuli into an intracellular biochemical signal, which 
cause different cellular responses. There are two current models that attempt to 
explain how primary cilia function; the compartment model, and the scaffold 
model. The compartment model states that the ciliary structure is essential for 
proper signaling, while the scaffold model states that IFT molecules must play a 
part in either signaling itself, or the acquisition of outside transduction intermedi-
ates [36, 37]. As stated in the ciliogenesis section, primary cilia form through IFT, 
which transports proteins along the microtubules of the axoneme. The axoneme 
acts like a scaffold for certain protein complexes, including kinesins and dyneins, 
which facilitate back-and-forth trafficking of cargo proteins along the length of 
the cilium. Along with their creation, IFT is also required for maintenance of the 
primary cilium, and possibly even their core functions [1, 10].
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The ciliary membrane is an extension of the cellular membrane where a host of 
proteins and receptors are housed due to the ciliary transition zone, which provides 
docking sites for molecular transport into and out of the cilioplasm (Figure 1) 
[38–40]. While there is no confirmed mechanism by which molecules enter and 
exit the cilia, several mechanisms have been proposed. One such mechanism is the 
active transport of vesicles from the Golgi apparatus to docking sites in the transition 
zone [41]. The vesicles are thought to interact with exocyst complexes, where they 
experience soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein 
receptor (SNARE) mediated diffusion across the cilioplasm/cytoplasm barrier [37]. 
The BBSome, which resides in the basal body and is an octameric protein complex, 
is involved in the movement of transmembrane proteins to the ciliary membrane. 
BBSomes are known to recognize ciliary targeting sequences and will readily interact 
with molecules that are upstream of Rab8 activation. BBSomes are not thought to 
be required for any aspect of ciliogenesis; nevertheless, if BBSomes fail to deliver 
certain vital proteins to the cilia, the cilia may lose functionality [42–45]. Another 
proposed mechanism of molecule trafficking is the action of transmembrane pro-
teins, of which some are associated with specific protein sequences that target cilia 
localization, such as the N-terminal RVxP sequence on polycystin-2 (PC-2) [42, 46].
Primary cilia serve many mechanosensory functions within the body. For exam-
ple, proper kidney function depends on regulated fluid flow through the nephrons 
and collecting ducts, which controls the glomerular filtration rate [47]. This flow 
is sensed by the epithelial primary cilia present in the kidney. Fluid redirection by 
the primary cilia causes an increase in intracellular calcium. This calcium influx 
is also mediated by the PC1/2 ion channel complex, and both the mechanosensi-
tive polycystin-1 (PC-1) membrane protein and the PC-2 channel localize to the 
primary cilia [48–50]. In renal cells, defects in this ion channel complex, along with 
complete disruption of cilia formation, is known to result in PKD [51].
3. Nitric oxide
Nitric oxide is a signaling molecule involved in a wide array of cellular pathways; 
mainly, NO contributes to the normal functions of a variety of organ systems [52]. 
NO is highly reactive, and readily diffuses across cellular membranes. As a result, 
NO is found in many paracrine signaling pathways. NO is mainly synthesized 
from l-arginine, oxygen, and NADPH in a redox reaction, catalyzed by nitric 
oxide synthase (NOS) [53]. NOS has three isoforms, but only endothelial NOS 
(eNOS) and neuronal NOS (nNOS) are constantly and consistently expressed in 
cells. Both eNOS and nNOS are calcium dependent, while the other NOS isoform, 
cytokine inducible NOS (iNOS), is expressed by pro-inflammatory cytokines on 
an as needed basis [54]. iNOS and nNOS are both soluble enzymes that exist within 
the cytosol. eNOS, however, is found to localize to the plasma or Golgi body mem-
branes. Because of its unique and wide cellular and subcellular distribution, NOS 
has many diverse functions throughout the entirety of the body [1, 54, 55].
4. Cilia and nitric oxide interplay
Although primary cilia and NO have various independent roles within the body, 
especially in the vasculature, their functions often intersect and cooperate with 
each other. Most research on the interaction between endothelial primary cilia and 
nitric oxide focuses on vascular homeostasis, but their interactions extend into 
other areas [1]. However, this chapter will focus on signaling cascades that lead 
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structure. This occurrence is indicative of MCCs being a solution to the need for local 
fluid flow, possibly due to their ability for hydrodynamic coupling [6, 26, 27].
Multicilia carry out their functions by beating, and the basic machinery and 
organization of cilia beating seems well conserved between eukaryotes, as well 
as between single motile cilium and multicilia. Some parameters, such as beat 
frequency, are under cellular control and are varied among cell types. In addition, 
only motile cilia and sperm flagella contain the dynein machinery needed to power 
axonemal beating during ATP hydrolysis [5, 28]. The ciliary beat cycle has two 
phases: the effective stroke, and the recovery stroke. The effective stroke is the 
initially bending from its upright position, while the recovery stroke sees it return to 
its original, unbent position [6, 29]. Ciliary motility is controlled by outer and inner 
axonemal dynein arms, which slide adjacent doublets in respect to one another. The 
sliding is mediated by protein bridges between doublets, and by the basal anchoring 
of the axoneme. As a result, cilia bend [6, 29].
The phenomenon metachrony occurs when cilia are organized in such a way that 
each cilium, in a two-dimensional array, will beat at the same frequency, but in a 
phase shifted manner. As a result, a traveling wave of ciliary action moves across 
the array, which propels fluids in a current. Even if each cilium in an array start off 
in synch, hydrodynamic forces between each cilium will nudge them back towards 
metachrony, possibly because in a metachronal array, the work each cilium must do 
is reduced, and more fluid is displaced. Because of this, multiciliation is thought to 
be a more evolutionarily efficient way to generate fluid flow [6, 30–32].
2.3 Primary cilia
Nearly all human cells house a single nonmotile cilium on their surface, and 
these primary cilia serve sensory and signaling purposes. The role of primary cilia 
function and formation on animal health and pathophysiology has only recently 
been brought to researcher’s attentions and is even now not fully understood. A 
wealth of new information about the primary cilia has been discovered within the 
last few decades, shedding some light on the function of the previously thought 
vestigial organelle [33].
Primary cilia are part of various signaling pathways in vertebrates, and usually 
lack a microtubule central pair (9 + 0 axoneme), as well as the structures associated 
with the central doublet pair, such as the inner and outer dynein arms required for 
ciliary movement [34, 35]. Primary cilia can be found in, but are not limited to; 
endothelia, epithelia, and neurons. Although found in nearly every mammalian 
cell, notable exceptions include the intercalated cells of the kidney collecting ducts, 
red blood cells, hepatocytes, and MCCs [34].
Primary cilia function mainly as sensory hubs and are host to many different 
groups of mechanosensory proteins, chemosensory receptors, and ion channels. 
These translate extracellular stimuli into an intracellular biochemical signal, which 
cause different cellular responses. There are two current models that attempt to 
explain how primary cilia function; the compartment model, and the scaffold 
model. The compartment model states that the ciliary structure is essential for 
proper signaling, while the scaffold model states that IFT molecules must play a 
part in either signaling itself, or the acquisition of outside transduction intermedi-
ates [36, 37]. As stated in the ciliogenesis section, primary cilia form through IFT, 
which transports proteins along the microtubules of the axoneme. The axoneme 
acts like a scaffold for certain protein complexes, including kinesins and dyneins, 
which facilitate back-and-forth trafficking of cargo proteins along the length of 
the cilium. Along with their creation, IFT is also required for maintenance of the 
primary cilium, and possibly even their core functions [1, 10].
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The ciliary membrane is an extension of the cellular membrane where a host of 
proteins and receptors are housed due to the ciliary transition zone, which provides 
docking sites for molecular transport into and out of the cilioplasm (Figure 1) 
[38–40]. While there is no confirmed mechanism by which molecules enter and 
exit the cilia, several mechanisms have been proposed. One such mechanism is the 
active transport of vesicles from the Golgi apparatus to docking sites in the transition 
zone [41]. The vesicles are thought to interact with exocyst complexes, where they 
experience soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein 
receptor (SNARE) mediated diffusion across the cilioplasm/cytoplasm barrier [37]. 
The BBSome, which resides in the basal body and is an octameric protein complex, 
is involved in the movement of transmembrane proteins to the ciliary membrane. 
BBSomes are known to recognize ciliary targeting sequences and will readily interact 
with molecules that are upstream of Rab8 activation. BBSomes are not thought to 
be required for any aspect of ciliogenesis; nevertheless, if BBSomes fail to deliver 
certain vital proteins to the cilia, the cilia may lose functionality [42–45]. Another 
proposed mechanism of molecule trafficking is the action of transmembrane pro-
teins, of which some are associated with specific protein sequences that target cilia 
localization, such as the N-terminal RVxP sequence on polycystin-2 (PC-2) [42, 46].
Primary cilia serve many mechanosensory functions within the body. For exam-
ple, proper kidney function depends on regulated fluid flow through the nephrons 
and collecting ducts, which controls the glomerular filtration rate [47]. This flow 
is sensed by the epithelial primary cilia present in the kidney. Fluid redirection by 
the primary cilia causes an increase in intracellular calcium. This calcium influx 
is also mediated by the PC1/2 ion channel complex, and both the mechanosensi-
tive polycystin-1 (PC-1) membrane protein and the PC-2 channel localize to the 
primary cilia [48–50]. In renal cells, defects in this ion channel complex, along with 
complete disruption of cilia formation, is known to result in PKD [51].
3. Nitric oxide
Nitric oxide is a signaling molecule involved in a wide array of cellular pathways; 
mainly, NO contributes to the normal functions of a variety of organ systems [52]. 
NO is highly reactive, and readily diffuses across cellular membranes. As a result, 
NO is found in many paracrine signaling pathways. NO is mainly synthesized 
from l-arginine, oxygen, and NADPH in a redox reaction, catalyzed by nitric 
oxide synthase (NOS) [53]. NOS has three isoforms, but only endothelial NOS 
(eNOS) and neuronal NOS (nNOS) are constantly and consistently expressed in 
cells. Both eNOS and nNOS are calcium dependent, while the other NOS isoform, 
cytokine inducible NOS (iNOS), is expressed by pro-inflammatory cytokines on 
an as needed basis [54]. iNOS and nNOS are both soluble enzymes that exist within 
the cytosol. eNOS, however, is found to localize to the plasma or Golgi body mem-
branes. Because of its unique and wide cellular and subcellular distribution, NOS 
has many diverse functions throughout the entirety of the body [1, 54, 55].
4. Cilia and nitric oxide interplay
Although primary cilia and NO have various independent roles within the body, 
especially in the vasculature, their functions often intersect and cooperate with 
each other. Most research on the interaction between endothelial primary cilia and 
nitric oxide focuses on vascular homeostasis, but their interactions extend into 
other areas [1]. However, this chapter will focus on signaling cascades that lead 
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to NO biosynthesis or increased NO bioavailability. The following discussion of 
the interactions between primary cilia and nitric oxide will focus on vasodilation, 
wound healing, dopamine signaling, and cellular proliferation.
4.1 Vasodilation
Primary cilia and NO independently effect the vasculature in different ways, 
but recent studies suggest a direct relationship may exist between the two. Vascular 
endothelial cells are present in the blood vessel wall and are in continuous contact 
with blood flow-generated fluid shear stress. Endothelial cells are known mecha-
notransducers of fluid shear stress, which causes the biosynthesis of NO. This 
helps regulate vascular tone; NO will diffuse into the surrounding smooth muscle, 
producing vasorelaxation [56].
Evidence supports primary cilia as the main sensor in this mechanosensitive 
pathway. As stated previously, PC-1, a mechanosensory protein that malfunctions in 
polycystic kidney disease, localizes to vascular endothelial primary cilia. In an in vitro 
study performed by Nauli et al., which investigated PC-1’s fluid shear mechanosen-
sory properties, it was found that in contrast to wildtype endothelial cells, the PC-1 
knockout cells failed to produce an increase in cytosolic calcium and the correspond-
ing NO flux in response to fluid shear stress. The authors, to demonstrate that calcium 
and NO signals are induced in response to ciliary PC-1 activation, used Tg737orpk/orpk 
endothelial cells that lack ciliary ultrastructure but have functional PC-1. The results 
showed that neither calcium nor NO signals were present at flow rates up to 50 dyne/cm2 
[3]. These results suggest that PC-1 is responsible for proper cilia mechanosensory 
function, and that ciliary PC-1 specifically elicits NO production.
Follow-up studies by AbouAlaiwi et al. Showed that PC-2, which, as stated 
previously, is a calcium permeable cation channel that forms a complex with PC-1, 
is also important for mechanotransduction. Studies using a PC-2 knockdown line of 
cells showed a reduction in calcium and NO flux under shear stress when compared 
to control cells. This was further validated in ex vivo studies, where endothelial 
cells isolated from pkd2−/− mice arteries failed to respond to fluid shear stress [4]. 
These results indicate both PC-1 and PC-2 are needed for cilia mechanosensa-
tion, and further suggest that activation of the PC-1/PC-2 complex will start the 
signaling cascade needed for calcium-dependent NO biosynthesis. In addition, the 
results show that the increase in intracellular calcium is caused by an increase in 
intra-ciliary calcium. However, other researchers have proposed that calcium moves 
bidirectionally between the cilia and the cytosol [57–59]. Regardless, the increase 
in intracellular calcium triggers the calcium/calmodulin complex, which activates 
constitutive NOS, such as eNOS, by binding to its target site on the enzyme [60].
The calcium/calmodulin complex can also indirectly activate eNOS through 
activation of the AKT/PKB pathway, which stimulates AMPK (Figure 2) [61]. 
eNOS activation is mainly calcium dependent, but some studies have shown that a 
calcium independent pathway exists, via heat shock protein 90 (HSP90). HSP90 
is also known to localize to cilia axonemes, and may act as a signal transductor that 
interacts with eNOS in the vasculature [62, 63]. HSP90 activation can lead to an 
increase in eNOS activity while calcium levels are high, and can also lead to more 
eNOS activity at low calcium levels due to its ability to directly bind to eNOS and 
increase the binding affinity for calmodulin [64, 65].
4.2 Wound healing
An under researched aspect of NO and primary cilia is their interaction in the 
vascular smooth muscle cell (VSMC) layer. Depending on blood vessel type, all 
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three isoforms of NOS may exist within the VSMC layers [66]. During normal 
function, the cilia on the VSMC layer extend towards the extracellular matrix. 
Under abnormal conditions, such as a scratch wound, VSMC primary cilia will 
migrate to the wound edge. A recent study showed that VSMC cilia express poly-
cystins, as well as α3-and β1-integrins. When the researchers blocked integrin 
function, the percent of cilia migrating to the wound edge dropped from about 
88% to around 30% [67]. This drop suggests that VSMC primary cilia may be 
involved in integrin-mediated wound healing.
In further support of the purported role primary cilia play in wound healing, 
results from experiments using VSMC that lacked cilia showed a slower scratch-
wound healing time than the ciliated control cells displayed [67]. While the cilia 
in the wounded area are directly exposed to constant fluid shear stress from blood 
flow, activation of the mechanosensory ciliary polycystin complex could occur, 
resulting in an increase in intracellular calcium [1]. This could potentially trigger 
vasoconstriction in VSMC, resulting in the isolation of the wounded area to allow 
the platelets to begin clot formation. As soon as the calcium amount reached a 
certain level, the calcium/calmodulin complex would form and activate eNOS and 
nNOS, leading to vasodilation and the next step in the wound healing process.
Further studies by Schneider et al. reveled that, once cellular growth was halted, 
platelet derived growth factor receptor alpha (PDGFRα), a tyrosine kinase with a 
prominent function in cellular proliferation, was found to localize to fibroblast pri-
mary cilia. Furthermore, ligand activation of PDGFRα will lead to the activation of 
the AKT and MEK/ERK proliferative pathways. Because AKT and ERK1/2 regulate 
eNOS activity in endothelial cells, PDGFRα activation could indirectly lead to eNOS 
Figure 2. 
Primary cilia activation via fluid shear stress and NO signaling in the vascular endothelia. The left panel shows 
primary cilia bending while under fluid shear stress, with the resultant production and release of nitric oxide 
(NO). The production and release of NO is dependent on the activation of endothelial primary cilia within 
the vasculature. The bending of cilia via fluid-shear stress activates the mechanosensory polycystins complex, 
which initiates the synthesis and the release of NO. This biochemical cascade, shown in the right panel, involves 
an extracellular calcium influx (Ca2+), followed by the activation of multiple calcium-dependent proteins, 
including calmodulin (CaM), protein kinase C (PKC) and Akt/PKB. Figure is adopted from Ref. [1].
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to NO biosynthesis or increased NO bioavailability. The following discussion of 
the interactions between primary cilia and nitric oxide will focus on vasodilation, 
wound healing, dopamine signaling, and cellular proliferation.
4.1 Vasodilation
Primary cilia and NO independently effect the vasculature in different ways, 
but recent studies suggest a direct relationship may exist between the two. Vascular 
endothelial cells are present in the blood vessel wall and are in continuous contact 
with blood flow-generated fluid shear stress. Endothelial cells are known mecha-
notransducers of fluid shear stress, which causes the biosynthesis of NO. This 
helps regulate vascular tone; NO will diffuse into the surrounding smooth muscle, 
producing vasorelaxation [56].
Evidence supports primary cilia as the main sensor in this mechanosensitive 
pathway. As stated previously, PC-1, a mechanosensory protein that malfunctions in 
polycystic kidney disease, localizes to vascular endothelial primary cilia. In an in vitro 
study performed by Nauli et al., which investigated PC-1’s fluid shear mechanosen-
sory properties, it was found that in contrast to wildtype endothelial cells, the PC-1 
knockout cells failed to produce an increase in cytosolic calcium and the correspond-
ing NO flux in response to fluid shear stress. The authors, to demonstrate that calcium 
and NO signals are induced in response to ciliary PC-1 activation, used Tg737orpk/orpk 
endothelial cells that lack ciliary ultrastructure but have functional PC-1. The results 
showed that neither calcium nor NO signals were present at flow rates up to 50 dyne/cm2 
[3]. These results suggest that PC-1 is responsible for proper cilia mechanosensory 
function, and that ciliary PC-1 specifically elicits NO production.
Follow-up studies by AbouAlaiwi et al. Showed that PC-2, which, as stated 
previously, is a calcium permeable cation channel that forms a complex with PC-1, 
is also important for mechanotransduction. Studies using a PC-2 knockdown line of 
cells showed a reduction in calcium and NO flux under shear stress when compared 
to control cells. This was further validated in ex vivo studies, where endothelial 
cells isolated from pkd2−/− mice arteries failed to respond to fluid shear stress [4]. 
These results indicate both PC-1 and PC-2 are needed for cilia mechanosensa-
tion, and further suggest that activation of the PC-1/PC-2 complex will start the 
signaling cascade needed for calcium-dependent NO biosynthesis. In addition, the 
results show that the increase in intracellular calcium is caused by an increase in 
intra-ciliary calcium. However, other researchers have proposed that calcium moves 
bidirectionally between the cilia and the cytosol [57–59]. Regardless, the increase 
in intracellular calcium triggers the calcium/calmodulin complex, which activates 
constitutive NOS, such as eNOS, by binding to its target site on the enzyme [60].
The calcium/calmodulin complex can also indirectly activate eNOS through 
activation of the AKT/PKB pathway, which stimulates AMPK (Figure 2) [61]. 
eNOS activation is mainly calcium dependent, but some studies have shown that a 
calcium independent pathway exists, via heat shock protein 90 (HSP90). HSP90 
is also known to localize to cilia axonemes, and may act as a signal transductor that 
interacts with eNOS in the vasculature [62, 63]. HSP90 activation can lead to an 
increase in eNOS activity while calcium levels are high, and can also lead to more 
eNOS activity at low calcium levels due to its ability to directly bind to eNOS and 
increase the binding affinity for calmodulin [64, 65].
4.2 Wound healing
An under researched aspect of NO and primary cilia is their interaction in the 
vascular smooth muscle cell (VSMC) layer. Depending on blood vessel type, all 
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three isoforms of NOS may exist within the VSMC layers [66]. During normal 
function, the cilia on the VSMC layer extend towards the extracellular matrix. 
Under abnormal conditions, such as a scratch wound, VSMC primary cilia will 
migrate to the wound edge. A recent study showed that VSMC cilia express poly-
cystins, as well as α3-and β1-integrins. When the researchers blocked integrin 
function, the percent of cilia migrating to the wound edge dropped from about 
88% to around 30% [67]. This drop suggests that VSMC primary cilia may be 
involved in integrin-mediated wound healing.
In further support of the purported role primary cilia play in wound healing, 
results from experiments using VSMC that lacked cilia showed a slower scratch-
wound healing time than the ciliated control cells displayed [67]. While the cilia 
in the wounded area are directly exposed to constant fluid shear stress from blood 
flow, activation of the mechanosensory ciliary polycystin complex could occur, 
resulting in an increase in intracellular calcium [1]. This could potentially trigger 
vasoconstriction in VSMC, resulting in the isolation of the wounded area to allow 
the platelets to begin clot formation. As soon as the calcium amount reached a 
certain level, the calcium/calmodulin complex would form and activate eNOS and 
nNOS, leading to vasodilation and the next step in the wound healing process.
Further studies by Schneider et al. reveled that, once cellular growth was halted, 
platelet derived growth factor receptor alpha (PDGFRα), a tyrosine kinase with a 
prominent function in cellular proliferation, was found to localize to fibroblast pri-
mary cilia. Furthermore, ligand activation of PDGFRα will lead to the activation of 
the AKT and MEK/ERK proliferative pathways. Because AKT and ERK1/2 regulate 
eNOS activity in endothelial cells, PDGFRα activation could indirectly lead to eNOS 
Figure 2. 
Primary cilia activation via fluid shear stress and NO signaling in the vascular endothelia. The left panel shows 
primary cilia bending while under fluid shear stress, with the resultant production and release of nitric oxide 
(NO). The production and release of NO is dependent on the activation of endothelial primary cilia within 
the vasculature. The bending of cilia via fluid-shear stress activates the mechanosensory polycystins complex, 
which initiates the synthesis and the release of NO. This biochemical cascade, shown in the right panel, involves 
an extracellular calcium influx (Ca2+), followed by the activation of multiple calcium-dependent proteins, 
including calmodulin (CaM), protein kinase C (PKC) and Akt/PKB. Figure is adopted from Ref. [1].
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activation [68]. Moreover, data from recent studies on endothelial progenitor cells 
indicate that platelet-derived growth factor AA (PDGF-AA) might contribute a 
vital role in wound healing, possibly by its effects on angiogenesis through the PI3K/
Akt/eNOS signaling pathway [69]. Bone morphological protein (BMP) receptor 
II (BMPRII), which is highly expressed on endothelial cells in lung vasculature, 
as well as moderately expressed in smooth muscle, is also involved in cell wound 
migration. In this pathway, migration is trigged by the ligands BMP2 and BMP4, 
which result in eNOS being phosphorylated [70]. While not conclusive, this evi-
dence, when taken all together, suggests that primary cilia may have a significant 
part to play in the wound healing process.
When tissues begin to repair themselves after a wound, clots must be dis-
solved to maintain proper blood flow. This is known as clot retraction and platelet 
inhibition. NO is known to inhibit platelet aggregation, secretion, adhesion, and 
fibrinogen binding; all through activation of guanylyl cyclase and cGMP, alongside 
the inhibition of thromboxane A2. By this mechanism, platelet aggregation and 
accumulation are reduced, enabling the clot to dissolve, and the wound to heal fully 
[71–73]. Given the evidence, it is possible that an interaction between primary cilia 
and NO could be important in the wound healing and repair processes.
4.3 Dopamine signaling
Hypertension present in polycystic kidney disease (PKD) patients in the later 
stages of the disease is made worse by increased kidney volume. However, hyper-
tension can also be seen in children, as well as the early stages of PKD, long before 
renal function starts to deteriorate. Some evidence suggests that an increase in 
sympathetic activation occurs in these patients, independently of their kidney func-
tion. Dopamine, an endogenous neuronal hormone that acts within the sympathetic 
nervous system, is confirmed to be involved in the regulation of blood pressure. 
Abnormal dopamine signaling can lead to hypertensive states in humans. Dopamine 
receptor 1 (D1) and dopamine receptor 5 (D5) receptors have been found to local-
ize to primary cilia [39, 74–76]. While there are no current therapies that target D1 
or D5, some studies using dopamine 1-like receptor subtypes showed vasodilatory 
effects in peripheral arteries [77].
The D5 receptor is thought to have both a chemosensory and mechanosensory 
role within primary cilia. Subjecting endothelial ciliary knockout cells pkd1−/− (lack-
ing PC-1), and Tg737orpk/orpk cells that have no cilia, to dopamine under static condi-
tions revealed a significantly subdued calcium influx when compared to the control 
cells. The researchers contributed this to the presence of underdeveloped cilia in 
the knockout cells, which would have less D5 receptors on them due to their smaller 
size. Under flow conditions with added dopamine, the mechanosensory function 
of the cilia knockout cells was restored, in comparison to the untreated knockout 
cells. Because calcium influx in these cell lines is associated with eNOS activation, 
the results of this study suggest a potential restoration of lost vasodilatory responses 
caused by a failed ciliary induction of NO biosynthesis [74]. There is additional 
evidence that suggests dopamine receptor 2 (D2) may also localize, or possibly 
get transported to, the primary cilia [78]. In one study, cerebral vasospasms were 
reversed with dopamine treatment; but when haloperidol, a D2 selective antagonist 
drug, was administered, the vasorelaxation failed to occur. It was also reported that, 
after administration of dopamine, a large increase in eNOS and iNOS expression 
was seen, and administration of haloperidol also blocked this effect [79].
D2 is also possibly transported to the primary cilia under specific conditions to 
mediate NOS activity within cells. Evidence supporting the role of ciliary dopamine 
receptors in the mediation of NO can be found in Autosomal Dominant Polycystic 
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Kidney Disease (ADPKD) patient clinical trials. ADPKD patients experience extra-
renal maladies that mainly affect their cardiovascular system, such as hypertension. 
The hypertensive state could be brought on, in part, by the inability of primary 
endothelial cilia to respond to alterations in blood pressure. This would cause a 
failure to synthesize NO. In a study conducted by Lorthioir et al., flow-mediated 
dilation of normotensive ADPKD patients was compared to that of adults without 
ADPKD. It was shown that ADPKD patients had significantly less vasodilation dur-
ing sustained flow increases, as well as a total loss of NO release when compared to 
those without ADPKD. When ADPKD patients were administered brachial infusions 
of 0.25–0.5 μg/kg/min of dopamine, there was an increase in flow-mediated dilation, 
and a statistically significant increase in dilatory response at the highest dose [80]. 
According to these results, dopamine receptors may facilitate a connection between 
primary cilia, NO, and blood pressure regulation in ADPKD patients [1].
4.4 Cell proliferation
Primary cilia also help regulate cell proliferation. As stated in the ciliogenesis 
section, the cilia extends from the basal body, which is composed of mother and 
daughter centrioles, and cilia are reabsorbed after cell cycle re-entry [12]. In cancer-
ous cell clusters, cilia are missing from the more prolific dividers, which suggests 
that despite not playing a major role in cell division, primary cilia are important for 
starting and stopping cell mitosis [81–84].
NO possibly plays a role in cell proliferation as well, in conjunction with primary 
cilia. NO has been proven to halt the cell cycle by preventing the transition from G1 
to S phase, in a dose dependent manner. The spike in NO is caused by an increase in 
free l-arginine, which is mediated by various cytokines. PC-1 is a known mediator 
of the JAK/STAT pathway by activating STAT3; when the cytosolic tail of PC-1 is 
cleaved upon once luminal flow halts, it can coactivate STAT-1, −3, and −6, along 
with JAK2. The PC-1 tail causes the cells to sensitize to cytokines and growth factor 
signaling, which then causes an exaggerated cellular response, which could poten-
tially lead to an increase in l-arginine [85, 86]. Through this mechanism, overly 
prolific cell division would be arrested.
The superfamily of TGF-β signaling provides a fascinating system of cellular 
crosstalk, in which the effects of the same ligand can be unique depending on the 
cell type and the physiological conditions. This family is composed of more than 30 
different ligand types of the TGF-β-activin-Nodal BMP subfamilies that can activate 
receptor serine/threonine kinases of types I and II (TGFβRI/II and BMP-RI/II, 
respectively). Ciliopathies widely overlap with phenotypes associated with aberrant 
TGF-β/BMP signaling. Prominent examples include structural heart defects associ-
ated with congenital heart disease (CHD) [87], suggesting that cardiac primary 
cilia may contribute to cellular events regulated by TGF-β/BMP signaling events 
during heart development. Moreover, different components of the TGF-β signalo-
some, including TGF-βRI, TGF-βRII, SMAD2/3, SMAD4, and SMAD7 are present 
at the cilia-centrosome axis. In a recent study, Feng et al. concluded that high salt 
(HS)-induced endothelial dysfunction and the development of salt-dependent 
increases in blood pressure (BP) were related to endothelial TGF-β signaling. 
Specifically, TGF-β-dependent ALK5 signaling increases endothelial NADPH 
oxidase-4 (NOX4), an enzyme that produces hydrogen peroxide, which limits NO 
bioavailability and ultimately promotes increased BP [88]. BMPRII contributes to 
cell proliferation through its interactions with primary cilia, eNOS, and NO. Using 
pulmonary artery endothelial cells, studies have shown that stimulation of BMPRII 
results in eNOS activation. BMPRII ligands BMP2 and BMP4 stimulate eNOS 
phosphorylation at a regulatory site via activation by protein kinase A. This eNOS 
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activation [68]. Moreover, data from recent studies on endothelial progenitor cells 
indicate that platelet-derived growth factor AA (PDGF-AA) might contribute a 
vital role in wound healing, possibly by its effects on angiogenesis through the PI3K/
Akt/eNOS signaling pathway [69]. Bone morphological protein (BMP) receptor 
II (BMPRII), which is highly expressed on endothelial cells in lung vasculature, 
as well as moderately expressed in smooth muscle, is also involved in cell wound 
migration. In this pathway, migration is trigged by the ligands BMP2 and BMP4, 
which result in eNOS being phosphorylated [70]. While not conclusive, this evi-
dence, when taken all together, suggests that primary cilia may have a significant 
part to play in the wound healing process.
When tissues begin to repair themselves after a wound, clots must be dis-
solved to maintain proper blood flow. This is known as clot retraction and platelet 
inhibition. NO is known to inhibit platelet aggregation, secretion, adhesion, and 
fibrinogen binding; all through activation of guanylyl cyclase and cGMP, alongside 
the inhibition of thromboxane A2. By this mechanism, platelet aggregation and 
accumulation are reduced, enabling the clot to dissolve, and the wound to heal fully 
[71–73]. Given the evidence, it is possible that an interaction between primary cilia 
and NO could be important in the wound healing and repair processes.
4.3 Dopamine signaling
Hypertension present in polycystic kidney disease (PKD) patients in the later 
stages of the disease is made worse by increased kidney volume. However, hyper-
tension can also be seen in children, as well as the early stages of PKD, long before 
renal function starts to deteriorate. Some evidence suggests that an increase in 
sympathetic activation occurs in these patients, independently of their kidney func-
tion. Dopamine, an endogenous neuronal hormone that acts within the sympathetic 
nervous system, is confirmed to be involved in the regulation of blood pressure. 
Abnormal dopamine signaling can lead to hypertensive states in humans. Dopamine 
receptor 1 (D1) and dopamine receptor 5 (D5) receptors have been found to local-
ize to primary cilia [39, 74–76]. While there are no current therapies that target D1 
or D5, some studies using dopamine 1-like receptor subtypes showed vasodilatory 
effects in peripheral arteries [77].
The D5 receptor is thought to have both a chemosensory and mechanosensory 
role within primary cilia. Subjecting endothelial ciliary knockout cells pkd1−/− (lack-
ing PC-1), and Tg737orpk/orpk cells that have no cilia, to dopamine under static condi-
tions revealed a significantly subdued calcium influx when compared to the control 
cells. The researchers contributed this to the presence of underdeveloped cilia in 
the knockout cells, which would have less D5 receptors on them due to their smaller 
size. Under flow conditions with added dopamine, the mechanosensory function 
of the cilia knockout cells was restored, in comparison to the untreated knockout 
cells. Because calcium influx in these cell lines is associated with eNOS activation, 
the results of this study suggest a potential restoration of lost vasodilatory responses 
caused by a failed ciliary induction of NO biosynthesis [74]. There is additional 
evidence that suggests dopamine receptor 2 (D2) may also localize, or possibly 
get transported to, the primary cilia [78]. In one study, cerebral vasospasms were 
reversed with dopamine treatment; but when haloperidol, a D2 selective antagonist 
drug, was administered, the vasorelaxation failed to occur. It was also reported that, 
after administration of dopamine, a large increase in eNOS and iNOS expression 
was seen, and administration of haloperidol also blocked this effect [79].
D2 is also possibly transported to the primary cilia under specific conditions to 
mediate NOS activity within cells. Evidence supporting the role of ciliary dopamine 
receptors in the mediation of NO can be found in Autosomal Dominant Polycystic 
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Kidney Disease (ADPKD) patient clinical trials. ADPKD patients experience extra-
renal maladies that mainly affect their cardiovascular system, such as hypertension. 
The hypertensive state could be brought on, in part, by the inability of primary 
endothelial cilia to respond to alterations in blood pressure. This would cause a 
failure to synthesize NO. In a study conducted by Lorthioir et al., flow-mediated 
dilation of normotensive ADPKD patients was compared to that of adults without 
ADPKD. It was shown that ADPKD patients had significantly less vasodilation dur-
ing sustained flow increases, as well as a total loss of NO release when compared to 
those without ADPKD. When ADPKD patients were administered brachial infusions 
of 0.25–0.5 μg/kg/min of dopamine, there was an increase in flow-mediated dilation, 
and a statistically significant increase in dilatory response at the highest dose [80]. 
According to these results, dopamine receptors may facilitate a connection between 
primary cilia, NO, and blood pressure regulation in ADPKD patients [1].
4.4 Cell proliferation
Primary cilia also help regulate cell proliferation. As stated in the ciliogenesis 
section, the cilia extends from the basal body, which is composed of mother and 
daughter centrioles, and cilia are reabsorbed after cell cycle re-entry [12]. In cancer-
ous cell clusters, cilia are missing from the more prolific dividers, which suggests 
that despite not playing a major role in cell division, primary cilia are important for 
starting and stopping cell mitosis [81–84].
NO possibly plays a role in cell proliferation as well, in conjunction with primary 
cilia. NO has been proven to halt the cell cycle by preventing the transition from G1 
to S phase, in a dose dependent manner. The spike in NO is caused by an increase in 
free l-arginine, which is mediated by various cytokines. PC-1 is a known mediator 
of the JAK/STAT pathway by activating STAT3; when the cytosolic tail of PC-1 is 
cleaved upon once luminal flow halts, it can coactivate STAT-1, −3, and −6, along 
with JAK2. The PC-1 tail causes the cells to sensitize to cytokines and growth factor 
signaling, which then causes an exaggerated cellular response, which could poten-
tially lead to an increase in l-arginine [85, 86]. Through this mechanism, overly 
prolific cell division would be arrested.
The superfamily of TGF-β signaling provides a fascinating system of cellular 
crosstalk, in which the effects of the same ligand can be unique depending on the 
cell type and the physiological conditions. This family is composed of more than 30 
different ligand types of the TGF-β-activin-Nodal BMP subfamilies that can activate 
receptor serine/threonine kinases of types I and II (TGFβRI/II and BMP-RI/II, 
respectively). Ciliopathies widely overlap with phenotypes associated with aberrant 
TGF-β/BMP signaling. Prominent examples include structural heart defects associ-
ated with congenital heart disease (CHD) [87], suggesting that cardiac primary 
cilia may contribute to cellular events regulated by TGF-β/BMP signaling events 
during heart development. Moreover, different components of the TGF-β signalo-
some, including TGF-βRI, TGF-βRII, SMAD2/3, SMAD4, and SMAD7 are present 
at the cilia-centrosome axis. In a recent study, Feng et al. concluded that high salt 
(HS)-induced endothelial dysfunction and the development of salt-dependent 
increases in blood pressure (BP) were related to endothelial TGF-β signaling. 
Specifically, TGF-β-dependent ALK5 signaling increases endothelial NADPH 
oxidase-4 (NOX4), an enzyme that produces hydrogen peroxide, which limits NO 
bioavailability and ultimately promotes increased BP [88]. BMPRII contributes to 
cell proliferation through its interactions with primary cilia, eNOS, and NO. Using 
pulmonary artery endothelial cells, studies have shown that stimulation of BMPRII 
results in eNOS activation. BMPRII ligands BMP2 and BMP4 stimulate eNOS 
phosphorylation at a regulatory site via activation by protein kinase A. This eNOS 
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stimulation results in increased NO bioavailability; loss of BMPRII function, 
therefore, is proposed to contribute to endothelial dysfunction [70].
5. Conclusion
Primary cilia and nitric oxide are both essential for normal tissue functions. 
While they can operate independently of one another, often their roles and cellular 
pathways are complementary. While this chapter only touched on a small portion 
of their possible connections, scattered research suggests a more complex linkage 
between the two in many more organ systems and cellular pathways. However, cur-
rent research on the direct links between primary cilia and NO are scarce. The aim 
of this chapter was to discuss the more well-known links between primary cilia and 
NO, and to initiate discussion leading to further examination of the topics covered. 
Revealing the connections between cilia and NO would provide insight into various 
ciliopathies and could reveal new targets for therapies.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Endogenous and Inhaled Nitric 
Oxide for the Treatment of 
Pulmonary Hypertension
Kazuo Maruyama, Junko Maruyama and Hirofumi Sawada
Abstract
Since the discovery of nitric oxide (NO) as a physiological substance produced 
in the endothelium, the impairment of endothelial NO production and reactiv-
ity of the pulmonary vasculature to NO have been described in animal models 
and patients with pulmonary hypertension (PH). The NO synthase-NO-cyclic 
guanosine monophosphate (cGMP) pathway is impaired in pulmonary arterial 
hypertension (PAH), pulmonary veno-occlusive disease (PVOD), pulmonary 
capillary hemangiomatosis (PCH), chronic obstructive pulmonary disease (COPD), 
and idiopathic pulmonary fibrosis (IPF). Pioneering clinicians conceived that NO 
can be administered to the lung by inhalation and used this strategy to treat PH 
in humans and acute hypoxic PH in animal models. Inhaled NO (iNO) selectively 
decreases pulmonary arterial pressure with no changes in systemic arterial pres-
sure. When iNO diffuses into the blood, it is converted to NO3−, thereby losing 
its vasodilatory effects. NO might then be recycled in hypoxic remote organs, 
where NO3− and NO2− are reduced to NO. In the present chapter, the metabolic 
fate of iNO, based on previous air pollution research in Japan, is discussed. Then, 
we describe recent clinical applications of iNO in pediatric patients with various 
diseases, including bronchopulmonary dysplasia (BPD), persistent PH of neonates, 
and congenital diaphragmatic hernia (CDH). We also summarize the role of iNO in 
the catheterization lab, including acute vasoreactivity testing to assess prognosis, 
indications for specific PH therapy, and operability of congenital heart disease.
Keywords: nitric oxide inhalation, pulmonary hypertension, metabolism of nitric 
oxide, nitrate, pediatric, neonate
1. Introduction
In 1980, Furchgott noted that the endothelium produces and releases a vasodila-
tory substance named endothelium-derived relaxing factor (EDRF), which diffuses 
into adjacent vascular smooth muscle cells and results in vascular relaxation [1]. 
In 1987, EDRF was identified as nitric oxide (NO) by Ignarro [2] and Moncada [3]. 
Murad reported the vasodilatory effect of nitroglycerin and NO formation from 
nitroglycerin in 1977 [4]. However, at the time, it was not known that endogenous 
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1. Introduction
In 1980, Furchgott noted that the endothelium produces and releases a vasodila-
tory substance named endothelium-derived relaxing factor (EDRF), which diffuses 
into adjacent vascular smooth muscle cells and results in vascular relaxation [1]. 
In 1987, EDRF was identified as nitric oxide (NO) by Ignarro [2] and Moncada [3]. 
Murad reported the vasodilatory effect of nitroglycerin and NO formation from 
nitroglycerin in 1977 [4]. However, at the time, it was not known that endogenous 
NO is produced and released as a physiological substance in the body, especially in 
the vascular endothelium.
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High-temperature combustion accelerates the reaction of oxygen and nitrogen 
in air to generate nitrogen oxides (NOx), such as NO, NO2, and N2O3. A common 
source of NOx is car engines, among which diesel engines have particularly high 
production. NO reacts with O2 to produce NO2, which is more toxic than NO. Thus, 
NOx, including NO, is considered an air pollutant. Accordingly, measuring instru-
ments and NO gas standards with known concentrations are needed to assess 
NO concentrations in air. In addition, NO gas has various industrial applications, 
including uses in the production of chemicals, semiconductors, integrated circuits, 
and memory storage elements and devices. Therefore, measuring instruments 
for NO and the delivery of NO from gas cylinders were developed long before the 
discovery of NO as a physiological substance in the body. NO is now recognized as 
a gas and a physiological substance. Pioneering clinicians determined that “as a gas, 
NO can be administered to the body through the lung.” It was fortunate for these cli-
nicians who first conducted NO inhalation in humans that measuring instruments 
for NO and NO cylinders were available.
The present chapter discusses endogenous NO production in normal and hyper-
tensive pulmonary vasculature, the history of NO inhalation for therapeutic use, 
the fate of inhaled NO (iNO), effects of iNO in remote organs other than the lung, 
and iNO as a therapeutic strategy in pediatrics.
2.  Endogenous NO and its role in the pathogenesis and pathophysiology 
of pulmonary hypertension
NO is primarily synthesized by endothelial NO synthase (eNOS, NOSIII) in 
pulmonary vascular endothelial cells. NO reacts with a receptor, soluble guanylate 
cyclase (sGC), in adjacent smooth muscle cells. Activated sGC produces cGMP, 
which stimulates protein kinase G (PKG) and exerts many physiological effects, 
including pulmonary vascular relaxation. The inhibition of NO production by 
l-NMMA (N-omega-monomethyl-l-arginine, a NOS inhibitor) decreases pulmo-
nary flow in conscious healthy adults [5]. A deficiency in eNOS, but not iNOS or 
neuronal NOS, induces augmented hypoxic pulmonary vasoconstriction and a lack 
of endothelium-dependent vasodilation [6]. These findings support the important 
roles of the eNOS-NO-cyclic guanosine monophosphate (GMP) pathway in main-
taining pulmonary circulation. Alteration of eNOS expression and/or function may 
contribute to decreased NO synthesis in pulmonary hypertension (PH). Human PH 
has many different etiologies. Depending on the pathological state, patients may 
exhibit alterations in the eNOS-NO-cGMP pathway.
2.1 Effects of NO in isolated pulmonary arteries
The effects of NO differ among cell types. NO induces relaxation in vascular 
smooth muscle cells, prevents aggregation and adhesion in platelets, prevents adhe-
sion in leucocytes, and acts as a neurotransmitter in synapses. Thus, NO regulates 
various cell functions. In the vasculature, NO is released from endothelial cells, 
reaches adjacent smooth muscle cells, and causes vascular relaxation, indicating 
that it functions in intercellular signaling. Among the physiological roles of endog-
enous NO, vascular relaxation was discovered first.
In isolated rat main pulmonary arterial rings precontracted with prostaglandin 
F2α (PGF2a), acetylcholine (ACh) induces relaxation in endothelium-preserved 
pulmonary arteries, but not in endothelium-denuded pulmonary arteries, suggest-
ing that the endothelium in pulmonary arteries produces a relaxation-inducing 
substance in response to acetylcholine (Figure 1(a) and (b)).
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In pulmonary arteries isolated from experimental PH models (chronic hypoxic 
PH in rat), the relaxation response to acetylcholine (ACh) is depressed, as observed 
in endothelium-denuded arteries, suggesting that endothelial function is impaired 
in PH arteries. Both ACh- and sodium nitroprusside (SNP, an NO donor)-induced 
relaxations were impaired in pulmonary arteries from rats with chronic hypoxic 
PH, suggesting that NO-induced relaxation is depressed in hypertensive pulmonary 
arteries [7, 8] (Figure 2). However, the magnitude of impairment seems to be 
higher in ACh-induced endothelium-dependent relaxation than in SNP-induced 
endothelium-independent relaxation [7].
Figure 1. 
(a) Acetylcholine induces relaxation in endothelium-preserved pulmonary arterial rings. Pulmonary artery 
rings were obtained from normal control air rats. Rings were suspended in an 20 ml organ bath, and isometric 
tension was measured. Relaxation responses to acetylcholine (Ach) in endothelium-preserved (END+) 
and endothelium-denuded (END-) rings of the extrapulmonary artery were obtained. Endothelium was 
removed by gently rubbing luminal surface by fine stainless wire in endothelium-denuded rings. Rings were 
precontracted with prostaglandin F2a (PGF2a). Relaxation induced by 10−4 M papaverine (Pap 4) was taken 
as 100%. Bars mean standard error. Relaxation responses to ACh were abolished in the endothelium-denuded 
pulmonary arterial rings, showing that pulmonary vascular endothelium releases vasorelaxation substance 
named endothelium-derived relaxing factor (EDRF). The absence of the endothelium was confirmed by 
scanning electron micrography (b). END−, endothelium-denuded rings; END+, endothelium-preserved rings; 
8, 10−8 mol/L, the same for 7, 6, 5, and 4. (B) Scanning electron micrograph of the endothelium-preserved 
pulmonary artery and endothelium-denuded pulmonary artery. Endothelium was removed by gently rubbing 
luminal surface by fine stainless wire. Left: luminal surface of the endothelium-preserved pulmonary artery. 
Right: luminal surface of the endothelium-denuded pulmonary artery.
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The relaxation responses to SNP are caused by the liberation of NO from SNP. To 
determine the vasodilatory effects of NO directly, a NO solution was made by bub-
bling 10% NO in pure N2 into deoxygenated distilled water. Although depressed, 
the relaxation responses were indeed induced by NO in hypertensive pulmonary 
arteries [7] (Figure 3). Importantly, iNO exhibits selectivity, resulting in vasodila-
tion in pulmonary arteries (Figure 4) when administered by inhalation through 
the trachea. The intravenous injection of NO donors simultaneously decreases both 
pulmonary and systemic arterial pressure.
2.2 Pulmonary arterial hypertension
2.2.1 eNOS in pulmonary arterial hypertension in humans
Although the role of the eNOS-derived NO-related pathway in pulmonary arte-
rial hypertension (PAH) has been determined, its pathophysiology remains unclear. 
eNOS plays a key role in this pathway. Giaid et al. detected decreased eNOS protein 
expression in human lungs with PAH [9]. Additionally, exhaled NO has been found 
to be lower in patients with PAH than in controls [10]. Subsequent studies have 
reported increased eNOS protein expression in plexiform lesions in PAH [11] and 
increased eNOS activity in idiopathic PAH (IPAH) lungs, despite no change in NOS 
expression [12]. The membrane protein caveolin-1 (CAV1) is a crucial negative 
regulator of eNOS activity. The CAV1 expression is decreased in IPAH lungs, which 
might lead to persistent eNOS activation, the accumulation of dysfunctional (i.e., 
uncoupled) eNOS, the formation of peroxynitrite, and the impairment of PKG 
Figure 2. 
The relaxation responses are depressed in isolated pulmonary arterial rings from chronic hypoxic 
pulmonary hypertensive rat. Pulmonary artery rings were obtained from normal control air rats and rats 
exposed to 10 days of hypoxia with chronic hypoxic pulmonary hypertension (PH). Isometric tension was 
measured. Relaxation responses to acetylcholine (ACh) in prostaglandin F2a (PGF2a)-precontracted rings 
of extrapulmonary were recorded. Relaxation induced by 10−4 M papaverine (Pap 4) was taken as 100%. 
Relaxation responses to ACh were depressed in rings from rats with chronic hypoxic PH, showing that the 
release of vasorelaxation substance is impaired in PH rings. Although the relaxation responses to sodium 
nitroprusside (SNP) are impaired in pH rings compared with control, this means that there was a room where 
SNP could cause relaxation in PH rings from chronic hypoxic PH.
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Figure 3. 
NO solution (0.16–0.2 mM NO) caused the relaxation responses in isolated normal and pulmonary 
hypertensive arterial rings. Pulmonary artery rings were obtained from normal control air rats (A), rats 
exposed to 10 days of hypoxia with chronic hypoxic pulmonary hypertension (PH) (B), and rats after 
28 days of recovery in room air from chronic hypoxia (C). NO solution was made by bubbling 10% NO 
through deoxygenated distilled water, which results in 0.16–0.2 mM concentration. Aliquots (0.5 ml) of this 
solution were applied to the organ bath. Papaverine (Pap) was introduced to obtain maximal relaxation. 
Relaxation responses to NO solution to prostaglandin F2a-precontracted rings were recorded. (A) 
NO-induced relaxation in pulmonary artery rings from normal rats. (B) Response to NO was depressed in 
pulmonary artery rings from chronic hypoxic rats. (C) The relaxation response returned to normal after 
28 days of recovery from chronic hypoxic pulmonary hypertension. The result of (B) showed that NO could 
dilate hypertensive pulmonary vascular smooth muscles, although depressed compared to normal.
Figure 4. 
Inhaled NO as selective pulmonary vasodilator in pulmonary hypertensive rats. A pulmonary artery catheter 
was introduced via the right external jugular vein into the pulmonary artery by a closed chest technique. 
Pulmonary arterial pressure(PAP) was recorded with rat fully awake in a pulmonary hypertensive rat (19 
days after the single injection of monocrotaline). About 20 ppm NO inhalation decreased PAP with no change 
of arterial pressure. When NO inhalation was discontinued, the PAP returned to baseline.
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exposed to 10 days of hypoxia with chronic hypoxic pulmonary hypertension (PH) (B), and rats after 
28 days of recovery in room air from chronic hypoxia (C). NO solution was made by bubbling 10% NO 
through deoxygenated distilled water, which results in 0.16–0.2 mM concentration. Aliquots (0.5 ml) of this 
solution were applied to the organ bath. Papaverine (Pap) was introduced to obtain maximal relaxation. 
Relaxation responses to NO solution to prostaglandin F2a-precontracted rings were recorded. (A) 
NO-induced relaxation in pulmonary artery rings from normal rats. (B) Response to NO was depressed in 
pulmonary artery rings from chronic hypoxic rats. (C) The relaxation response returned to normal after 
28 days of recovery from chronic hypoxic pulmonary hypertension. The result of (B) showed that NO could 
dilate hypertensive pulmonary vascular smooth muscles, although depressed compared to normal.
Figure 4. 
Inhaled NO as selective pulmonary vasodilator in pulmonary hypertensive rats. A pulmonary artery catheter 
was introduced via the right external jugular vein into the pulmonary artery by a closed chest technique. 
Pulmonary arterial pressure(PAP) was recorded with rat fully awake in a pulmonary hypertensive rat (19 
days after the single injection of monocrotaline). About 20 ppm NO inhalation decreased PAP with no change 
of arterial pressure. When NO inhalation was discontinued, the PAP returned to baseline.
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kinase activity via tyrosine nitration [12]. Increased eNOS activity and/or expres-
sion might not be associated with NO production in PAH.
2.2.2 eNOS-NO pathway in animal models of pulmonary arterial hypertension
Animal studies using a monocrotaline (MCT)-induced PAH rat model, which 
is characterized by pulmonary endothelial damage and perivascular inflamma-
tion in the early pathological stage, have shown decreased eNOS expression [13] 
and/or phosphorylated eNOS activity [14] as well as decreases in sGC and 
PKG. Vasodilation induced by ACh, an endothelium-dependent NO-related vaso-
dilator, was also impaired. Another adult rat model of severe PAH with precapillary 
obliterative lesion (SU/Hx model) shows similarities in the pulmonary vascular 
pathology to that of PAH in adults. This SU/Hx model, induced by combined 
SUGEN5416 (a vascular endothelial growth factor receptor II antagonist) and 
exposure to chronic hypoxia, showed a reduction of ACh-induced NO produc-
tion and/or release in pulmonary arteries [15]. Another recent study has reported 
decreased CAV1 expression in the same model [16]. eNOS also translocates from cell 
surface caveolae to cytoplasmic and perinuclear regions in pathological state [17]. 
Consequently, the amount of NO production is decreased. Accordingly, the patho-
genesis and progression of PAH may be partially induced by endothelial dysfunc-
tion associated with suppression of the eNOS-NO-related pathway.
2.2.3 eNOS-NO-cGMP pathway and BMPRII
Genetic variants in the eNOS-NO-cGMP pathway might cause PAH. CAV1 plays 
an important role in NO signaling in PAH. Mutations in CAV1 have been identified 
in PAH [18]. The gene encoding bone morphogenetic protein receptor 2 (BMPRII) 
is frequently mutated in heritable PAH [19, 20] and adult IPAH [19, 21]. BMPRII 
is a member of the transforming growth factor (TGF)-β receptor superfamily, 
localized to caveolae, and interacts with CAV1 in vascular smooth muscle cells 
[22, 23]. Recent studies have demonstrated that BMPRII deficiency promotes 
SRC-dependent caveolar trafficking defects [24]. In addition, CAV1-deficient mice 
have shown reduced BMPRII expression after exposure to chronic hypoxia [16]. In 
MCT-treated pulmonary arterial endothelial cells, BMPRII was increasingly trapped 
intracellularly together with increased trapping CAV1 and eNOS. These results sug-
gest that NO-cGMP-related dysfunction and BMPRII deficiency are closely related 
to and play a significant role in the pathogenesis of PAH.
2.3  Pulmonary veno-occlusive disease and pulmonary capillary 
hemangiomatosis
Pulmonary veno-occlusive disease (PVOD), classified as a PAH subgroup, is 
inextricably associated with pulmonary capillary hemangiomatosis (PCH) [25]. 
Pulmonary vascular lesions in this condition are mainly detected in postcapillary 
venules and veins but are also found in pulmonary capillaries and arteries [25]. The 
pathogenesis is heterogeneous and poorly understood [25]. These are rare diseases, 
and few studies have focused on the pathogenesis and pathophysiology. Kradin 
et al. reported that eNOS expression in abnormal capillary lesions is significantly 
decreased in patients with PCH with pulmonary vascular remodeling and con-
comitant pulmonary hypertension and is minimally decreased or not decreased 
in patients without pulmonary vascular remodeling [26]. These results suggest 
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that the alteration of eNOS expression is associated with the pathogenesis of these 
complicated conditions. Further experiments are necessary to determine the precise 
role of the eNOS-NO-cGMP pathway in PVOD/PCH.
Biallelic mutations in eukaryotic translation initiation factor 2α kinase 4 
(EIF2AK4) have been identified in familial and idiopathic PVOD/PCH. EIF2AK4 
encodes general control nonderepressible 2 (GCN2) [27]. The most common 
experimental models of these conditions are mitomycin C (MMC)-treated rats and 
mice [28]. Interestingly, MMC dose dependently induces pulmonary GCN2 deple-
tion [28]. EIF2AK4 mutations are also found in sporadic PVOD/PCH [27]. Mutation 
carriers have distinct histological features, including strong muscular hyperplasia of 
the interlobular septal vein as well as arterial severe intimal fibrosis [29]. EIF2AK4 
is activated by amino acid depletion. Because l-arginine, a substrate of NOS, is 
depleted during NO production, EIF2AK4 activation can be induced by eNOS activ-
ity associated with l-arginine depletion.
2.4 Lung disease-related and/or alveolar hypoxia-induced pH
The pathophysiologic features of lung diseases include chronic obstructive 
pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) and mixed 
pathologic diseases, including combined pulmonary fibrosis and emphysema. All 
involve alveolar hypoxia and subsequent hypoxic pulmonary vasoconstriction. 
eNOS expression is upregulated in acute hypoxia in rat lungs [30]. eNOS expression 
increases in a time-dependent manner in rats during the development of hypoxia-
induced PH [31–33], while eNOS activity is impaired [34]. The production of tetra-
hydrobiopterin (BH4), an obligatory cofactor for generating the active dimer form 
of eNOS, was altered in hypoxic conditions [34]. An imbalance between BH4 and 
dihydrobiopterin (BH2) may cause eNOS uncoupling and inactive monomer forma-
tion [34]. Several studies have reported decreased eNOS expression and/or activity 
in patients with COPD [35, 36], with severity of endothelial dysfunction correlated 
with degree of airflow obstruction [36]. eNOS is also absent in pulmonary arteries 
of patients with IPF [37]. As the histological features of this disease differ from 
those of COPD, the pathogenesis of IPF-induced PH may include a multifactorial 
and complex process involving proinflammatory cytokines and growth factors.
3. Inhaled nitric oxide
3.1 Inhaled NO as a selective pulmonary vasodilator
In 1988, at the international conference of the American Thoracic Society, 
Higenbottam presented his team’s paper titled “Inhaled endothelium-derived relax-
ing factor (EDRF) in primary pulmonary hypertension (PPH),” including the first 
description of NO inhalation in humans with pulmonary arterial hypertension for 
laboratory use [38]. In 1991, Lancet published the study [39], showing that 40 ppm 
NO inhalation selectively reduces PAP, with no changes in systemic pressure. 
Frostell et al. also showed that inhaled NO (5–80 ppm) causes selective pulmonary 
arterial dilatation, without changes in systemic arterial pressure in sheep [40], 
where PAP elevation was induced by hypoxic pulmonary vasoconstriction. Both 
research groups referenced the studies by Yoshida, Kasama, and Kitabatake about 
the metabolic fate of iNO [41, 42] because toxicity and retention in the human body 
should be minimal. NO has been a focus in air pollution research and thus provides 
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a basis for work by clinicians evaluating NO inhalation in humans. In rats with 
chronic hypoxia- and MCT-induced PH, iNO results in a decrease in PAP with no 
changes in systemic arterial pressure [43–45] (Figure 4).
3.2 Clinical effects of iNO
iNO dilates the pulmonary vasculature by NO combining with guanylate 
cyclase Fe in pulmonary vascular smooth muscle cells. Most NO diffuses into the 
blood at alveoli, where it reacts with the Fe of oxygenated hemoglobin (oxy-Hb, 
O2Hb, O2Hb(Fe2+)) in red blood cells and is converted to NO3−. When NO reacts 
with oxy-Hb Fe2+ or combines with the Fe2+ of deoxygenated Hb (deoxy-Hb, 
deoxy-Hb(Fe2+)) in red blood cells, iNO does not have direct vasodilatory effects 
because it reacts or combines with Hb Fe2+ and becomes unable to combine with 
guanylate cyclase Fe of smooth muscle cells in systemic arteries. Thus, iNO is 
a selective pulmonary vasodilator, causing decreased PAP with no changes in 
systemic pressure (Figure 4).
The clinical use of NO inhalation is aimed at inducing selective pulmonary arte-
rial dilation and treating PH and right ventricular failure. NO inhalation is also used 
to test pulmonary vascular reactivity in catheterization labs, which will be discussed 
in the last section of this chapter. Improved arterial oxygenation is also expected in 
patients with high intrapulmonary shunting [46]. Thus, the main target of iNO is 
lung and pulmonary circulation. In addition, iNO effects on remote organs, such as 
the kidney [47], liver [48, 49], heart [50], and muscle [51], have been investigated, 
with iNO shown to ameliorate inflammation and ischemia-reperfusion injury.
3.3 Substances that react with NO
NO reacts or combines with transition metal ions, such as thiols (–SH, –SS–, and 
HS–). Many enzymes and substances involved in regulating cell function include 
in their structure Fe, a transitional metal, thus suggesting its importance as an NO 
target. Because hemoglobin (Hb) and guanylate cyclase contain heme, which includes 
Fe in its structure, NO reacts or combines with Hb and guanylate cyclase. NO also 
combines with enzymes containing Fe–S in their structure, and combined NO (nitra-
tion) and Fe–S can prevent enzymatic activity. High concentrations of NO induce cell 
damage, which presumably result from this enzymatic dysfunction. Thus, NO is a 
double-edged sword. Although an appropriate amount is important for regulating cell 
function, an excess dysregulates cell function and causes damage.
RS–NO is a complex of SH– and NO. Nitrosothiol is a thionitrite includ-
ing S-nitroso-albumin, where NO combines with cysteine, a component of 
albumin. –SH is a component of amino acids, peptides, and proteins. NO binds 
to –SH, forming S-nitrosothiol, 96% of which is S-nitrosoprotein. About 82% of 
S-nitrosoprotein is serum S-nitrosoalbumin. Thus, endogenous NO circulates in the 
form of S-nitrosoalbumin [52].
NO targets are transition metal ions, oxygen, nucleophilic centers (thiols, 
amides, carboxyls, and hydroxyls), and free radicals. iNO targets are (Figure 5) also 
transition metal ions, namely, in the guanylate cyclase Fe, Hb Fe, iron-sulfur (Fe-S) 
center. Other targets include oxygen (gaseous oxygen in the airway and alveoli), 
dissolved oxygen in the tissue and body fluids, the nucleophilic center of organic 
compounds (–S–S– and –SH), and free radicals (reactive oxygen species produced 
in leucocytes and macrophages). Among these substances that react with iNO, The 
main target of an approved medical iNO gas is guanylate cyclase Fe in pulmonary 
vascular smooth muscle cells.
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3.4 Metabolic fate of iNO
3.4.1 Oxidation and reduction of NO
Oxidation refers to electron loss and reduction to electron gain. Reducing agents 
release electrons, whereas oxidizing agents receive electrons. The term redox is a 
combination of “reduction and oxidation reaction.” Reduction and oxygenation 
occur simultaneously so that when a reducing agent is oxidized, an oxidizing agent 
is also reduced. Nitrogen monoxides involve an array of species: NO+ (nitrosonium), 
NO·, and NO− (nitroxyl anion) [53]. Among these, NO· has a single electron, and its 
removal forms NO+, whereas its addition yields NO−. NO· is electrically neutral, which 
contributes to its free diffusibility in aqueous medium and across cell membranes.
The main NO· targets are oxygen and transition metal ions. The various redox 
forms of oxygen, such as superoxide (O2−) and (di)oxygen, are candidates in both 
the gas phase and aqueous solution. Metalloproteins, such as heme-containing 
protein and non-heme-containing protein, and iron-sulfur clusters also react with 
NO·.
iNO reacts with oxy-Hb. NO oxidizes oxy-Hb to form MetHb. In other words, 
MetHb is oxidized oxy-Hb. Oxidized iron (MetHb) species do not catch NO, and 
iNO during cardiopulmonary bypass (CPB) decreases acute kidney injury [47]:
  O 2 Hb ( Fe 2+ ) 
 [oxy‐Hb] 
 + NO →  Hb ( Fe 3+ ) 
 [MetHb] 
 +  NO 3 
−
                  (1)
3.4.2 NO and Hb
NO reacts or combines with Hb in three ways: (1) NO combines with in the 
heme Fe to form NOHb (nitrosyl Hb), a metal nitrosyl species; (2) NO− combines 
Figure 5. 
The substances in the lung to react or combine with iNO. NO reacts with Fe in the guanylate cyclase (GC) and 
induces cyclic GMP and subsequent pulmonary vascular relaxation; NO reacts with Fe2+ in O2Hb and forms 
MetHb and NO3−; NO and Fe2+ in deoxy-Hb combine in NOHb; NO and O2 combine in NO2; NO and O2- 
combine in ONOO-; NO and OH- combine in NO2-; NO and thiol (sulfhydryl group, -SH group), amine, and 
iron-sulfur (Fe-S) center combine in nitrosothiol, nitrosamine, and Fe-S NO, respectively. RSH is a compound 
including SH group. S-nitro-Hb is combination of NO and SH in the cysteine in the Hb beta subunit. Reactive 
oxygen species (O2−, OH−) are produced in leucocytes and macrophages.
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with amines in Hb to form S-nitroso-Hb, a nitrosamine, where NO combines with 
cysteine in the beta subunit of Hb; and (3) O− or NO+ combines with the sulfhy-
dryl center (-SH) in Hb. NO reacts with oxy-Hb and combines with deoxy-Hb. 
If NO reacts with oxy-Hb (Fe2+), MetHb (Fe3+) and nitrate (NO3−) are formed. If 
NO combines with deoxy-Hb (Fe2+), NOHb (Fe2+) is formed, after which NOHb 
(Fe2+) reacts with O2 to form MetHb (Fe3+) and NO3−. MetHb (Fe3+) is reduced to 
deoxy-Hb (Fe2+) by MetHb reductase. The depletion of MetHb reductase or high 
production of MetHb causes methemoglobinemia. NO3− is excreted in the urine 
(Figures 6, 7).
In an in vitro experiment, Wennmalm [54] incubated NO with arterial and 
venous blood and measured MetHb, NOHb, NO3−, and NO2−. The reaction of NO 
with O2Hb was rapid in the arterial blood (oxygen saturation 94–99%). NOHb was 
low in arterial blood and high in venous blood (oxygen saturation 36–86%). These 
results suggest that O2Hb (oxy-Hb) gives O2 to NO making NO3−. In contrast, 
deoxy-Hb directly combines with NO making NOHb in the absence of oxy-Hb 
(i.e., in the presence of deoxy-Hb). The NO and oxy-Hb reaction is completed in 
100 ms [55].
3.4.3 NOHb
Nakajima and Oda have shown that the NOHb concentration is 0.13% in the 
blood during 20 min of 10 ppm NO inhalation [56]. This low concentration suggests 
the rapid turnover of NOHb, in which NOHb is presumably an intermediate in the 
conversion from NO to NO2− and NO3−.
3.4.4 Conversion of NO2− to NO3−
When 5 mM NO2− is added to human blood, NO3− changes are detected within 
10 min [57]. The intravenous injection of sodium nitrite to rabbits results in the 
rapid disappearance of NO2−. After the intratracheal injection of 13NO2−, 70% of 
13NO2− changed to 13NO3−, and 26% remained as 13NO2− [58]. These observations 
suggest that NO2− is converted to NO3− in red blood cells [59]. NO2− and NO3− are 
stable and unchanged in plasma without red blood cells.
Figure 6. 
Reaction of NO with Hb. NO reacts with Fe2+ of oxy-Hb making MetHb and NO3− and combines with 
deoxy-Hb making NOHb. NOHb reacts with O2 making MetHb and NO3−.
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3.4.5 No retention of iNO in the body
A clear understanding of the fate of iNO is critical for its clinical use in humans. 
As previously mentioned, the metabolic fate of iNO was examined in the early 
1980s, and it was found that retention of iNO in the body was lacking (Figure 7).
An inhalation study of 15NO in rats investigated the metabolism of iNO. In the 
carcasses, 1.6% of total inhaled 15N was detected, similar to the level of natural 
15N. This result suggests that iNO largely does not remain in the body. About 55% of 
total inhaled 15N was recovered in urine [41, 42], including 45% as nitrates and 10% 
as urea (Figure 7). About 10% of total inhaled 15N was recovered as undetermined 
nitrogen compounds in feces. The remaining 35% was not recovered but is assumed 
to be N2 produced from the reduction of NO3− → NO2− → N2 by stomach flora.
3.5 iNO effects in remote organs
During cardiopulmonary bypass(CPB), hemolysis causes an increase in Hb 
plasma concentration due to the destruction of red blood cells. Hb includes oxy-Hb 
and deoxy-Hb. Oxy-Hb causes vasoconstriction, which is partly due to the depletion 
of NO available to induce vascular smooth muscle relaxation. NO is produced in and 
released from endothelial cells, some of which reaches adjacent vascular smooth 
muscles, causing vasorelaxation, and some of which diffuses into the plasma. If the 
amount of oxy-Hb in the plasma increases, the binding of NO to oxy-Hb increases, 
resulting in less NO reaching adjacent smooth muscle cells. Thus, the presence of 
large amounts of oxy-Hb might decrease NO availability in vascular smooth muscle 
cells (Figure 8).
Figure 7. 
Metabolic fate of NO. Almost all inhaled NO is converted to NO3−. Forty-five percent of NO3− is excreted in 
urine; 10% is changed to nitrogen compound except NO3− and NO2− and excreted in feces; 10% is changed to 
urea through the digestive tract and liver and excreted in urine. The rest will be changed to N2 in the stomach 
and discharged outside of the body.
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Acute kidney injury is a common complication after cardiac surgery with pro-
longed CPB. Because oxygen tension is high during CPB, plasma oxy-Hb exhibits 
substantial hemolysis, causing vasoconstriction in the kidney. Recently, NO was 
demonstrated to decrease the occurrence of acute kidney injury and chronic kidney 
disease 1 year postoperatively [47]. NO inhalation at 80 ppm was started at the onset 
of CPB via a CPB machine and was continued after CPB via a mechanical ventilator 
for 24 h or less if patients were ready to be extubated early. Under NO inhalation, 
oxy-Hb was converted to MetHb, which recovered NO availability to vascular smooth 
muscle cells due to the decrease in oxy-Hb. Thus, exogenous NO inhalation might 
increase endogenous NO availability to counteract renal vasoconstriction during CPB.
In brief, the reduction of nitrite and nitrate produces NO (Figure 9). Nitrite is 
reduced by deoxy-Hb, respiratory chain enzymes, xanthine oxidoreductase, deoxy-
genated myoglobin, and protons, facilitating the transfer of protons to NO2− and 
thereby producing NO. These reactions are intensified under acidic and hypoxic 
states. After iNO is converted to NO2− and NO3−, NO can be recycled from nitrite 
and used to protect organs from ischemia-reperfusion injury [48, 51].
In liver transplantation, the inhalation of 80 ppm NO until reperfusion amelio-
rates apoptosis, attenuated increases of liver enzymes, and enhanced the recovery 
of coagulation factors [48].
In orthopedic knee surgery, NO inhalation prevented increases in the adhesion 
molecule expression on granulocytes, plasma selectin levels, and NF-κB expres-
sion in quadriceps muscles [51]. NO inhalation was started before the tourniquet 
application and was continued during reperfusion until the completion of surgery.
Figure 8. 
NO formed in the endothelium is scavenged by plasma oxygenated Hb. (A) NO produced in the endothelium 
diffuses into adjacent smooth muscle cells and binds with guanylate cyclase. (B) If O2Hb (Fe2+) increases, NO 
produced in the endothelium diffuses into the blood and scavenged by O2Hb (Fe2+), decreasing the amount of 
NO diffused into smooth muscle cells. (C) If O2 Hb(Fe2+) is converted to MetHb(Fe3+) by NO inhalation, NO 
is not scavenged, which recovers the amount of NO diffusing to the smooth muscle side.
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4. Update on the clinical application of iNO in pediatric patients
After NO was identified as an endothelial cell-derived relaxation factor and fol-
lowing preclinical studies, iNO therapy has been studied extensively in multicenter 
randomized trials as well as in early pilot studies of infants with severe hypoxemia 
associated with PH or infants with congenital diaphragmatic hernia (CDH) [60]. 
These studies have demonstrated improved oxygenation and reduction in the 
need for extracorporeal membrane oxygenation (ECMO) therapy, leading to the 
approval of iNO therapy by the Food and Drug Administration for use in patients 
at >34-week gestation with hypoxemic respiratory failure and persistent PH of the 
newborn (PPHN). Over the last two decades, the discussion of its application has 
been extended to premature infants and acute pulmonary vascular response testing 
to assess indications for specific pulmonary vasodilator therapy for patients with 
PAH or operability for children with congenital heart disease.
4.1  Role of inhaled NO in the prevention of bronchopulmonary dysplasia in 
premature newborns
Bronchopulmonary dysplasia (BPD), which is characterized by impaired 
pulmonary development resulting from insults affecting the immature lung, 
including inflammation, hyperoxia, and mechanical ventilation, is associated with 
high mortality and adverse long-term neurological and respiratory outcomes in 
infants born very preterm. Although the effectiveness of iNO for the treatment of 
PPHN is largely due to its function as a selective pulmonary vasodilator, labora-
tory observations also suggest other important biological effects of NO, such as 
roles in decreasing lung inflammation (e.g., lung vascular protein leak; pulmonary 
neutrophil accumulation) [61], reducing oxidant stress [62], decreasing pulmonary 
vascular cell proliferation [63], and enhancing alveolarization and lung growth 
[64–66]. These observations have led to investigations into the use of iNO to 
prevent the development of BPD in premature newborns. In an initial randomized, 
Figure 9. 
Recycle of NO from nitrite and nitrate. Nitrate is reduced to nitrite, and subsequent reduction of nitrite forms 
NO. Reducing substances are deoxy-Hb [Hb(Fe2+)], myoglobin [Mb(Fe2+)], xanthine oxidase, hydrogen ion 
(H+), and cytochrome enzymes (Fe2+). NO2− is reduced by deoxy-Hb(Fe2+) to NO showing stoichiometric 
relation. Please count the number of O before and after the reduction responses.
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placebo-controlled study in a single center, 7 days of iNO prevented chronic lung 
disease in premature infants [67]. Despite promising findings in some subsequent 
studies showing a reduction in BPD in premature newborns [68, 69], later trials 
did not confirm the beneficial effects [70]. Meta-analyses of these studies have not 
found evidence for a net improvement in either chronic lung disease or develop-
mental sequelae [71], leading to the conclusion by the National Institutes of Health 
Consensus Development Conference [72] and the American Academy of Pediatrics 
Committee on the Fetus and Newborn [73] that the use of iNO to prevent BPD is 
not supported by available evidence [74].
4.2 iNO for the treatment of severe pulmonary hypertension in preterm infants
In addition to the use of iNO for BPD prevention, its use in preterm infants 
for acute management of severe hypoxemic respiratory failure has been dis-
cussed. Several case series have described responses to iNO in premature new-
borns with PPHN associated with prolonged oligohydramnios and pulmonary 
hypoplasia. Chock et al. evaluated a subset of 12 premature newborns enrolled in 
the Preemie Inhaled Nitric Oxide Trial with pulmonary hypoplasia after preterm 
premature rupture of membranes (PPROM) [75]. Six infants were treated with 
iNO with a mortality rate of 33% compared with 67% mortality for six infants 
in the placebo control group. Shah and Kluckow described outcomes for infants 
with PPROM and reported that survival improved from 62 to 90% after the 
introduction of iNO and high-frequency oscillatory ventilation [76]. Semberova 
et al. reported a series of 22 premature infants with a history of PPROM, pul-
monary hypoplasia, and PPHN who were treated with iNO, with a survival rate 
of 86% [77]. Thus, iNO therapy may have important benefits in subgroups of 
preterm infants with severe PH, especially in patients with oligohydramnios 
and lung hypoplasia. Further studies of the precise effects of iNO in premature 
neonates are needed.
4.3 Role of iNO in newborns with congenital diaphragmatic hernia
iNO in neonates with CDH has been evaluated in three randomized trials 
[78–80]. Finer and Barrington performed a Cochrane Review [81] of the use of iNO 
for respiratory failure in infants born at or near term. They concluded that while 
iNO might transiently improve oxygenation, its use is not recommended for infants 
with CDH because the risks of a composite of either death or ECMO are similar to 
or worse than those of controls [82].
Based on this evidence, iNO cannot be recommended for the routine treat-
ment of PH in patients with CDH. However, iNO continues to be regularly used 
for CDH. Indeed, iNO was used at some point during preoperative stabilization 
in 36% (191/526) of infants with CDH from the population-based CAPSNet 
database. The ability of iNO to improve oxygenation and reduce the need for 
ECMO in non-CDH patients with PH explains its continued use in patients with 
CDH. The lack of a response to pulmonary vasodilators in CDH is speculated to 
be likely due to left atrial/pulmonary vein hypertension rather than to functional 
changes in the pulmonary arterial vasculature [83]. A recent study suggests that 
the response to pulmonary vasodilators in neonates with CDH may be limited 
by the severity of left ventricular (LV) dysfunction and/or hypoplasia, which 
impairs LV filling. Careful echocardiographic assessment, therefore, may guide 
treatment by identifying patients who may benefit from pulmonary vasodilators, 
including iNO [83].
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4.3.1  Acute vasoreactivity testing to assess prognosis and indications for specific PH 
therapy
The prognosis of children with PAH has improved in the past decade owing 
to new therapeutic agents and aggressive treatment strategies [84]. In idiopathic 
or heritable PAH (I/H-PAH), acute vasodilator testing (AVT) is recommended 
to identify patients who have a good long-term prognosis when treated with a 
long-term calcium channel blocker (CCB), accounting for 7–37% of children with 
PAH. For example, a >20% decrease in PAP or pulmonary vascular resistance (PVR) 
to inhaled NO accurately predicts a subsequent response to oral vasodilators, such 
as nifedipine. To identify such patients, the Sitbon criteria for positive AVT, as 
defined by a decrease in mean PAP by ≥10 mmHg to a value of <40 mmHg with an 
increased or unchanged cardiac output, is commonly used in adult I/H-PAH [85]. 
The Sitbon criteria can also be used to identify children who are expected to show a 
sustained response to CCB therapy [86]. Based on these data, the use of the Sitbon 
criteria is advised for AVT in children. Because only half of adult responders have 
a long-term hemodynamic and clinical improvement in response to CCB therapy, 
close long-term follow-up is required [87].
4.3.2  Acute vasoreactivity testing to assess operability of PAH associated with 
congenital heart disease
AVT (Figure 10) is also used to assess operability in children with PAH associ-
ated with a systemic-to-pulmonary shunt [87, 88]. Although pulmonary vasodilators 
other than iNO, such as inhaled iloprost or other orally or intravenously administered 
compounds (e.g., sildenafil and treprostinil), can be used for AVT, iNO ± oxygen is 
recommended [87]. The hemodynamic change that defines a positive response to AVT 
Figure 10. 
Acute vasoreactivity testingto assess operability. AVT is also used to assess operability in children with PAH 
associated with a systemic-to-pulmonary shunt [87, 88]. (Figure 10, unpublished). A 5-month-old infant 
with Down syndrome and an atrial septal defect was evaluated for operability by acute vasoreactivity testing 
using inhaled nitric oxide. Pulmonary hemodynamic parameters at baseline, including pulmonary arterial 
pressure (76/29/49 mmHg), pulmonary vascular resistance index (6.7 Wood units m2), the ratio of pulmonary 
to systemic vascular resistance (0.45), and the ratio of pulmonary to systemic blood flow (1.74), are changed 
to 60/14/32 mmHg, 3.14 Wood units m2, 0.20, and 2.2 after nitric oxide inhalation, respectively. The patient 
underwent surgical closure of the shunt, and no postoperative pulmonary hypertension was observed. NO, 
nitric oxide; AO, aorta; PA, pulmonary artery.
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in PAH associated with a shunt (a ratio of pulmonary to systemic blood flow >1.5) 
for children should be a >20% decrease in PVR index and a ratio of pulmonary to 
systemic vascular resistance with respective final values of <6 Wood units m2 and <0.3. 
However, specific criteria for defining a positive AVT response that predicts the rever-
sal of PAH and good long-term prognosis have not been described. The pediatric task 
force of the Sixth World Symposium on Pulmonary Hypertension agreed on a general 
guidance for assessing operability in CHD-PAH but emphasized that the long-term 
impact of defect closure in the presence of PAH with increased PVR is unknown [84].
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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Endothelial Dysfunction in 
Cardiovascular Diseases
Indranil Biswas and Gausal A. Khan
Abstract
Endothelium is the inner most cell layer of blood vessels. Endothelial cells 
make special barrier that separate blood from extravascular tissues. Intact 
endothelium regulates vascular tone and permeability and maintains non-inflam-
matory, anti-thrombotic surface. Through its ability to express pro-coagulants, 
anticoagulants, vasoconstrictors, vasodilators, cell adhesion molecules, and 
cytokines, the endothelium has emerged as one of the pivotal regulators of 
vascular homeostasis. Under physiological conditions, endothelial cell sustains a 
vasodilatory, anticoagulant, and fibrinolytic state in which coagulation, platelet 
adhesion, as well as leukocyte activation and inflammation are suppressed. In 
contrast, during endothelial disturbances, a prothrombotic and pro-inflammatory 
state of vasoconstriction gets support from the endothelial surface. Release of 
platelet-activating factor (PAF) and endothelin-1 promotes vasoconstriction, 
whereas production of von Willebrand factor (vWF), tissue factor (TF), and 
plasminogen activator inhibitor (PAI)-1 shifts the haemostatic balance towards a 
procoagulant state. Several factors like infection, hyperglycaemia, hyperlipidae-
mia, malignancy, oxidative stress, and aging can interfere in endothelial function. 
It is believed that most of the cardiovascular diseases originate from endothelial 
dysfunction. Endothelial dysfunction has been shown to be involved in athero-
sclerosis, thrombosis, hypertension, diabetes, and other cardiovascular diseases. 
In this review we will specifically highlight the role of endothelial dysfunction in 
development of cardiovascular diseases.
Keywords: endothelial dysfunction, atherosclerosis, hypertension, heart failure, 
stroke
1. Introduction
Vascular endothelium is considered as a largest endocrinal organ in the body, 
which has been shown to have a role in homeostasis in the body by exerting vari-
ous functions [1]. It is made up of simple squamous epithelial cells that line blood 
vessels, lymphatic vessels, and the heart. The vascular endothelium has a total weight 
of about 1.5 kg. The endothelium has been recognized as a smart barrier and a key 
regulator of blood flow in micro- and macro-vascular circulation [2]. Endothelial 
function is very important, as it interacts with nearly every system in the body 
and selectively supplies nutrients and growth factors to every organ. On the other 
hand, endothelium also receives active metabolites and delivers them back to the 
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circulation. Previously, it was believed that, endothelium is an inactive barrier 
between blood and extravascular tissues. However, recent research has shown that 
the vascular endothelium is an active paracrine, endocrine, and autocrine organ that 
is indispensable for the regulation of vascular tone and the maintenance of vascular 
homeostasis.
2. Physiological function of endothelium
When immediate surrounding tissues are at basal conditions, the endothelium 
functions to maintain the vessel homeostasis, which favors vessel dilatation over 
vasoconstriction [3]. The endothelium being a dynamic reactive tissue, responds to 
various intrinsic physical stimuli, that is, shear stress, temperature, and transmural 
pressure and external stimuli, that is, temperature, mental stress, neurohumoral 
responses, immune response, and medications [2, 4].
Under normal conditions, endothelial cell maintains basal perfusion, which is 
determined by cardiac output, systemic, and local vascular resistance. Endothelial 
metabolism, which is a key regulator of perfusion, is impaired during several 
disease states like infection, injury, aging, and inflammation [5]. Local blood flow 
is the result of vascular relaxation and contraction that is balanced by endothelium-
derived vaso-dilatative and vaso-constrictive factors. Among these factors, one 
signal molecule stands out as hub and target of many pathways and mechanisms 
that is nitric oxide (NO) [6]. It is important to understand the biochemical founda-
tions of NO for endothelial function. NO, a potent vasodilator, is released form 
the endothelium due to shear stress. This NO is released by endothelial nitric oxide 
synthase (eNOS) by utilizing L-arginine as a substrate, which leads to the produc-
tion of intracellular cyclic GMP [7]. However, in an event when the NO-dependent 
vasodilator mechanism is compromised, then the cytochrome-derived factors, 
natriuretic peptide [8], and prostacyclin [9]-dependent vasodilator mechanism 
came in action.
During disease state, there is impaired endothelial function, and this results in 
the balance shift towards prevailing constrictive factors and/or down-regulation 
of vaso-dilatative factors. An important counterweight in the vascular balance is 
cyclooxygenase (COX). This mostly induces COX-1 which is endogenous and may 
involve COX-2 if it is induced. The COXs have a key role in generating vasoconstric-
tive factors.
The COX enzymes transform arachidonic acid into endoperoxides and further 
into thromboxane A2 (TXA2) [10], prostaglandins, and prostacyclin [11]. Local 
presence of thrombin evokes inducible NO release. Platelet release of serotonin and 
ADP in turn increases NO synthesis and release in healthy endothelium to induce 
dilatation [12]. When vasodilatory function of endothelium is impaired, then the 
thrombus formation is mechanically promoted by vasoconstriction via TXA2 and by 
the direct effect of serotonin on smooth muscle cells [13].
3. Endothelial dysfunction
Traditionally, endothelial dysfunction has been associated to pathological 
conditions that have altered anticoagulant function, impaired anti-inflammatory 
properties of the endothelium, impaired modulation of vascular growth, and 
dysregulation of vascular remodeling. For instance, a plethora of studies have con-
firmed the impairment of endothelium-dependent vasorelaxation caused by a loss 
of NO bioactivity/availability in the vessel wall [4]. The loss of NO bioavailability 
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is the salient feature of a dysfunctional endothelium, which in turn is the sentinel 
of systemic or focal vascular disease. A number of previous studies have showed 
that most of the cardiovascular diseases were initiated from endothelial dysfunc-
tion. The decline in NO bioavailability may be caused by decreased expression of 
the endothelial cell eNOS [14], a lack of substrate or cofactors for eNOS [15], the 
presence of inhibitor of NOS [16], and alterations of cellular signaling, and finally, 
accelerated NO degradation by ROS [17]. Another aspect of endothelial dysfunction 
is impaired endothelial barrier function. Depending on the mode of pathophysi-
ological change, this loss in barrier function may be localized or systemic. Localized 
loss of the selective barrier function (manifested as edema), coupled with the 
emigration of leukocytes, has been recognized as cardinal signs of inflammation 
[18]. From an immunological context, the body’s primary reaction to tissue injury 
or infection is the leukocyte interacting with endothelium. However, from the 
perspective of hemostasis and thrombosis, endothelial dysfunction is character-
ized by activation of pro-inflammatory and pro-coagulant molecules, as well as the 
suppression of anti-inflammatory and anti-coagulant molecules. The intact and 
normal functioning endothelial lining provides a stable reservoir for blood as its 
luminal surface does not activate the coagulation cascade or promote leukocyte-
platelet adhesion, and it also exhibits anticoagulant and fibrinolytic properties [19]. 
Systemic endothelial dysfunction may lead to widespread inflammation, vascular 
leakage, thrombocytopenia, and disseminated intravascular coagulation (DIC). 
On the other hand, localized endothelial dysfunction and leukocyte adhesion may 
lead to venous thrombosis. Other than altered endothelial barrier function, local-
ized endothelial dysfunction also leads to tissue factor induction and increased 
von Willebrand factor (vWF) release that shifts the homeostatic balance towards 
the pro-coagulant-pro-inflammatory phenotype [20]. Intact endothelium release 
pro-fibrinolytic molecules like tissue plasminogen activator (TPA) [21]. Endothelial 
dysfunction suppressed TPA release, thereby impairing fibrinolytic function 
of endothelium [22]. In contrast to venous endothelial cells and microvascular 
endothelial cells, arterial endothelial cells are surrounded by a vascular smooth 
muscle layer and adventitial layer. Arterial endothelial cells physiologically experi-
ence high sheer stress and synthesize ample amount of NO that facilitate vascular 
relaxation. In the context of atherogenesis, endothelial cell dysfunction is mainly 
characterized by a loss of anatomical integrity of the intima, as described by the 
seminal “Response-to-Injury Hypothesis”. Endothelial cell injury and subsequent 
sub-endothelial matrix exposure lead to platelet adhesion and activation mediated 
through sub-endothelial collagen layer [23]. The initiating event in the atherogenic 
process is some form of overt injury to the intimal endothelial lining that is induced 
by noxious substances (e.g., oxidized cholesterol, cigarette smoke, hyperlipid-
emia, hypercholesterolemia, hyperglycemia, etc.) or altered hemodynamic sheer 
stress (e.g., abnormal blood flow caused by hypertension) [24]. In particular, 
local endothelial mechanical tearing was seen as the inciting stimulus for platelet 
adhesion, activation, and the localized release of platelet-derived growth factors. 
This would then elicit the migration, proliferation, and phenotypic modulation 
of medial smooth muscle cells and thus generate a fibromuscular plaque [25]. It is 
of great interest to establish the sequential event that leads to atherogenesis from 
endothelial injury. But, the direct link between endothelial injury and the genesis of 
atherosclerotic lesion is still unclear. However, the detailed morphologic examina-
tion in diet-induced fatty streak lesions in animal models failed to demonstrate 
unconcealed intimal injury or platelet adhesion. In this context, it is highly relevant 
that several molecules including high mobility group protein (HMGB-1) [26] and 
heat shock proteins (HSPs) [27] are released from injured endothelial cells and 
facilitate monocyte adhesion, a crucial step for plaque formation.
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4. Endothelial dysfunction in atherosclerosis
Endothelial dysfunction of lesion-prone areas of the arterial vasculature leads to 
atherosclerotic plaque formation [28]. Sequential deterioration of arterial vascula-
ture along with increased sheer stress contributes to lesion formation. Endothelial 
dysfunction is one of the early events that are responsible for the deterioration of 
arterial vasculature [29]. Recent insight into the cellular mechanisms involved in 
atherogenesis shows that deleterious modifications of endothelial physiology or 
metabolism is the initial event of vascular remodeling that represents a crucial step 
in the development of atherosclerosis and are also involved in the development 
of plaque and the occurrence of atherosclerosis [2]. The sequential event includ-
ing focal permeation, trapping, and physicochemical modification of circulating 
lipoprotein particles in the sub-endothelial space constructs an inflammatory 
lesion [30]. This initiates a coordinated cellular signaling, followed by complex 
pathogenic sequence and endothelial activation. Activated endothelial cells express 
several cell adhesion molecules, which facilitate selective recruitment of circulating 
monocytes from the blood, and invade the tunica intima, where they differenti-
ate into macrophages. These macrophages also abnormally take up modified 
lipoproteins to become foam cells (the hallmark of early fatty streak lesions) [31, 
32]. The activated endothelium and macrophages release multiple chemokine and 
growth factors which act on neighboring smooth muscle cells (or precursors cell) 
[33] to induce their proliferation and synthesis of extracellular matrix components 
within the intimal compartment, thus generating a fibromuscular plaque34. This 
progressive structural remodeling of developing lesions results in the formation of 
a fibrous cap, overlying a lipid-rich necrotic core that consists of oxidized lipopro-
teins, cholesterol crystals, and cellular debris. This is also accompanied by varying 
degrees of matrix remodeling and calcification [34, 35]. The lateral edges of these 
complicated plaques also contain a rich population of inflammatory cells, that 
is, activated macrophages, T-lymphocyte, and dendritic cells [36], which secrete 
several cytokines and chemokines that further activate endothelial pro-inflam-
matory phenotype and contribute to structural instability of the plaque through 
release of proteolytic enzymes (matrix metalloproteases) that lead to modifica-
tion of sub-endothelial matrix components [37]. Another aspect of atherogenesis 
is governed by lipoproteins, mainly low-density lipoproteins (LDL). This initial 
arterial remodeling through accumulation of lipids is known as fatty streak forma-
tion. The first changes in the arterial wall occur at the branch points of arteries, 
where adaptive intimal thickening occurs in response to normal hemodynamic 
stresses [38]. During the early stage of atherogenesis, LDL particles leave the blood 
and enter the arterial intima, composed of endothelial cells. Fat droplets (LDL) 
may also accumulate in the cytoplasm of vascular smooth muscle cells (VSMCs) 
[35]. LDL particles are then modified by enzymes and are oxidized into a highly 
reactive pro-inflammatory molecule (oxidized LDL), that is recognized by pattern 
recognition receptors, that is, Toll-like receptors (TLRs) present in endothelial cells 
as well as pro-inflammatory macrophages [39]. Oxidized LDL incites the reaction 
of the innate inflammatory system within the intima and contributes to vascular 
remodeling. Inflammation begins when activated endothelial cells (through TLRs) 
express cell adhesion molecules and VSMCs secrete chemokines and chemoattrac-
tants, which together draw monocytes, lymphocytes, mast cells, and neutrophils 
into the arterial wall [40]. Once monocytes enter into the arterial wall through 
the intima, they become activated into macrophages. These macrophages take up 
lipids as multiple small inclusions and become transferred into foam cells [41]. The 
degree of lipid accumulation is critical for early stage diagnosis of atherosclerosis. 
Atherosclerosis is believed to start when the lipid accumulation appears as confluent 
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extracellular lipid pools and extracellular lipid cores with and decreased cellular-
ity [42]. Endothelial cell dysfunction is also responsible for VSMC proliferation 
and differentiation to myofibroblast. In an intact vessel, VSMCs never come into 
contact with plasma proteins and are therefore devoid of growth factor present in 
plasma. In physiological conditions, VSMCs are always maintained in quiescent 
states. During early inflammation and endothelial cell activation, VSMCs receive 
signal from dying cells or growth factors that modify VSMCs to myofibroblast 
(more proliferative counterpart). Altered VSMCs (myofibroblast) also secrete 
proteoglycans, collagen, and elastic fibers into the sub-endothelial matrix [43]. This 
transformation of VSMCs further worsens the histological structure and leads to 
formation of thin-cap fibroatheroma formation [44]. Fibroatheroma can be of two 
different types depending on the content and stability of the plaque. Stability of the 
plaque also determines the fate of the fibroatheroma. Unstable fibroatheroma leads 
to thrombotic plaque formation, whereas stable fibroatheroma accumulates cal-
cium, becomes stiff, and eventually leads to occlusion [44, 45]. Unstable or vulner-
able plaques may lead to a catastrophic transition into atherosclerotic lesion—frank 
plaque rupture, with luminal release of the highly thrombogenic contents [46, 
47]. Else, some significant clinical sequelae can be seen from superficial intimal 
erosions, without any indication of plaque rupture [48]. Therefore, lately an acute 
transition appears leading to endothelial cell apoptosis, with localized endothelial 
denudation and thrombus formation leading to obstruction in regional blood flow 
[49, 50], whereas the stable lesions, having thick fibrous cap and less lipid as well as 
inflammatory cell content, can gradually invade on the lumen of the vessel caus-
ing ischemic symptoms without atherothrombotic events [51, 52]. Many ruptures 
of thin fibrous caps are clinically silent in that they heal by forming fibrous tissue 
matrices of cells, collagen fibers, and extracellular space but may rupture again with 
thrombus formation of the necrotic core, triggering an atherothrombotic occlusion. 
These cyclic changes of rupture, thrombosis, and healing may recur as many as 
four times at a single site in the arterial wall, resulting in multiple layers of healed 
tissue. In all these steps, calcium deposition in the wall of the vessels forms small 
aggregates initially, which turns into large nodules at later stage. In later stage, these 
plaques may rupture and expose the nodules, and it became sites for thrombus 
formation [47]. Therefore, the increasing number of plaques itself might become 
adequate to form significant stenosis, which may cause a shattering ischemic event 
due to flow restriction [53]. Based on its multiple regulatory roles throughout this 
complex series of events, it is evident that endothelial dysfunction constitutes a 
well-coordinated multicellular pathogenic sequence that leads to atherosclerosis.
5. Endothelial dysfunction in hypertension
Hypertension affects significantly to worldwide cardiovascular morbidity 
and mortality and is considered as a diagnostic factor for cardiovascular disease. 
Hypertension appears to have a complex association with endothelial dysfunction, a 
phenotypical alteration of the vascular endothelium that precedes the development 
of adverse cardiovascular events. Endothelial cells along with the vascular smooth 
muscle cells of resistance vessels (arteries and arterioles) regulate hypertension 
[54] as they continuously constrict and dilate according to the rhythm of cardiac 
cycle. In response to the blood flow (perfusion), the quiescent healthy endothelium 
continuously releases potent vasodilators, which have the potential to lower vas-
cular resistance, thereby regulating the blood pressure [55]. In normal condition, 
basal perfusion is determined by cardiac output, systemic, and local resistance. In 
an intact healthy vessel, endothelial cell always maintains a vasodilatory rather than 
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a vasoconstrictive phenotype. Endothelial dysfunction is a condition comprising 
not only attenuated endothelium-dependent vasodilatation but also an augmented 
inflammatory endothelial activation that leads to vasoconstriction. Endothelial 
dysfunction contributes to hypertension, whereas hypertension also leads to endo-
thelial dysfunction. In healthy endothelial tissues, a balance between endothelium-
derived relaxing factors (EDRFs) and endothelium-derived contracting factors 
(EDCFs) is maintained. Endothelial dysfunction disturbs this balance. Several 
vasodilatory and vasoconstrictive factors regulate this balance. The endothelium 
secretes a number of vasodilator factors including NO. Generation of NO can 
activate guanylate cyclase (cGMP), which causes vasodilation through relaxation of 
vascular smooth muscle cells [56]. Another vasodilatory factor PGI2 secreted by the 
endothelium inhibits platelet aggregation and vascular smooth muscle cell prolifer-
ation [57]. Endothelial cells also secrete several vascular contracting factors includ-
ing angiotensin-II (Ang-II), endothelin-I (ET-I), dinucleotide uridine adenosine 
tetraphosphate (UP4A), and COX-derived TXA2 [58]. Endothelins (ETs) are potent 
vasoconstrictor molecules having a key role in vascular homeostasis. Although there 
are three types of ET, vascular ECs mainly produce only ET-1, which has prominent 
roles in vasoconstriction. Active ET molecule is generated by the actions of an ET 
converting enzyme (ECE) found on the endothelial cell membranes. There are two 
basic types of ET-1 receptors: ET-A and ET-B, G-protein coupled receptors. Under 
normal conditions, the ET-A receptor is dominant in blood vessels [59]. ET-1 exerts 
vasoconstriction through activation of dihydropyridine channel or DHP channel 
or long lasting Ca++ channels (L-type) by binding to ET-A receptors on vascular 
smooth muscle cells. Smooth muscle cells expressed both ET-A and ET-B receptors. 
However, endothelial cells express only ET-B receptors, which negatively regulate 
NO release. Another vasorelaxation factor adenosine released from endothelial 
cells acts through purinergic receptor and maintains vascular perfusion [60]. Other 
than these factors, several cytokines and chemokines also play an important role in 
hypertension. Inflammatory cytokine induces generation of reactive oxygen species 
(ROS), one of the critical factors that link endothelial dysfunction and hyperten-
sion [61]. It is well established that Ang-II induces NADPH oxidases (NOX). But 
recent finding indicates additional source of ROS generation. In small subcutaneous 
arteries, a significant portion of Ang-II induced ROS is produced by COX-2. In the 
mouse aorta, the mitochondrial monoamine oxidase is another mediator of ROS 
generation and Ang-II or inflammation-induced endothelial dysfunction [62]. 
Therefore, mitochondrial monoamine oxidase-A and monoamine oxidase-B are 
also induced due to endothelial dysfunction in the vessels and generate a significant 
amount of H2O2 sufficient to quench endothelial NO. In spite of that, other mito-
chondrial ROS generating systems, that is, p66Shc, also contribute to hypertension-
induced ROS production. ROS production is also regulated by several intracellular 
signaling, which further attenuate endothelial dysfunction and hypertension.
6. Endothelial dysfunction in heart failure
Heart failure (HF) is the most common cause of hospitalization in cardiovascu-
lar disease with a high mortality rate. Despite novel treatment options for patients 
suffering from HF, morbidity and mortality rates are still high. The impact of the 
growing HF on global public health is a great concern in health care research. With 
the advancement of medical management, survival of acute coronary disease and 
cardiac ischemia has been improved. However, in myocardial infarction, prognosis 
is still poor, as HF with preserved ejection fraction (HFpEF) has a 65% mortal-
ity rate at 5 years. While the heart as the failing “pumping” organ was an initial 
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focus in research and treatment, neurohumoral activation and subsequently the 
role of a failing endothelium were recognized and investigated in recent years. 
Traditionally, HF was recognized as impairment of cardiac muscle activity, known 
as cardiomyopathy. Later, it was found that altered perfusion in cardiac arteries due 
to atherogenesis also contributes to cardiac ischemia that leads to cardiomyopathy. 
Reduced myocardial perfusion due to impaired ventricular function is at least in 
part a consequence of reduced endothelium-dependent vasodilator capacity of 
coronary arteries. The prominent regulatory activity of the vascular endothelium 
in HF was discovered about two decades ago, and its assessment in different cardio-
vascular disorders, including HF, has been the focus of intense research [63]. On the 
other hand, declined peripheral vasodilation causes higher systemic and pulmonary 
vascular resistance and together with stiffness of conductance arteries leads to 
increased afterload. Elevated afterload further increases cardiac workload and 
therefore worsens myocardial function. The decreased exercise capability is aggra-
vated by vasomotor dysfunction of the skeletal muscle vessel by increases vascular 
resistance. Altered endothelial metabolism further contributes to increasing cardiac 
afterload [13]. Indeed, various aspects of endothelial function are affected in heart 
failure, including vasomotor, hemostatic, antioxidant, and anti-inflammatory 
activities [63, 64]. Differences also exist in the pattern of endothelial dysfunc-
tion depending on etiology, severity, and stability of HF in individual patients. 
Endothelial dysfunction also plays a central role in HF. The failing heart is charac-
terized by an altered redox state with overproduction of ROS. The increasing evi-
dence suggests that the abnormal cardiac and vascular phenotypes characterizing 
the failing heart are caused in large part by imbalances between NO bioavailability 
and oxidative stress [65]. During initial stages of HF, inflammatory mediators from 
the myocardium and altered local shear forces modulate gene expression, leuko-
cyte infiltration, increased cytokine production, increased ROS generation, and 
diminished NO bioavailability. Clinical studies showed significant up-regulation of 
plasma markers of endothelial activation (e.g. E-selectin) and endothelial dam-
age (e.g. vWF) in HF [22, 63]. However, it is difficult to determine if endothelial 
dysfunction is the cause or effect of the HF. Therefore, HF is regarded as thrombotic 
complication. As mentioned earlier, during atherogenesis, decreased lumen of 
cardiac arteries leads to reduced perfusion to the heart muscle. This phenomenon is 
coupled with increased sheer stress and impaired blood flow. This reduced perfu-
sion either led to ischemia–reperfusion injury or coronary artery thrombosis [63]. 
Studies showed that endothelial dysfunction is one of the principle mediators of 
ischemia–reperfusion injury and thrombosis. This explains the increased endothe-
lial dysfunction markers in coronary artery disease, HF, and thrombosis.
7. Endothelial dysfunction in stroke
The global burden of neurological diseases including cerebrovascular stroke 
has significantly increased, and development of new treatment modalities for 
cerebrovascular diseases is an urgent need. Cerebrovascular stroke can be broadly 
subdivided into acute ischemic stroke and hemorrhagic stroke [66]. Acute 
ischemic stroke is among the leading causes of death and long-term disability. 
Cerebrovascular stroke in small vessel has functional (lacunar stroke, cognitive 
impairment, gait, and movement disorders) and structural (small subcortical 
infarct, lacunar infarct, lacunes, white matter lesions, and micro bleeds) conse-
quences. In the past few decades, the immense development of neuro-radiological 
methods enabled better imaging of cerebral blood vessels. From the clinical point 
of view, it is very important to identify the location of vascular lesion. However, 
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a vasoconstrictive phenotype. Endothelial dysfunction is a condition comprising 
not only attenuated endothelium-dependent vasodilatation but also an augmented 
inflammatory endothelial activation that leads to vasoconstriction. Endothelial 
dysfunction contributes to hypertension, whereas hypertension also leads to endo-
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However, endothelial cells express only ET-B receptors, which negatively regulate 
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is still poor, as HF with preserved ejection fraction (HFpEF) has a 65% mortal-
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the treatment strategies do not depend on the location of vascular impairment. 
It is now well recognized that endothelial dysfunction represents a systemic 
syndrome involving multiple vascular beds, including the cerebral vasculature 
[67]. Endothelial function is not uniform throughout the arterial system. It dif-
fers between organs and potentially also between different vascular beds within 
the same organ. Cerebral endothelium is probably one of the most specific types 
since it is the crucial element of the well-known blood-brain barrier (BBB). The 
BBB is a term used to describe the unique properties of the microvasculature of 
the central nervous system that protects the brain from harmful agents and patho-
gens [68]. CNS vessels are continuous non-fenestrated vessels, but also contain a 
series of additional properties that allow them to tightly regulate the movement of 
molecules, ions, and cells between the blood and the CNS. This heavily restricting 
barrier capacity allows BBB ECs to tightly regulate CNS homeostasis, which is criti-
cal to allow for proper neuronal function, as well as protect the CNS from toxins, 
pathogens, inflammation, injury, and disease. The cell-to-cell interaction with 
astrocytes, microglia, and neurons mainly played an important role for mainte-
nance of BBB controlled by endothelial cells and pericytes [69].
However, the integrity of BBB is mainly disrupted due to decrease in endothelial 
cell-cell junction proteins and the detachment of pericytes from the endothelial 
membrane in homorganic condition [70]. Cerebral autoregulation maintains 
constant blood flow (CBF) through the brain in spite of changing mean arterial 
pressure. Autoregulation of cerebral blood flow consists of mechano- and chemo-
regulation. The serum level of carbon dioxide (CO2) is directly controlled by the 
chemo-regulation independent of changes in mean arterial pressure [71]. However, 
mechano-regulation depends on transmural pressure gradient and endothelial 
vasodilatation.
8. Conclusion
From the above discussion, it is evident that CVDs and cardiovascular morbid-
ity are associated with endothelial dysfunction, but the mechanistic links between 
inflammatory diseases, endothelial dysfunction, and CVDs have not been fully elu-
cidated. The role of traditional cardiovascular risk factors in patients with inflam-
mation, especially sterile inflammation, has received considerable attention, though 
traditional factors alone are insufficient to explain the excess burden of CVDs. It 
seems likely that sterile inflammation, a shared feature of CVDs, is involved in the 
pathogenesis of accelerated endothelial dysfunction.
Patients with chronic inflammatory/and or sterile inflammatory diseases are 
at high risk for cardiovascular morbidity and mortality. In many inflammatory 
diseases, this heightened risk of CVDs is reflected in early endothelial dysfunction, 
even in the absence of any other detectable diseases. Several others mechanisms, 
that is, auto-antibodies, oxidative stress, and interactions with traditional risk fac-
tors like dyslipidemia and insulin resistance might be involved. Therefore, further 
research in future is required to delineate the importance of these processes. So, the 
current approaches to diminish cardiovascular morbidity and mortality are focused 
on controlling traditional modifiable cardiovascular risk factors and reduction of 
disease risk. Therefore, the precise mechanisms leading to development of CVDs 
due to inflammation/or sterile inflammation need to explore. These studies might 
help to identify unique therapeutic targets to combat these diseases.
The endothelium therefore represents an integrator of vascular risk, and the 
study of its dysfunction may help elucidate mechanisms driving accelerated CVDs 
in future, which could help to develop therapeutic targets for control of CVDs.
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Abstract
The authors present an analysis of current research and their own data on the
link between endothelial dysfunction (ED) and the severity of depression in
middle-aged patients with cerebral microangiopathy. Levels of peripheral inflam-
matory and endothelial dysfunction markers were measured using the enzyme-
linked immunosorbent assay (ELISA). The results of the comparative and correla-
tion analyses showed a statistically significant correlation between the severity of
depression and increased levels of inflammatory, as well as endothelial dysfunction
Keywords: inflammatory marker, endothelial dysfunction maker, depression,
cerebral microangiopathy, Divaza
1. Introduction
Depression and cardiovascular diseases (CVD) are the leading problems of
modern healthcare [1]. The global prevalence of depressive disorders ranges from
4.4 to 20%. Аbout 350 million people suffer from depression [2, 3].
The World Health Organization (WHO) considers depression and atherosclero-
sis as the main causes of disability in CVD and predicts that by 2030, depression will
be the leading one. The fact that a depressive disorder is more common in women
and the elderly people (in whom CVD is often underestimated) determines the
need for effective preventive measures in these risk groups [4, 5].
Themultiple factors contributing to the strong association between depression and
atherosclerosis are not well studied. Authors discuss various mechanisms of linkage
between these diseases [6–12], i.e., the activation of neuroendocrine system [5].
Frequently, depression is considered an unfavorable prognostic factor for the
CVD development [6–8]. Unhealthy lifestyle (physical inactivity, smoking), as well
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1. Introduction
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as inflammation and metabolic syndrome, has been proposed to explain the rela-
tionship between depression and the development of atherosclerosis [9, 10, 12, 13].
In patients with depression, elevated levels of such markers of systemic inflam-
mation as pro-inflammatory cytokines (tumor necrosis factor alpha (TNF-α),
interleukin-6 (IL-6)), C-reactive protein (CRP), as well as reduced levels of inter-
leukin-1 (IL-1) and interleukin-8 (IL-8) [14–17], lead to hyperactivation of the
hypothalamic-pituitary-adrenal axis [18]. Also intestinal inflammation causes
remote effect on the brain and depression. Unbalanced gut microbiota shifts tryp-
tophan metabolism toward kynurenine pathway affecting gamma-aminobutyric
acid (GABA), dopamine, and serotonin levels [19, 20]. Studies have shown that
stimulation of the vagus nerve modulates the inflammatory response and relieves
the depression symptoms [21, 22].
Many studies focus on the activation of inflammatory processes as a common
pathogenetic pathway between CVD, cerebrovascular disorders, and depression. In
this respect, there are two aspects of the role of pro-inflammatory mechanisms: the
first reveals the causal relationship between depression and inflammation and/or
endothelial dysfunction (ED); the second shows the connection between inflam-
mation, ED, and atherosclerosis [5]. ED and/or elevated levels of peripheral markers
of inflammation are found in atherosclerosis and cardiovascular events [23].
Patients at high risk of acute coronary syndrome can be identified based on the
elevated levels of inflammatory markers [24]. These markers are associated with
atherosclerosis and activation of the immune system. The immune system compo-
nents can indirectly influence the progression of atherosclerotic vascular lesions.
Risk factors for CVD, which at the same time predispose to atherosclerosis, cause
dysfunction of the vascular endothelium. The vascular endothelium, as a regulator
of vascular homeostasis, is involved in different processes, such as keeping a balance
between vasodilatation and vasoconstriction, inhibition and stimulation of smooth
muscle cell proliferation and migration, thrombus formation, and fibrinolysis [25].
When imbalance occurs, ED develops, causing excessive vascular permeability,
platelet aggregation, leukocyte adhesion, and production of cytokines. A failure in
synthesis or a violation of the activity of nitric oxide (NO) (which is manifested by
insufficient vasodilatation) also is considered as a potential mechanism by which
endothelial dysfunction leads to atherosclerosis. The low systemic levels of NO have
been postulated to be responsible for the increased risk of cardiovascular events
observed in subjects with depression, as NO produces vasodilatation [26].
Among other cardiovascular risk factors, obesity increases morbidity and mor-
tality from CVD. The relationship between depression and obesity is complex and
includes behavioral, biological, and pathological associations [27]. The mechanisms
leading to the development of obesity affect the vascular system and especially the
endothelium function, mainly due to the pathological role of TNF-α in the genera-
tion of reactive oxygen species and reducing the availability of NO [28].
Significantly more research is needed to further study the multiple associations
between inflammation, markers of ED, and depression in patients with CVD [29].
Therefore, we have performed our own study aimed at identifying the relationship
between the levels of peripheral inflammatory markers and markers of ED with the
level of depression in patients with cerebral microangiopathy associated with arte-
rial hypertension and cerebral atherosclerosis.
2. Materials and methods, results, discussion
The study included middle-aged (44–60 years old) outpatients of both sexes,
with cerebral microangiopathy. The diagnosis was based on (1) the presence of a
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vascular disease (arterial hypertension and/or cerebral atherosclerosis) and focal
neurological symptoms in combination with cerebral symptoms (headache, dizzi-
ness, noise in the head, memory loss, etc.), (2) ultrasonic signs of cerebrovascular
atherosclerosis according to duplex scanning of the main arteries of the head, and
(3) signs of morphological changes in the brain according to neuroimaging data
(subcortical and periventricular leucoaraiosis and/or focal changes of gray and
white matter in the form of postischemic cysts and/or lacunary strokes and/or
diffuse atrophic changes in the form of ventricular dilatation or subarachnoid
spaces). Also all patients had depression (≥8 points on the Hospital Anxiety and
Depression Scale (HADS)). Study participants were capable of communicating with
the researcher, understanding and signing the informed consent form.
All patients received Divaza for 3 months. Divaza is a drug with endothelial
protective as well as nootropic (neuroprotective, neurotrophic) activity and good
safety profile [30–54].
Combination drug Divaza was developed based on previously discovered
pharmacological effects of its active pharmaceutical ingredients—release-active anti-
bodies to S100 (RAF of Abs to S100) and release-active antibodies to endothelial NO
synthase (RAF of Abs to eNOS) (including their different technological versions). The
important feature of RA forms of a substance is the ability to exert modifying effect on the
original substance or its target [Symmetry, 2018]. Since this activity is released during
technological processing of the original substance, it has been termed as the released
activity and the produced drug as the released-active drug.
Preclinical studies have shown that Divaza successfully combines properties of the
monocomponents [see Appendix 1]. The overall therapeutic effect results in an enhanced
ability of experimental animals to remember and reproduce the developed skills as well as
overcome artificially induced anxiety and depression. Furthermore, therapeutic effect of
Divaza on functional activity of endothelium has been confirmed by normalizing such
integrative indicator of the physiological status as blood pressure: RAF of Abs to eNOS
exerted hypotensive effect in animals with arterial hypertension and, at the same time,
did not alter parameters of system hemodynamics in normotensive condition. Impor-
tantly, RAF of Abs to eNOS given to animals along with nitroglycerin, an exogenous
NO-donor, resulted neither in a drug-drug interaction nor in excessive vasodilation (the
drug did not enhance the nitroglycerin effect in normotensive animals).
Noteworthy, Divaza, while exerting a normalizing psychotropic effect, did not cause
sedation and/or muscle relaxation (unpublished data).
RAF of Abs to S100, RAF of Abs to eNOS, and combination drug Divaza did
not exert any toxic effect as assessed by evaluation of single- and repeat-dose
(chronic) toxicity, genotoxicity, reproductive and developmental toxicity,
local tolerance, allergenic properties and immunotoxicity even when administered
at doses more than 100 times exceeding the recommended human daily doses
[31, 32].
During the study, patients were allowed to take concomitant drugs for
correcting the main risk factors for CVD development (antihypertensive drugs,
diuretics, antiplatelet drugs, anticoagulants, statins, and antidiabetic drugs).
An assessment of the dynamics of clinical and laboratory parameters was
performed at baseline and after 3 months of therapy. Clinical examination of
patients included collecting and analyzing complaints, anamnesis, anthropometric
measurements of body weight and height to calculate body mass index (BMI), and
thorough neurological examination, including neuropsychological testing and
emotional status assessment using HADS.
Serum levels of peripheral markers of endothelial inflammation (CRP, monocyte
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as inflammation and metabolic syndrome, has been proposed to explain the rela-
tionship between depression and the development of atherosclerosis [9, 10, 12, 13].
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Many studies focus on the activation of inflammatory processes as a common
pathogenetic pathway between CVD, cerebrovascular disorders, and depression. In
this respect, there are two aspects of the role of pro-inflammatory mechanisms: the
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synthesis or a violation of the activity of nitric oxide (NO) (which is manifested by
insufficient vasodilatation) also is considered as a potential mechanism by which
endothelial dysfunction leads to atherosclerosis. The low systemic levels of NO have
been postulated to be responsible for the increased risk of cardiovascular events
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vascular disease (arterial hypertension and/or cerebral atherosclerosis) and focal
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the researcher, understanding and signing the informed consent form.
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protective as well as nootropic (neuroprotective, neurotrophic) activity and good
safety profile [30–54].
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factor, fibrinogen) were determined by ELISA. The amount of circulating desqua-
mated endothelial cells (CECs) was detected according to J. Hladovec with modifi-
cations.
ELISA reference values of biomarkers were CRP up to 1 mg/l, MCP-1 0.228–
0.475 ng/ml, endothelin-1 0.3–0.5 ng/ml, eNOS y < 450 units VEGF 101–409 pg/
ml, S100B protein 29–56.5 μg/l, CECs 2–4 cells/100 μl, von Willebrand factor < 4
cu, and fibrinogen 2–4 g/l.
The study included a total of 262 patients between 44 and 60 years of age (mean
age 54.2  7) with cerebral microangiopathy and depression. Among patients there
were 110 (42.1%) men (mean age 50.8  6.3) and 152 (57.9%) women (mean age
57.4  8.1). One hundred ninety-eight (75.6%) patients had grade 1 arterial hyper-
tension, 64 (24.4%) had grade 2 arterial hypertension, 152 (58%) had type 2 diabe-
tes mellitus, and 169 (64.5%) had obesity (BMI > 30 kg/m2). The severity of
depression on the HADS hospital scale was 12.84  5.67 points.
The sociodemographic and clinical characteristics of patients are presented in
Table 1.
The initial patient sample (n = 262) was divided into two groups: a group with
clinically significant depression (≥11 points on the HADS scale) (n = 146) and a
group with subclinically significant depression (8–10 points on the HADS scale)
(n = 116). At the time of inclusion in the study, no statistically significant differ-
ences between groups by sociodemographic characteristics were identified.
A comparative analysis revealed that in the group of patients with clinically
significant depression (n = 146), the CRP level was 6.11 mg/l, which was
statistically different from the group of patients with subclinical depression
(n = 116) where CRP was 2.03 mg/L (p < 0.05). The level of MCP-1 in the group
of patients with clinically significant depression (n = 146) was 2.02 ng/ml, while
in the group of patients with subclinical depression (n = 116), it was 0.66 ng/ml
(p < 0.05).
After a correlation analysis, the presence of a statistically significant direct linear
association between the severity of depression and the level of CRP (correlation
coefficient r = 0.85, p < 0.05) as well as between the severity of depression and the
level of MCP-1 (r = 0.8, p < 0.05) was shown.
It was revealed that elevated values of peripheral markers of endothelial inflam-
mation are associated with clinically significant depression. The results are
presented in Table 2. A reliable association was determined between inflammation
and depression (p < 0.001), which remained significant after adjusting for risk
factors for CVD.
Table 1.
Baseline clinical characteristics of patients.
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After 12 weeks of treatment with Divaza, we observed a statistically significant
change in the values of peripheral inflammatory markers toward the reference
values: before treatment, the mean CRP value was 9.25  3.5 mg/l, and after
treatment it was 7.73  3.12 mg/l (p < 0.01); before treatment the average value
of MCP-1 was 2.81  1.3 ng/ml, and after treatment it became 1.9  1.2 ng/ml
(p < 0.01).
Depending on the individual dynamics of peripheral inflammatory marker
values, all patients (n = 262) were divided into two groups: with positive (n = 176)
and with negative (n = 45) dynamics. The values of peripheral markers of endothe-
lial inflammation in the groups before and after treatment are presented in Table 3.
Normalization of peripheral inflammatory and endothelial dysfunction markers
led to psycho-emotional status improvement in patients (Table 4).
The results show that the reduction of inflammation was accompanied by a
decrease in the severity of depressive symptoms, which, in turn, confirms the
association between inflammation and depression.
Table 2.
Association between peripheral markers of endothelial inflammation and depression#.
Table 3.
Peripheral markers of endothelial inflammation level before and after treatment with Divaza.
Table 4.
The severity of depression before and after Divaza treatment.
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level of MCP-1 (r = 0.8, p < 0.05) was shown.
It was revealed that elevated values of peripheral markers of endothelial inflam-
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After 12 weeks of treatment with Divaza, we observed a statistically significant
change in the values of peripheral inflammatory markers toward the reference
values: before treatment, the mean CRP value was 9.25  3.5 mg/l, and after
treatment it was 7.73  3.12 mg/l (p < 0.01); before treatment the average value
of MCP-1 was 2.81  1.3 ng/ml, and after treatment it became 1.9  1.2 ng/ml
(p < 0.01).
Depending on the individual dynamics of peripheral inflammatory marker
values, all patients (n = 262) were divided into two groups: with positive (n = 176)
and with negative (n = 45) dynamics. The values of peripheral markers of endothe-
lial inflammation in the groups before and after treatment are presented in Table 3.
Normalization of peripheral inflammatory and endothelial dysfunction markers
led to psycho-emotional status improvement in patients (Table 4).
The results show that the reduction of inflammation was accompanied by a
decrease in the severity of depressive symptoms, which, in turn, confirms the
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Table 2.
Association between peripheral markers of endothelial inflammation and depression#.
Table 3.
Peripheral markers of endothelial inflammation level before and after treatment with Divaza.
Table 4.
The severity of depression before and after Divaza treatment.
109
Association between Peripheral Blood Inflammatory Markers, Endothelial Dysfunction Markers,…
DOI: http://dx.doi.org/10.5772/intechopen.88693
To assess the possible involvement of other endothelial mediators in the devel-
opment of depression in patients with cerebral microangiopathy, an integrative
endothelial dysfunction index was calculated.
In factor analysis the most significant variables involved in the formation of
the integrative endothelial dysfunction index were identified. The levels of laboratory
markers of ED with evidence or possible role in the development of endothelial
dysfunction, CRP, MCP-1, VEGF, fibrinogen, Willebrand factor, S100 protein, CECs,
eNOS activity, and endothelin-1, were considered as variables.
CRP, MCP-1, endothelin-1, CECs, and fibrinogen levels statistically significantly
formed one active factor—the integrative endothelial dysfunction index.
Using group of patients who had all laboratory values of ED within the reference
range (n = 41), we defined an average value of the integrative endothelial dysfunc-
tion index equal to 1.32  0.38 conv. units as the age norm.
Comparative analysis of the integrative endothelial dysfunction index values
revealed its statistically significant increase in the group of patients with clinically
significant depression (0.12  0.04 conv. units) compared with the group of
patients with subclinical depression (1.14  0.3 conv. units) (p < 0.05).
A correlation analysis identified the presence of an inverse statistically signifi-
cant correlation between the integrative endothelial dysfunction index and severity
of depression (r = 0.83; p < 0.05).
When evaluating associations, we found that the integrative endothelial dys-
function index is associated with clinically significant depression (OR 1.36, 95% CI
1.23–1.45). The data are presented in Table 5.
The main hypothesis of this study was that in middle-aged patients with cerebral
microangiopathy, the presence of depression is associated with modified levels of
both peripheral inflammatory and endothelial dysfunction markers. To the best of
our knowledge, patients with clinically significant depression were more likely to
have elevated values of peripheral markers associated with endothelial inflamma-
tion and modified levels of ED markers compared with patients with subclinical
depression (p < 0.05).
When studying the correlation between the severity of depression and elevated
values of peripheral markers of inflammation, as well as altered levels of markers of
ED, a significant correlation was found; furthermore there were no association with
age, obesity, and diabetes mellitus (p < 0.001).
The concomitant administration of drugs aimed to correcting the main risk
factors of CVD with Divaza helped to normalize the levels of peripheral inflamma-
tory markers (p < 0.05), which was accompanied by the reduction of depressive
symptoms in middle-aged patients with cerebral microangiopathy.
Table 5.
Integrative endothelial dysfunction index#.
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The study revealed the association between abnormal levels of peripheral
markers of inflammation, markers of ED, and the severity of depression in middle-
aged patients with cerebral microangiopathy accompanied by arterial hypertension
and cerebral atherosclerosis. Drug therapy of endothelial dysfunction contributed to
the normalization of the emotional status in these patients.
Inflammation can be considered as a causative agent of the development of
depression, which is associated with the brain vascular network damage. Damage
of the endothelium stimulates the release of pro-inflammatory cytokines, which
play a leading role in the deposition of lipids in the arterial wall and proliferation
and migration of smooth myocytes into the intima of the blood vessels, causing
thrombus formation followed by occlusion of the blood vessels.
Previous studies showed that patients with severe types of depression had
elevated levels of peripheral inflammatory markers compared with patients without
depression [54]. In particular, a major depressive disorder is accompanied by the
dysregulation of the immune system with activation of the factors participating in
the inflammatory response [55]. An increase in the secretion of pro-inflammatory
cytokines (IL-1β, IL-2, IL-6, Interferon-gamma, TNF-α, etc.) and CRP has been
demonstrated [56]. Our results further indicate the dependence of the level of
depression on the levels of inflammatory markers.
As a possible mechanism of the association between peripheral inflammatory
markers and depression, the involvement of microglia, which is able to use pro-
inflammatory cytokines as catalysts for tryptophan degradation, was considered.
Alteration of tryptophan metabolism can cause depressive symptoms by reducing
serotonin synthesis [57].
IL-6 is a potent stimulator of the hypothalamic-pituitary-adrenal axis and
induces the release of other pro-inflammatory cytokines [58]. These observations
led Leonard B.E. to the conclusion that depression is a disease of inflammation in
response to chronic psychological stress. The author considered stress as a common
denominator in the etiopathology of cerebrovascular diseases, cardiovascular
diseases, and depression [59].
CRP is a protein of the acute phase of inflammation that is activated by pro-
inflammatory cytokines (e.g., IL-6) [60]. CRP is usually studied in the context of
vascular medicine; however, elevated CRP levels are a risk factor for atherosclerosis
and cardiovascular diseases. Therefore, the relationship between CRP and cardio-
vascular diseases was beyond the scope of cardiology. In recent decades, CRP has
become a central element for psychiatric research, especially in the area of depres-
sion. Depressed patients have been shown to exhibit significantly higher levels of
CRP compared to patients in the control group [61].
Wium-Andersen et al. demonstrated an association between CRP levels and
psychological stress in 73,131 Copenhagen residents. After adjusting for age, gender,
smoking, physical activity, and chronic somatic diseases, it was noted that elevated
levels of CRP correlated with depression [62].
The meta-analysis performed by Howren et al. summarizes data from studies on
participants with elevated level of inflammatory markers (CRP, IL-1, IL-6) and
depression, taking into account the BMI. Researchers concluded that there are
associations between high CRP level and depression after adjusting for BMI [63].
This suggests that the relationship between CRP and depressive disorders does not
depend on BMI. In our study, similar results were obtained: an association was
found between the level of CRP and depression—OR 4.17 (95% CI 1.18–14.7,
p < 0.001), which persisted after adjustment for age, obesity, and diabetes mellitus
—OR 1.5 (95% CI 1.3–1.8, p < 0.001). These facts demonstrate the independent
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The main hypothesis of this study was that in middle-aged patients with cerebral
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and cardiovascular diseases. Therefore, the relationship between CRP and cardio-
vascular diseases was beyond the scope of cardiology. In recent decades, CRP has
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character of the mutual effects between the activity of the inflammatory processes
and the level of depression.
Despite this, many hypotheses have been proposed regarding the association of
elevated CRP values with depression using various covariates that can affect these
relationships: from BMI and general physical health to the type of depression, which
makes it likely that there is a multifactorial and bi-directional relationship between
depression and inflammation [64].
Frasure-Smith et al. demonstrated that the association between CRP level and
depression is important for predicting future adverse cardiovascular events [65].
There is a lot of evidence in the scientific literature about significant and sustained
elevations of CRP level in depressed patients, which may or may not normalize after
remission of depression symptoms, indicating a continued possibility of adverse
cardiovascular events even after recovery from depression [66].
In 2015, the results of Setiawan E. et al. were published, where authors con-
cluded that depression causes inflammation. The researchers obtained the first
nonexperimental evidence that besides neurons, glial cells, namely, microglia, play
an important role in depressive disorders [67]. However, despite these findings, it is
difficult to conclude that depressive disorders are a trigger of inflammation. It is
possible that stress and other risk factors lead to depressive disorders that affect the
activation of microglia and a change in its structure, in turn, increasing the level of
depression, i.e., it may be a continuum. The data obtained in the present study on
the reduction of the level of depression (p < 0.05) accompanied by a decrease in the
inflammatory activity of the endothelium with the help of a therapy that does not
have an antidepressant effect also suggest the two-sided associations between
inflammation and depression.
ED is a vascular phenotype that predisposes to atheromatosis and atherosclerosis
and, therefore, may be a predictor of cardiovascular events [68].
Endothelial dysfunction can lead to immunological changes, activation, adhesion
of white blood cells, and aggregation of platelets in the vascular damage area. The
attachment of monocytes and lymphocytes to endothelial cells is associated with the
activation of cell adhesion molecules [69]. Chronic mild inflammation is known as a
predictor of myocardial infarction and ischemic stroke. ED is a “critical intermedi-
ate phenotype” in the association between mild inflammation and CVD. ED can be
considered as an “intermediate phenotype” in depression based on the presence of
mild chronic inflammation in many patients with depressive symptoms [70].
Depression can be regarded as a chronic stressor that contributes to the develop-
ment of ED due to the disruption of cell adhesion, platelet hypercoagulation.
Depression is associated with higher levels of MCP-1, p-selectin, and others. Some
researchers consider ED as a biomarker of arterial atheromatosis, which can be a
sign of depression [71]. The present study has shown that there are strong associa-
tions between inflammatory markers and markers of proatherogenic activity
(endothelin-1, CECs, and fibrinogen). Based on the values of CRP, MCP-1,
endothelin-1, CECs, and fibrinogen, an integrative indicator of endothelial dys-
function had higher values in patients with clinically significant depression, com-
pared with patients with subclinical depression (p < 0.01). An inverse statistically
significant correlation was found between the integrative endothelial dysfunction
index and severity of depression (r = 0.83; p < 0.05). Moreover, this association
between the integrative endothelial dysfunction index and depression did not
depend on age, type 2 diabetes mellitus, and obesity (p < 0.001)—the risk factors
known to raise the incidence of CVD.
Do et al. focused on the association of individual symptoms of depression
(a symptom of hopelessness that can turn into suicidality) with markers of ED.
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The researchers concluded that negative psychosocial features which can affect
cardiovascular diseases in part through their impact on the early stages of athero-
sclerosis, as well as specific psychosocial features such as hopelessness, may play a
more significant role in this process than other depressive symptoms [72].
Thus, ED is a crucial factor in the bilateral relationship between depression,
chronic inflammation, and cardiovascular diseases [73].
3. Conclusions
Despite growing evidence that underlines the bilateral relationship between
depression and CVD and the fact that the mechanisms of their connection were
partially identified (e.g., inflammation, ED), further research with a large sample
size is required.
Novel pharmacological approaches based on discoveries related to the immune
and neurotransmitter systems are in high demand.
The development and implementation of preventive measures and lifestyle cor-
rection, which can reduce the burden of cerebrovascular diseases and depression,
are required as well.
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character of the mutual effects between the activity of the inflammatory processes
and the level of depression.
Despite this, many hypotheses have been proposed regarding the association of
elevated CRP values with depression using various covariates that can affect these
relationships: from BMI and general physical health to the type of depression, which
makes it likely that there is a multifactorial and bi-directional relationship between
depression and inflammation [64].
Frasure-Smith et al. demonstrated that the association between CRP level and
depression is important for predicting future adverse cardiovascular events [65].
There is a lot of evidence in the scientific literature about significant and sustained
elevations of CRP level in depressed patients, which may or may not normalize after
remission of depression symptoms, indicating a continued possibility of adverse
cardiovascular events even after recovery from depression [66].
In 2015, the results of Setiawan E. et al. were published, where authors con-
cluded that depression causes inflammation. The researchers obtained the first
nonexperimental evidence that besides neurons, glial cells, namely, microglia, play
an important role in depressive disorders [67]. However, despite these findings, it is
difficult to conclude that depressive disorders are a trigger of inflammation. It is
possible that stress and other risk factors lead to depressive disorders that affect the
activation of microglia and a change in its structure, in turn, increasing the level of
depression, i.e., it may be a continuum. The data obtained in the present study on
the reduction of the level of depression (p < 0.05) accompanied by a decrease in the
inflammatory activity of the endothelium with the help of a therapy that does not
have an antidepressant effect also suggest the two-sided associations between
inflammation and depression.
ED is a vascular phenotype that predisposes to atheromatosis and atherosclerosis
and, therefore, may be a predictor of cardiovascular events [68].
Endothelial dysfunction can lead to immunological changes, activation, adhesion
of white blood cells, and aggregation of platelets in the vascular damage area. The
attachment of monocytes and lymphocytes to endothelial cells is associated with the
activation of cell adhesion molecules [69]. Chronic mild inflammation is known as a
predictor of myocardial infarction and ischemic stroke. ED is a “critical intermedi-
ate phenotype” in the association between mild inflammation and CVD. ED can be
considered as an “intermediate phenotype” in depression based on the presence of
mild chronic inflammation in many patients with depressive symptoms [70].
Depression can be regarded as a chronic stressor that contributes to the develop-
ment of ED due to the disruption of cell adhesion, platelet hypercoagulation.
Depression is associated with higher levels of MCP-1, p-selectin, and others. Some
researchers consider ED as a biomarker of arterial atheromatosis, which can be a
sign of depression [71]. The present study has shown that there are strong associa-
tions between inflammatory markers and markers of proatherogenic activity
(endothelin-1, CECs, and fibrinogen). Based on the values of CRP, MCP-1,
endothelin-1, CECs, and fibrinogen, an integrative indicator of endothelial dys-
function had higher values in patients with clinically significant depression, com-
pared with patients with subclinical depression (p < 0.01). An inverse statistically
significant correlation was found between the integrative endothelial dysfunction
index and severity of depression (r = 0.83; p < 0.05). Moreover, this association
between the integrative endothelial dysfunction index and depression did not
depend on age, type 2 diabetes mellitus, and obesity (p < 0.001)—the risk factors
known to raise the incidence of CVD.
Do et al. focused on the association of individual symptoms of depression
(a symptom of hopelessness that can turn into suicidality) with markers of ED.
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The researchers concluded that negative psychosocial features which can affect
cardiovascular diseases in part through their impact on the early stages of athero-
sclerosis, as well as specific psychosocial features such as hopelessness, may play a
more significant role in this process than other depressive symptoms [72].
Thus, ED is a crucial factor in the bilateral relationship between depression,
chronic inflammation, and cardiovascular diseases [73].
3. Conclusions
Despite growing evidence that underlines the bilateral relationship between
depression and CVD and the fact that the mechanisms of their connection were
partially identified (e.g., inflammation, ED), further research with a large sample
size is required.
Novel pharmacological approaches based on discoveries related to the immune
and neurotransmitter systems are in high demand.
The development and implementation of preventive measures and lifestyle cor-
rection, which can reduce the burden of cerebrovascular diseases and depression,
are required as well.
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the number of punished water
intakes in Vogel conflict test by
1.6-times
[42]
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of diene conjugates in the
cerebral hemispheres by 9.7-
27.8% in the heptane fraction
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Anti-amnestic activity Adult Wistar male
rats with β-amyloid-
induced amnesia
Divaza increased the latency of
the entry into the dark
compartment of CPAR
experimental chamber by 3-
times
[46]
Antidepressive activity Adult outbred male
rats
Divaza increased the number
of the wheel turns in Nomura
[47]
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CHO and CHO-K1
cells
RAF of Abs to S100 increased
specific radioligands binding to
5-HT1F-, 5-HT2B-, 5-
HT2Cedied- and 5-HT3-
receptors by 142.0%, 131.9%,
149.3% and 120.7%,
respectively; also RAF of Abs to
S100 exerted antagonist effect
at 5-HT1B-receptors inhibiting
their functional activity by
23.2% and agonist effect at 5-
HT1A-receptors enhancing
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of Abs to S100 effects
CHO and CHO-K1
cells
RAF of Abs to S100 increased
specific radioligand binding to
D3-receptors by 126.3% and
exerted antagonism at D3-
receptors inhibiting their
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adult Wistar male rats
RAF of Abs to eNOS increased
eNOS activity, the content of
NO derivates and the content
of cGMP by 2.4-, 1.3- and 4-
times, respectively
[53]








Divaza increased the amplitude
of tissue contraction induced
by standard agonist by 2-times
[54]
Notes: * - adapted from [73], CPAR - conditioned passive avoidance reflex, EPM - elevated plus maze, LPT - long-
term potentiation.
Appendix 1.
Experimental studies of pharmacological activity and mechanisms of action of RAF of Abs to S100, RAF of Abs
to eNOS and combination drug Divaza.
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Chapter 7
The Role of Vasoregulatory 
Markers in the Formation of 
Microcirculatory Changes in 
Premature Babies with Hypoxic: 
Ischemic Encephalopathy
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Abstract
Endothelial function plays an important role in the extrauterine adaptation of 
newborn infants. Endothelium produces different biologically active mediators, 
which play the central role in physiological and pathological processes and also in the 
extrauterine adaptation of newborn infants. The imbalance between vasoconstric-
tive and vasodilatation factors results in impaired cardiovascular adaptation and 
microcirculation and also brain injury. Microcirculatory disturbances are observed 
very often in preterm babies, who have a serious risk for perinatal brain injury and 
further neurodevelopment disabilities. Present chapter presents the pathogenetic role 
of vascular tone regulators of endothelial genesis in the formation of microcirculatory 
changes in preterm babies with a high risk of perinatal hypoxic encephalopathy.
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1. Introduction
The largest research object of modern perinatology and neonatology is preterm 
and growth retarded children. Despite the rapid development of perinatal care 
and the early prevention of many pathologies, worldwide perinatal morbidity and 
mortality remain high [1–4].
The results of the scientific researches prove that perinatal pathologies play a 
leading role in the formation of illness, death, disability, social and biological disar-
ray, and different types of neurodevelopmental disorders [5–10]. It is known that 
birth is a complicated biological process regulated by numerous signal molecules and 
biologically active substances. The fetal inflammatory response plays a major role in 
the pathogenesis of premature birth [11]. In addition to prematurity, the hypoxic-
ischemic changes in feto-placental system can result in different perinatal patholo-
gies, such as acute intraventricular bleeding, periventricular leukomalation, necrotic 
enterocolitis, bronchial lung dysplasia, myocardial dysfunction, sepsis, etc. [12–15].
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gies, such as acute intraventricular bleeding, periventricular leukomalation, necrotic 
enterocolitis, bronchial lung dysplasia, myocardial dysfunction, sepsis, etc. [12–15].
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Uteroplacental ischemia and circulatory changes in maternal-fetal system are the 
main chain in formation intrauterine hypoxia and different perinatal pathologies 
[16–18]. Previous investigations confirmed the significant role of endothelial func-
tion in the formation of different pregnancy pathologies and birth defects [19–22]. 
The pathogenetic mechanisms of the formation of endothelial dysfunction during 
uteroplacental ischemia have not yet been investigated. Present chapter explores the 
role of vascular tone regulators of endothelial genesis in formation of microcircula-
tory and ischemic changes in preterm infants.
2.  The pathophysiology of brain injury in hypoxic: ischemic 
encephalopathy (HIE)
Adaptation of the child to the extrauterine life significantly depends on the 
morpho-functional maturity of the organism, and it is more intense and more 
complicated in preterm babies than mature children [23–25].
The progress of all complicated pathophysiologic processes occurring in the 
newborn after birth significantly depends on cardiorespiratory adaptation [23, 24]. 
The changes in the cardiovascular and respiratory functions in the body related to 
the primarily changes in the microcirculation [25]. Microcirculatory changes are not 
only clinical symptoms of various pathologies of perinatal period but also one of the 
major factors that aggravate their course [26, 27].
HIE is one of the most serious birth complications accompanying with microcir-
culatory changes of different severity [28]. The pathogenesis of vascular changes in 
preterm infants is quite complicated and involves series of biochemical and molecu-
lar reactions (Figure 1). Persistent membrane depolarization results in excessive 
presynaptic glutamate release which follows with a series of cellular changes. The 
activation of NMDA receptors stimulates profound Ca2+ influx, which mediates 
cascades to cell death. Primary energy failure associated with the depletion of oxygen 
prevents oxidative phosphorylation, and the disrupting Na-K pump activity is 
Figure 1. 
The pathogenesis of hypoxic-ischemic encephalopathy [33].
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followed by anaerobic metabolism with accumulation of lactic acid. With the resto-
ration of blood flow, there is a brief period of normalization of cerebral metabolism 
called a latent period. The reperfusion is necessary for the recovery and stopping of 
processes leading to necrotic neuronal injury during the primary phase of injury. 
However when the brain has not recovered from the initial injury, the reperfusion 
can simultaneously cause additional (delayed) injury, and mitochondrial dysfunc-
tion continues. When cerebral ischemia is more acute and prolonged, especially in 
the result of accompanying pathological processes (infection, hereditary factors, 
environmental and other damaging factors), primary injury is followed by second-
ary injury, which is often characterized by subsequent resulting in more serious 
neurological and somatic disintegration in development [29]. Secondary injury is 
often associated with edema of the brain cells. Compensatory restoration of energy 
reactions is followed by the intracellular edema and by more complex inflammatory 
response cascade with the presence of free oxygen radicals [30].
Increased amount of free radicals and nitric oxide (NO), increased synthesis 
of nitric oxide synthase (NOS), activated intercellular adhesion, and apoptosis 
are the tightly connected chains of this pathological process (10–13). However it 
is confirmed that endothelial NOS (eNOS) genesis plays very important role in 
maintaining pulmonary blood flow and preventing pulmonary hypertension. Some 
experimental studies suggested that inhibiting NOS could prevent further brain injury 
[31]. Selective inhibition of NO of neuronal genesis is more promising in the direc-
tion of pathogenetic treatment of HIE in newborn infants [31–33].
The severity of inflammatory processes is correlated with the activation of differ-
ent mediators, especially cytokines and adhesion molecules. These molecules cause 
to the migration of leukocytes to the inflammation center and compact adhesion of 
migrated leukocytes to vascular endothelium [34, 35]. The main stimulus factor for 
the synthesis of inflammatory mediators is the activation of endothelial cells of the 
fetus. Thus, endothelial dysfunction is the main factor that stimulates intracellular 
and vascular adhesion and leads to the activation of fetal leukocytes [36, 37].
There is much to be investigated how the inflammatory response to hypoxia is 
regulated and the complete role of different mediators as well as vasoregulatory, 
anti-inflammatory, and apoptosis molecules under physiological and pathological 
conditions is unknown. The goal of this chapter is to present the results of recent 
investigations about the role of vasoregulatory markers in the formation of micro-
circulatory disorders in hypoxic-ischemic encephalopathy of preterm infants.
3.  Endothelial dysfunction and microcirculatory disorders in HIE of 
preterm infants
Several clinical and experimental studies confirmed the role of endothe-
lial dysfunction in the pathogenesis of hypoxic-ischemic brain injury. The 
prospective clinical trial of Azerbaijan Medical University Neonatology group 
(ACTRN12612000342819) determined that the eNOS activity is declined in the 
background of increased NO concentrations depending on the severity of HIE [38].
The aim of the same study was also to study of the peripheral blood concen-
trations of vasoregulatory mediators of endothelial genesis in the pathogenesis of 
microcirculatory changes in newborn children with the birth asphyxia. It inves-
tigated 240 preterm infants with a high risk of HIE during early neonatal period. 
The main groups of children were classified into four groups depending on the 
degree of the microcirculation changes. The first group included preterm infants 
without microcirculatory changes of the body. The children with mild-degree 
microcirculatory disorders (continued less than 1 day and self-regenerating 
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peroral and acrocyanosis, capillary refilling time duration less than 3 s) were 
included in the second group. The third group consisted of children with moder-
ate microcirculatory disorders (such as peroral and acrocyanosis, marbling of the 
skin, capillary refilling time up to 7 s and continuing from 1 day up to 3 days). 
The fourth group consisted of children with severe microcirculatory disorders 
(acute peroral and acrocyanosis, marbling of the skin continuing more than 
3 days, capillary refilling time with the duration of more than 7 s and continuing 
more than 3 days). The parameters were compared with the data of 2 control 
groups, which consisted of infants without perinatal and neonatal pathologies: 
22 healthy preterm infants were included in control 1 and 30 healthy term infants 
in control 2.
Depending on the magnitude of the microcirculatory defects, the levels of 
vasoregulatory markers included in the study is shown in Table 1. The statistically 
significant reduction in eNOS activity in the first few days of life is noticeable, 
depending on the degree of severity of the microcirculatory disturbances. However 
toward the end of the early neonatal period in mild and moderate group children, 
eNOS concentrations significantly increased compared with children with severe 
microcirculatory changes and control groups.
As shown in Table 1, during severe microcirculation defects, NO synthesis of 
vascular endothelium remains at very low levels. In contrast, NO levels in the early 
days of the neonatal period were noted to significantly increase in infants with 
severe microcirculatory disturbances, and in the dynamics of the neonatal period, 
regardless of the microcirculatory changes severity, it is observed the increase 
of NO concentrations. At the same time, vasoconstrictor endothelin-1 levels rise 
during mild and moderate grades of microcirculation changes, while in infants with 
severe changes, it is reduced. This also proves once again that severe microcircula-
tion disturbances lead to a violation of blood supply both in peripheral and vital 
organs during acute brain damage. We suggest that the lack of adequate levels of 
endothelin-1 synthesis, which is vasoconstrictor mediator of vascular endothelium 
in addition to decreased endothelial NOS activity, becomes one of the main points 
in the pathophysiology of HIE in preterm infants.
The follow-up results of these children included in this study identified sig-
nificant relationships between peripheral endothelial vasoregulatory markers in 
the perinatal period and the formation of developmental disorders at an early age 
[39]. It was found that, in the presence of high concentrations of NO, early eNOS 
activity was insufficient in infants with moderate-to-severe neurodevelopmental 
disorders compared to neonates with mild neurologic changes or without evidence 
of neurological impairment (Table 2). These findings suggest that depressed eNOS 
activity and increased non-endothelial NO synthesis play also important roles in the 
formation of developmental impairments.
It is known that there is a disturbance of vasoregulation in the pathogenesis 
of various pathologies of the HIE and prenatal period [40–42]. Depending on the 
complexity of the pathological process and the degree of morphologic and func-
tional immaturity of the body, hypoxic-ischemic lesions can lead to generalized 
system damage from mild to generalized severe dysfunctions and changes [43–47]. 
Acceleration of blood supply to vital organs during HIE is accompanied by periph-
eral vasospasm. However, the depletion of vascular tone’s regulating mechanisms 
during the severe and long-lasting processes leads to the tissue hypoxia and acidosis 
[40–47]. This often leads to changes in vital organs, especially in brain tissue whose 
results are with changes that cannot be restored.
It is considered that statistically significant increase of NO levels in peripheral 
blood circulation during severe hypoxic changes is due to the exhaustion of endo-
thelial NOS sources and the activation of non-endothelial NO synthesis sources. 
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It is likely that in high endothelin-1 levels in children, mild and moderate changes 
are likely to compensate for an increase in peripheral vein tone and vital organs to 
maintain normal blood circulation. Reduced vasoconstrictor endothelium-1 levels 
in children with severe HIE symptoms are likely to be associated with decreased 
vascular tone and tissue hypoperfusion. In conclusion, the changes of capillary 
blood circulation in the result of endothelial dysfunction have the main role in the 
pathogenesis of hypoxic-ischemic inflammation in preterm infants.
Table 1. 
The level of vasoregulatory indicators in microcirculatory disturbances in children with HIE risk (p<0,05 in 
comparison with children with 0-none of, 1- mild, 2-moderate, 3-severe microcirculatory changes, and with 
# - Control 1, ^ - Control 2 infants).
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Modern diagnostic technologies provide access to data which until recently 
were not available to specialists. Laser Doppler flowmetry (LDF) with amplitude-
frequency wavelet analysis of tissue perfusion oscillations in patients with essential 
arterial hypertension (AH) revealed two completely opposite functional states 
of resistive precapillary arterioles. One group of patients (48%) had a significant 
increase in the sympathetic vascular tone component and vasomotor microvascular 
endothelial dysfunction (precapillary resistance). The second group of patients 
(52%), on the contrary, exhibited a significant reduction in myogenic tone accom-
panied by raised arterial blood inflow and increased blood filling of the venular 
microcirculatory bloodstream (postcapillary resistance). Since the main target of 
most pharmaceuticals is the resistive vessels, LDF can be useful for the selection of 
personalized antihypertensive therapy that considers the functional state of resis-
tive microvessels.
Keywords: vasomotion, arteriole tone, peripheral vascular resistance, arterial 
hypertension, laser Doppler flowmetry, wavelet analysis
1. Introduction
In the past two decades, the interest in microcirculatory blood flow in patients 
with arterial hypertension (AH) has been steadily increasing due to the significant 
role of microcirculatory disorders in the pathogenesis of this disease [1–3] and 
unsatisfactory treatment results, when despite achievement of the target blood 
pressure with antihypertensive therapy, residual cardiovascular risks remain sub-
stantial [4]. Laser Doppler flowmetry (LDF) is a modern noninvasive technique for 
examining the microcirculatory blood flow in humans. Even though the skin vessels 
are not subjected to baroreflex regulation, the accumulated data suggests that the 
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increase in the sympathetic vascular tone component and vasomotor microvascular 
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panied by raised arterial blood inflow and increased blood filling of the venular 
microcirculatory bloodstream (postcapillary resistance). Since the main target of 
most pharmaceuticals is the resistive vessels, LDF can be useful for the selection of 
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1. Introduction
In the past two decades, the interest in microcirculatory blood flow in patients 
with arterial hypertension (AH) has been steadily increasing due to the significant 
role of microcirculatory disorders in the pathogenesis of this disease [1–3] and 
unsatisfactory treatment results, when despite achievement of the target blood 
pressure with antihypertensive therapy, residual cardiovascular risks remain sub-
stantial [4]. Laser Doppler flowmetry (LDF) is a modern noninvasive technique for 
examining the microcirculatory blood flow in humans. Even though the skin vessels 
are not subjected to baroreflex regulation, the accumulated data suggests that the 
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microvascular bed of the skin may reflect the microcirculatory system state in other 
bodily organs and systems [5–8]. The results of functional LDF tests demonstrate a 
significant correlation between the left ventricular ejection fraction and the end-
diastolic volume [9], flow-mediated vasodilation [10], and renal resistive index [11]. 
Discontinuation of antihypertensive therapy leads to a decrease in post-occlusive 
reactive hyperemia [12], which, in turn, correlates with the cardiovascular risk 
factors in the female population [13]. In 2011, the Peripheral Circulation Working 
Group of the European Society of Cardiology included LDF in the list of the recom-
mended methods to study endothelial function [14].
Arterial hypertension is a hemodynamic disease with a blood pressure (BP) rise 
due to an increase in the cardiac output and/or peripheral vascular resistance [15]. 
In the classic work on normo-, hypo-, and hypertensive cats, Zweifach demon-
strated that in the mesentery microvessels the greatest pressure gradient is recorded 
in arterioles <50 μm in diameter [16, 17]; at this level the Reynolds number is less 
than one and the viscous blood forces prevail over kinetic ones [18]. As in LDF 
resistive microvessels <50 μm in diameter are included in the probed volume [19], 
the interest in their functional state in AH is quite natural.
A fundamental feature of resistive arterioles is their high vasomotor activity. 
The arterioles are in constant motion, changing their tone and their lumen size, 
which manifests as vasomotions [20] with the respective changes in tissue perfu-
sion. The vasomotion phenomenon is due to the ability of smooth muscle cells to 
spontaneously contract with an average frequency of 6 times per minute. It is the 
myogenic resistance at the capillary sphincter level that is the last blood flow control 
link before the exchange vessels, i.e. capillaries. Myogenic vasomotions are clearly 
conducted into the capillary bed of the human skin [21], and their amplitude is 
positively correlated with the number of functioning capillaries [22]. In arterioles, 
the basal tone and vasomotor activity of smooth muscle cells are modulated from 
the outer layer of the vessel wall by sympathetic nervous system 2–3 times per 
minute, and from the lumen by endothelial factors with a frequency of less than 
once per minute. The vascular tone-forming mechanisms (endothelial, neurogenic, 
and myogenic) act directly via the smooth muscle cells of microvessels and, as a 
result of periodic changes in blood flow resistance, generate the corresponding 
fluctuations in tissue perfusion [23, 24]. Due to the alternating contractions and 
relaxations of the smooth muscle in the arterioles and capillary sphincters, the 
arterial blood flowing into the capillaries is modulated to the optimal volume for 
transcapillary exchange [25–28]. During self-organization of microcirculation, all 
regulatory mechanisms interact with each other in positive and negative feedback 
loops that are aimed at maintaining tissue homeostasis. Thus, the tone-forming 
mechanisms function mainly at the resistive arteriole level, thereby determining 
not only the capillary hemodynamic parameters but also the peripheral vascular 
resistance (PVR).
Other microcirculation modulation mechanisms are passive in relation to the 
arteriolar smooth muscle cells, but they determine the blood filling volume of the 
microvascular bed (MVB) by changing the longitudinal pressure gradient caused 
by periodic changes in BP at the “inlet” (pulse BP) and pressure variation in the 
venules during the respiratory cycles at the “outlet” of MVB. The pulse oscillation 
amplitude reflects the condition of the inflow tracts (arterioles) and the arterial 
blood inflow into the MVB, and the amplitude of respiratory-associated blood flow 
oscillations characterizes the state of the capillary outflow tract, thereby reflecting 
the blood volume in the venular section of MVB [26, 29–31].
The main aim of this pilot study was to evaluate the functional state of resistive 
vessels of the skin in patients with essential arterial hypertension according by LDF 
with an amplitude-frequency wavelet analysis of microcirculation fluctuations.
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2. Materials, methods and results
The skin perfusion was assessed in the supine position after a 15-min period 
of adaptation in a laboratory with a constant microclimate (+23 ± 1°С) in the 
morning (09:00–12:00 AM). The microcirculatory blood flow was recorded by 
a LAKK-02 single-channel laser analyzer of blood microcirculation in the visible 
red spectrum (wavelength of 630 nm) and a LAKK-TEST complex (OOO Research 
and Production Enterprise LAZMA, Russia) that allow evaluating the perfusion 
parameters in ~ 1.0–1.5 mm3 of skin, at a constant temperature in the studied region 
of +32°С. The sensor was located on the outer surface of the right forearm, in the 
midline 3–4 cm proximal to the wrist joint. The perfusion was recorded for 6 min. 
After the microcirculation study, all subjects received 24-h ambulatory blood pres-
sure monitoring (ABPM) on the left shoulder.
The initial LDF recording (Figure 1A) was subjected to amplitude-frequency 
wavelet analysis. The time-averaged amplitude of vasomotions was estimated 
by the maximum values (Amax) in the corresponding [32, 33] blood flow 
modulation frequency range: endothelial (Ae)—0.0095 − 0.021 Hz; neurogenic 
(An)—0.021 − 0.052 Hz; myogenic (Am)—0.052 − 0.145 Hz; respiratory-venular 
(Av)—0.145 − 0.6 Hz; pulse-cardial (Ac) —0.6 – 2 Hz (Figure 1B). The perfu-
sion level (M) and the amplitudes of the blood flow modulation mechanisms were 
assessed in perfusion units (PU).
The functional activity of the tone-forming blood flow modulation mechanisms 
(endothelial, neurogenic, and myogenic) was evaluated as follows – the higher the 
vasomotion amplitude, the lower the tone, and vice versa, the lower the vasomotion 
amplitude, the higher the tone generated by this regulatory mechanism. If we take 
the zero amplitude as the longitudinal axis of a microvessel (LAV), and the maxi-
mum vasomotion amplitude as the vascular wall (Figure 1B), then the dependence 
of the microvessel lumen size on the vasomotion amplitude is clearly evident.
At the first stage of the study, the main objective was to assess the functional 
activity of resistive arterioles depending on the blood pressure level. At this stage, the  
subjects included 90 people (47 men and 43 women) divided into three groups. The 
control group (NT) consisted of 32 clinically healthy normotensive volunteers.  
The second group consisted of 32 patients with stage 1 essential AH (AH1). The 
third group included 26 patients with stage 2 AH (AH2). All patients with AH who 
were receiving antihypertensive therapy had their therapy discontinued 10–14 days 
prior to the study (washed out). In the rest of the patients, AH was newly diagnosed 
Figure 1. 
Laser Doppler flowmetry (LDF). (A) It is a perfusion characteristic during 6 min. (B) It is amplitude-
frequency wavelet analysis of blood flow oscillations. Dotted lines indicate a microvessel, arrows mark the 
activity of tone forming mechanisms in blood flow modulation. LAV, the longitudinal axis of the vessel.
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microvascular bed of the skin may reflect the microcirculatory system state in other 
bodily organs and systems [5–8]. The results of functional LDF tests demonstrate a 
significant correlation between the left ventricular ejection fraction and the end-
diastolic volume [9], flow-mediated vasodilation [10], and renal resistive index [11]. 
Discontinuation of antihypertensive therapy leads to a decrease in post-occlusive 
reactive hyperemia [12], which, in turn, correlates with the cardiovascular risk 
factors in the female population [13]. In 2011, the Peripheral Circulation Working 
Group of the European Society of Cardiology included LDF in the list of the recom-
mended methods to study endothelial function [14].
Arterial hypertension is a hemodynamic disease with a blood pressure (BP) rise 
due to an increase in the cardiac output and/or peripheral vascular resistance [15]. 
In the classic work on normo-, hypo-, and hypertensive cats, Zweifach demon-
strated that in the mesentery microvessels the greatest pressure gradient is recorded 
in arterioles <50 μm in diameter [16, 17]; at this level the Reynolds number is less 
than one and the viscous blood forces prevail over kinetic ones [18]. As in LDF 
resistive microvessels <50 μm in diameter are included in the probed volume [19], 
the interest in their functional state in AH is quite natural.
A fundamental feature of resistive arterioles is their high vasomotor activity. 
The arterioles are in constant motion, changing their tone and their lumen size, 
which manifests as vasomotions [20] with the respective changes in tissue perfu-
sion. The vasomotion phenomenon is due to the ability of smooth muscle cells to 
spontaneously contract with an average frequency of 6 times per minute. It is the 
myogenic resistance at the capillary sphincter level that is the last blood flow control 
link before the exchange vessels, i.e. capillaries. Myogenic vasomotions are clearly 
conducted into the capillary bed of the human skin [21], and their amplitude is 
positively correlated with the number of functioning capillaries [22]. In arterioles, 
the basal tone and vasomotor activity of smooth muscle cells are modulated from 
the outer layer of the vessel wall by sympathetic nervous system 2–3 times per 
minute, and from the lumen by endothelial factors with a frequency of less than 
once per minute. The vascular tone-forming mechanisms (endothelial, neurogenic, 
and myogenic) act directly via the smooth muscle cells of microvessels and, as a 
result of periodic changes in blood flow resistance, generate the corresponding 
fluctuations in tissue perfusion [23, 24]. Due to the alternating contractions and 
relaxations of the smooth muscle in the arterioles and capillary sphincters, the 
arterial blood flowing into the capillaries is modulated to the optimal volume for 
transcapillary exchange [25–28]. During self-organization of microcirculation, all 
regulatory mechanisms interact with each other in positive and negative feedback 
loops that are aimed at maintaining tissue homeostasis. Thus, the tone-forming 
mechanisms function mainly at the resistive arteriole level, thereby determining 
not only the capillary hemodynamic parameters but also the peripheral vascular 
resistance (PVR).
Other microcirculation modulation mechanisms are passive in relation to the 
arteriolar smooth muscle cells, but they determine the blood filling volume of the 
microvascular bed (MVB) by changing the longitudinal pressure gradient caused 
by periodic changes in BP at the “inlet” (pulse BP) and pressure variation in the 
venules during the respiratory cycles at the “outlet” of MVB. The pulse oscillation 
amplitude reflects the condition of the inflow tracts (arterioles) and the arterial 
blood inflow into the MVB, and the amplitude of respiratory-associated blood flow 
oscillations characterizes the state of the capillary outflow tract, thereby reflecting 
the blood volume in the venular section of MVB [26, 29–31].
The main aim of this pilot study was to evaluate the functional state of resistive 
vessels of the skin in patients with essential arterial hypertension according by LDF 
with an amplitude-frequency wavelet analysis of microcirculation fluctuations.
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2. Materials, methods and results
The skin perfusion was assessed in the supine position after a 15-min period 
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morning (09:00–12:00 AM). The microcirculatory blood flow was recorded by 
a LAKK-02 single-channel laser analyzer of blood microcirculation in the visible 
red spectrum (wavelength of 630 nm) and a LAKK-TEST complex (OOO Research 
and Production Enterprise LAZMA, Russia) that allow evaluating the perfusion 
parameters in ~ 1.0–1.5 mm3 of skin, at a constant temperature in the studied region 
of +32°С. The sensor was located on the outer surface of the right forearm, in the 
midline 3–4 cm proximal to the wrist joint. The perfusion was recorded for 6 min. 
After the microcirculation study, all subjects received 24-h ambulatory blood pres-
sure monitoring (ABPM) on the left shoulder.
The initial LDF recording (Figure 1A) was subjected to amplitude-frequency 
wavelet analysis. The time-averaged amplitude of vasomotions was estimated 
by the maximum values (Amax) in the corresponding [32, 33] blood flow 
modulation frequency range: endothelial (Ae)—0.0095 − 0.021 Hz; neurogenic 
(An)—0.021 − 0.052 Hz; myogenic (Am)—0.052 − 0.145 Hz; respiratory-venular 
(Av)—0.145 − 0.6 Hz; pulse-cardial (Ac) —0.6 – 2 Hz (Figure 1B). The perfu-
sion level (M) and the amplitudes of the blood flow modulation mechanisms were 
assessed in perfusion units (PU).
The functional activity of the tone-forming blood flow modulation mechanisms 
(endothelial, neurogenic, and myogenic) was evaluated as follows – the higher the 
vasomotion amplitude, the lower the tone, and vice versa, the lower the vasomotion 
amplitude, the higher the tone generated by this regulatory mechanism. If we take 
the zero amplitude as the longitudinal axis of a microvessel (LAV), and the maxi-
mum vasomotion amplitude as the vascular wall (Figure 1B), then the dependence 
of the microvessel lumen size on the vasomotion amplitude is clearly evident.
At the first stage of the study, the main objective was to assess the functional 
activity of resistive arterioles depending on the blood pressure level. At this stage, the  
subjects included 90 people (47 men and 43 women) divided into three groups. The 
control group (NT) consisted of 32 clinically healthy normotensive volunteers.  
The second group consisted of 32 patients with stage 1 essential AH (AH1). The 
third group included 26 patients with stage 2 AH (AH2). All patients with AH who 
were receiving antihypertensive therapy had their therapy discontinued 10–14 days 
prior to the study (washed out). In the rest of the patients, AH was newly diagnosed 
Figure 1. 
Laser Doppler flowmetry (LDF). (A) It is a perfusion characteristic during 6 min. (B) It is amplitude-
frequency wavelet analysis of blood flow oscillations. Dotted lines indicate a microvessel, arrows mark the 
activity of tone forming mechanisms in blood flow modulation. LAV, the longitudinal axis of the vessel.
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and they had not received any drug therapy before the inclusion in the study 
(primary). The main characteristics of the analyzed groups and the hemodynamic 
parameters at the 10th minute of the adaptation period before LDF are presented 
in Table 1. According to the ABPM, the mean blood pressure (MBP) in the daytime 
was 89.8 ± 7.8 mm Hg in NT, 101.3 ± 5.2 mm Hg in AH 1, and 112.5 ± 6.9 mmHg in 
AH 2.
The functional activity of the main tone-forming microcirculation modulation 
mechanisms is shown in Figure 2A. Neither the expected increase in the basal myo-
cyte tone (Am), nor a rise in sympathetic activity (An), nor signs of microvascular 
endothelial vasomotor dysfunction (Ae) were observed in any of the groups.
Figure 2B presents the analysis results of the tissue perfusion (M) and passive 
blood flow modulation mechanisms (Ac and Av) that determine the blood filling 
Figure 2. 
LDF with amplitude-frequency wavelet analysis of blood flow in the first stage of the study. (A) The functional 
activity of tone-forming mechanisms (Ae, An, Am) of blood flow modulation. (B) The tissue perfusion (M) 
and the functional activity of the passive blood flow modulation mechanisms that reflect the condition of the 
blood inflow tracts to the capillary bed (Ac) and the outflow (Av) tracts. The rectangle indicates a range of 
25–75 percentiles, and the median is indicated by a line.
NT (n = 32) AH1 (n = 32) AH2 (n = 26)
Age (years) 48.9 ± 10.4 48.7 ± 11.2 49.8 ± 10.8
Sex (men/women) 13/19 17/15 17/9
primary/washed – / – 20/12 9/17
SBP (mmHg) 117.5 ± 9.8 141.5 ± 12.8* 156.0 ± 15.4*,#
DBP (mmHg) 74.5 ± 8.6 86.8 ± 9.8* 95.2 ± 12.3*,#
HR (beats/min) 65.6 ± 6.9 68.2 ± 8.1 70.6 ± 9.3
*Differences are significant with respect to NT (p < 0.000001).
#Differences are significant with respect to AH1 (p < 0.0001).
Table 1. 
The main characteristics of the analyzed groups—first stage of the study.
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of the microvascular bed (MVB). The data obtained demonstrate that statistically 
significant differences are present only in blood volume in the venular section of 
the MVB (Av), which indicates a gradual increase in the venular blood volume as 
AH progresses. It is very important that out of all six parameters analyzed, only the 
amplitude of respiratory-associated blood flow oscillations (Av) had a weak but 
significant positive correlation with the MBP in the daytime (r = 0.25; p = 0.035) 
and night time (r = 0.29; p = 0.013). This correlation means that the more blood 
there is in the venular MVB, the higher the BP.
From the results obtained, it can be concluded that the functional state of the 
blood outflow tracts from the capillary bed plays a more significant role in the total 
peripheral vascular resistance (TPVR) than the functional state of resistive precapil-
lary arterioles. The obtained data are in agreement with the opinion of Coulson et al. 
who distinguish two vascular resistance levels: the first is before the capillary plexus 
with an estimated contribution to TPVR of 67% according to the authors, and the 
second is after the capillary plexus with a contribution to TPVR of about 33% [34].
Functional disorders were dominant not in the blood inflow to the capillaries 
(resistive arterioles) but in the outflow system (venules), and that was a completely 
unexpected finding and does not fit into any of the existing AH development 
hypotheses (neurogenic, salt, membrane, etc.). It is also highly important that LDF 
demonstrated changes in tissue perfusion associated with respiratory movements of 
the chest in far from all AH patients.
And what is the nature of respiratory-associated tissue perfusion oscillations? 
The blood flow oscillations synchronous with breathing spread into microvessels 
from the capillary blood outflow side and are recorded in the venules. A mechanical 
passive transmission of respiratory intrathoracic pressure changes mediated by the 
venous system is discussed as their origin.
Normally, no respiratory-associated tissue perfusion oscillations are identified 
in LDF, regardless of the arterial blood volume flowing into the microcirculatory 
bloodstream. This is due to several factors. Firstly, the cross-sectional area and vol-
ume of the venular MVB significantly exceed the cross-sectional area and volume 
of the arteriolar MVB. Secondly, veins collapse. To maintain a round vein shape, a 
pressure of about 6–9 mmHg is required, and at lower values, the veins are ellipsoi-
dal. With the same perimeter, the cross-sectional area of an ellipse is much smaller 
than that of a circle, so when the pressure increases from 0 to 6–9 mmHg, the 
capacity of the venous segment of the vascular bed increases substantially. Already 
at 10 mmHg, the increase in venous capacity is more than 60% of the maximum 
possible. Then the increase in the venous volume decelerates dramatically and is 
about 30% with a pressure rise from 10 to 80 mmHg [35].
How can intrathoracic pressure changes during respiration be conducted along 
the venous vasculature to the periphery, that is, to the postcapillary skin vessels? 
At low pressures, the collapsed venous walls will obviously dampen the retrograde 
respiratory wave propagation. Consequently, the propagation of the respiratory 
wave to the periphery can be observed only with fully expanded veins. Thus, the 
higher the blood volume in the venous bed, and hence the pressure in them, the 
better the respiratory waves are propagated to the periphery, and the higher is  
the Av amplitude. It is obvious that there is a certain critical Av value that reflects the 
degree of blood filling of the venous bed. During a long period of observation and 
measurements, the maximum Av value was found empirically to be 0.08 PU, which 
suggests that the veins are not yet fully expanded because the respiratory waves are 
not observed during the recording of tissue perfusion. At Av values of 0.09 PU, 
respiratory-associated oscillations of perfusion begin to appear in the LDF record-
ing. These oscillations have a low amplitude and are not observed at every breath, 
which most likely depends on the volume and rate of respiratory movements.
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and they had not received any drug therapy before the inclusion in the study 
(primary). The main characteristics of the analyzed groups and the hemodynamic 
parameters at the 10th minute of the adaptation period before LDF are presented 
in Table 1. According to the ABPM, the mean blood pressure (MBP) in the daytime 
was 89.8 ± 7.8 mm Hg in NT, 101.3 ± 5.2 mm Hg in AH 1, and 112.5 ± 6.9 mmHg in 
AH 2.
The functional activity of the main tone-forming microcirculation modulation 
mechanisms is shown in Figure 2A. Neither the expected increase in the basal myo-
cyte tone (Am), nor a rise in sympathetic activity (An), nor signs of microvascular 
endothelial vasomotor dysfunction (Ae) were observed in any of the groups.
Figure 2B presents the analysis results of the tissue perfusion (M) and passive 
blood flow modulation mechanisms (Ac and Av) that determine the blood filling 
Figure 2. 
LDF with amplitude-frequency wavelet analysis of blood flow in the first stage of the study. (A) The functional 
activity of tone-forming mechanisms (Ae, An, Am) of blood flow modulation. (B) The tissue perfusion (M) 
and the functional activity of the passive blood flow modulation mechanisms that reflect the condition of the 
blood inflow tracts to the capillary bed (Ac) and the outflow (Av) tracts. The rectangle indicates a range of 
25–75 percentiles, and the median is indicated by a line.
NT (n = 32) AH1 (n = 32) AH2 (n = 26)
Age (years) 48.9 ± 10.4 48.7 ± 11.2 49.8 ± 10.8
Sex (men/women) 13/19 17/15 17/9
primary/washed – / – 20/12 9/17
SBP (mmHg) 117.5 ± 9.8 141.5 ± 12.8* 156.0 ± 15.4*,#
DBP (mmHg) 74.5 ± 8.6 86.8 ± 9.8* 95.2 ± 12.3*,#
HR (beats/min) 65.6 ± 6.9 68.2 ± 8.1 70.6 ± 9.3
*Differences are significant with respect to NT (p < 0.000001).
#Differences are significant with respect to AH1 (p < 0.0001).
Table 1. 
The main characteristics of the analyzed groups—first stage of the study.
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of the microvascular bed (MVB). The data obtained demonstrate that statistically 
significant differences are present only in blood volume in the venular section of 
the MVB (Av), which indicates a gradual increase in the venular blood volume as 
AH progresses. It is very important that out of all six parameters analyzed, only the 
amplitude of respiratory-associated blood flow oscillations (Av) had a weak but 
significant positive correlation with the MBP in the daytime (r = 0.25; p = 0.035) 
and night time (r = 0.29; p = 0.013). This correlation means that the more blood 
there is in the venular MVB, the higher the BP.
From the results obtained, it can be concluded that the functional state of the 
blood outflow tracts from the capillary bed plays a more significant role in the total 
peripheral vascular resistance (TPVR) than the functional state of resistive precapil-
lary arterioles. The obtained data are in agreement with the opinion of Coulson et al. 
who distinguish two vascular resistance levels: the first is before the capillary plexus 
with an estimated contribution to TPVR of 67% according to the authors, and the 
second is after the capillary plexus with a contribution to TPVR of about 33% [34].
Functional disorders were dominant not in the blood inflow to the capillaries 
(resistive arterioles) but in the outflow system (venules), and that was a completely 
unexpected finding and does not fit into any of the existing AH development 
hypotheses (neurogenic, salt, membrane, etc.). It is also highly important that LDF 
demonstrated changes in tissue perfusion associated with respiratory movements of 
the chest in far from all AH patients.
And what is the nature of respiratory-associated tissue perfusion oscillations? 
The blood flow oscillations synchronous with breathing spread into microvessels 
from the capillary blood outflow side and are recorded in the venules. A mechanical 
passive transmission of respiratory intrathoracic pressure changes mediated by the 
venous system is discussed as their origin.
Normally, no respiratory-associated tissue perfusion oscillations are identified 
in LDF, regardless of the arterial blood volume flowing into the microcirculatory 
bloodstream. This is due to several factors. Firstly, the cross-sectional area and vol-
ume of the venular MVB significantly exceed the cross-sectional area and volume 
of the arteriolar MVB. Secondly, veins collapse. To maintain a round vein shape, a 
pressure of about 6–9 mmHg is required, and at lower values, the veins are ellipsoi-
dal. With the same perimeter, the cross-sectional area of an ellipse is much smaller 
than that of a circle, so when the pressure increases from 0 to 6–9 mmHg, the 
capacity of the venous segment of the vascular bed increases substantially. Already 
at 10 mmHg, the increase in venous capacity is more than 60% of the maximum 
possible. Then the increase in the venous volume decelerates dramatically and is 
about 30% with a pressure rise from 10 to 80 mmHg [35].
How can intrathoracic pressure changes during respiration be conducted along 
the venous vasculature to the periphery, that is, to the postcapillary skin vessels? 
At low pressures, the collapsed venous walls will obviously dampen the retrograde 
respiratory wave propagation. Consequently, the propagation of the respiratory 
wave to the periphery can be observed only with fully expanded veins. Thus, the 
higher the blood volume in the venous bed, and hence the pressure in them, the 
better the respiratory waves are propagated to the periphery, and the higher is  
the Av amplitude. It is obvious that there is a certain critical Av value that reflects the 
degree of blood filling of the venous bed. During a long period of observation and 
measurements, the maximum Av value was found empirically to be 0.08 PU, which 
suggests that the veins are not yet fully expanded because the respiratory waves are 
not observed during the recording of tissue perfusion. At Av values of 0.09 PU, 
respiratory-associated oscillations of perfusion begin to appear in the LDF record-
ing. These oscillations have a low amplitude and are not observed at every breath, 
which most likely depends on the volume and rate of respiratory movements.
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For the second stage of the study, a homogeneous group of 63 patients with AH 
was selected with mean daytime SBP of 140–159 mmHg according to ABPM and/or 
mean daily DBP of 90–99 mmHg. Just as at the first stage, all AH patients receiving 
antihypertensive therapy had their therapy discontinued 10–14 days prior to the 
study (washed out), or AH was diagnosed for the first time with no drug therapy 
before inclusion into the study (primary). The control group (NT) consisted of 
30 clinically healthy normotensive volunteers. Based on the functional state of the 
venular microvessels (Av), the AH patients were divided into two groups. The first 
(VN) included 30 patients (48%) with no signs of an increased blood volume in 
the venular MVB (Av ≤ 0.08 PU). The second group (VP) consisted of 33 patients 
(52%) with signs of hypervolemia in the blood outflow tracts from the capillary bed 
(Av ≥ 0.09 PU) of varying severity. The groups characteristics and the hemody-
namic parameters immediately before LDF (10th minute of the adaptation period) 
are presented in Table 2.
Based on the grouping parameter (Av) value, 8 subjects in the NT group (27%) 
had a moderate increase in blood volume in the venular MVB – Av = 0.09 PU 
(n = 3), Av = 0.1 PU (n = 4), Av = 0.12 PU (n = 1).
Figure 3 presents clinical examples of LDF in the groups analyzed. BP was 
measured 5 min before the start of LDF. Figure 3B shows that not every respira-
tory movement of a normotensive volunteer from the NT group is accompanied 
by a distinct change in tissue perfusion, and the main differences are observed 
in the amplitude of respiratory-associated blood flow oscillations. In a VP 
patient (Figure 3D), the differences are more pronounced not in amplitude 
but in the frequency of perfusion changes that coincide with the respiration 
frequency.
An analysis of the perfusion level and microcirculatory blood flow modulation 
mechanisms which determine the MVB blood filling demonstrated that in the VN 
group there was no statistically significant difference in tissue perfusion and pulse 
oscillation amplitude relative to NT, and the blood filling of venules is lower  
(Figure 4A). The situation is totally different in the VP group. A statistically sig-
nificant rise in tissue perfusion relative to NT (p < 0.0003) can be explained by an 
increased contribution to the power of the signal reflected from red blood cells in the 
venular MVB. An unexpected finding was a significant increase in the amplitude of 
pulse oscillations relative to NT (p < 0.004), which indicates a higher arterial blood 
inflow to the exchange vessels. The obtained results demonstrate that the increase in 
the MVB perfusion is caused not only by a larger blood volume in the venular section 
(disrupted outflow) but also by an increased inflow of arterial blood.
An analysis of the functional activity of the tone-forming mechanisms dem-
onstrated a significant (p < 0.002) decrease was also observed in the amplitude of 
NT (n = 30) VN (n = 30) VP (n = 33)
Age (years) 44.9 ± 10.4 48.9 ± 10.3 47.8 ± 10.3
Sex (men/women) 15/15 17/13 17/16
primary/washed – / – 12/18 11/22
SBP (mmHg) 118.0 ± 10.1 140.0 ± 14.1* 142.6 ± 14.7*
DBP (mmHg) 76.5 ± 9.0 88.3 ± 9.8* 91.1 ± 8.9*
HR (beats/min) 65.8 ± 8.5 68.1 ± 7.9 67.2 ± 9.1
*Differences are significant with respect to NT (p < 0.000005).
Table 2. 
The main characteristics of the analyzed groups—second stage of the study.
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Figure 3. 
The first minute of LDF. The functional state of the venular MVB. (A) NT group, BP is 115/70 mmHg: 
Respiratory-associated blood flow oscillations are not detected, perfusion (M) is 3.81 PU, respiration rate (RR) 
is 16/min, and Av is 0.05 PU. (B) NT group, BP is 130/80 mmHg: М – 3.82 PU, RR – 16/min, Av – 0.10 PU.  
(C) VN group, BP is 145/80 mmHg: M – 3.56 PU, RR – 16/min, Av – 0.07 PU. (D) VP group, BP is 
150/90 mmHg: M – 3.89 PU, RR – 16/min, Av – 0.20 PU. The dotted lines reflect the changes in tissue perfusion 
synchronized with the respiratory chest movements.
Figure 4. 
LDF with amplitude-frequency wavelet analysis of blood flow in the second stage of the study. (A) The tissue 
perfusion (M) and the functional activity of the microcirculation modulation mechanisms which determine 
the blood filling of the microcirculatory bloodstream – The pulse (Ac) and respiratory-associated (Av) blood 
flow oscillation amplitude. (B) The functional activity of the tone-forming microcirculation modulation 
mechanisms (Ae, an, Am).
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by a distinct change in tissue perfusion, and the main differences are observed 
in the amplitude of respiratory-associated blood flow oscillations. In a VP 
patient (Figure 3D), the differences are more pronounced not in amplitude 
but in the frequency of perfusion changes that coincide with the respiration 
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An analysis of the perfusion level and microcirculatory blood flow modulation 
mechanisms which determine the MVB blood filling demonstrated that in the VN 
group there was no statistically significant difference in tissue perfusion and pulse 
oscillation amplitude relative to NT, and the blood filling of venules is lower  
(Figure 4A). The situation is totally different in the VP group. A statistically sig-
nificant rise in tissue perfusion relative to NT (p < 0.0003) can be explained by an 
increased contribution to the power of the signal reflected from red blood cells in the 
venular MVB. An unexpected finding was a significant increase in the amplitude of 
pulse oscillations relative to NT (p < 0.004), which indicates a higher arterial blood 
inflow to the exchange vessels. The obtained results demonstrate that the increase in 
the MVB perfusion is caused not only by a larger blood volume in the venular section 
(disrupted outflow) but also by an increased inflow of arterial blood.
An analysis of the functional activity of the tone-forming mechanisms dem-
onstrated a significant (p < 0.002) decrease was also observed in the amplitude of 
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Figure 3. 
The first minute of LDF. The functional state of the venular MVB. (A) NT group, BP is 115/70 mmHg: 
Respiratory-associated blood flow oscillations are not detected, perfusion (M) is 3.81 PU, respiration rate (RR) 
is 16/min, and Av is 0.05 PU. (B) NT group, BP is 130/80 mmHg: М – 3.82 PU, RR – 16/min, Av – 0.10 PU.  
(C) VN group, BP is 145/80 mmHg: M – 3.56 PU, RR – 16/min, Av – 0.07 PU. (D) VP group, BP is 
150/90 mmHg: M – 3.89 PU, RR – 16/min, Av – 0.20 PU. The dotted lines reflect the changes in tissue perfusion 
synchronized with the respiratory chest movements.
Figure 4. 
LDF with amplitude-frequency wavelet analysis of blood flow in the second stage of the study. (A) The tissue 
perfusion (M) and the functional activity of the microcirculation modulation mechanisms which determine 
the blood filling of the microcirculatory bloodstream – The pulse (Ac) and respiratory-associated (Av) blood 
flow oscillation amplitude. (B) The functional activity of the tone-forming microcirculation modulation 
mechanisms (Ae, an, Am).
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neurogenic vasomotions (An), which can be regarded as an increase in the sympa-
thetic adrenergic tone. Meanwhile, the basal tone of smooth muscle cells (Am) was 
unchanged and comparable to that in the control group (Figure 4B).
The tone-forming mechanisms were in a completely opposite state in the VP 
group. Relative to NT, there were no significant differences in the functional 
activity of the endothelial and neurogenic arteriolar tone regulation mecha-
nisms, although there was a trend towards a vasomotion amplitude increase by 
these regulatory mechanisms. However, the basal tone of the smooth muscle 
cells in precapillary arterioles and capillary sphincters was significantly reduced 
(p < 0.05), which was indicated by the myogenic vasomotion amplitude (Am) 
increase.
Thus, according to the functional state of the skin microcirculatory vessels, 
we obtained two completely opposite groups of patients with AH that initially 
seemed homogeneous. The differences between the groups were observed in all 
the six parameters analyzed: tissue perfusion (p < 0.002), amplitude of pulse 
(p < 0.002) and respiratory-associated (p < 0.000001) blood flow oscillations, 
amplitude of endothelial (p < 0.002), neurogenic (p < 0.003), and myogenic 
(p < 0.003) vasomotions.
From the data obtained it can be assumed that in AH patients without dis-
ruptions blood outflow from the capillary bed, hypertension is caused by an 
increase in the sympathetic adrenergic vascular tone regulation mechanism and 
by a vasomotor dysfunction of the microvascular endothelium. In patients with 
impaired blood outflow from the capillary bed associated with a decline in the 
myogenic tone of precapillary arterioles, an increase in the arterial blood inflow 
is observed.
The ABPM results were no less interesting. Figure 5 shows significantly 
higher BP during both day and nighttime in the VP patients relative to VN, 
except for the nocturnal diastolic BP. A paradoxical situation arose – BP was 
higher in patients with a reduced resistive arteriolar tone than in patients with an 
increased tone.
Figure 5. 
The results of 24-h arterial blood pressure monitoring (ABPM). (А) Systolic BP (SBP). (B) Diastolic BP 
(DBP). (C) Mean BP (MBP).
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3. Discussion
The pilot study of the functional state of the skin microvascular bed in essential 
arterial hypertension raised fundamental questions that require reflection and 
detailed consideration.
The first fundamental question is the validity of LDF in assessing the functional 
state of the resistive vascular bed in AH. On the one hand, there is no statistically 
significant correlation of BP with the functional activity of the tone-forming 
mechanisms in resistive arterioles. This can be explained by the absence of regula-
tory baroreflex mechanisms in the skin microvessels in contrast to microvessels in 
the striated muscle. On the other hand, the amplitude-frequency wavelet analysis 
of microcirculatory blood flow oscillations demonstrated that the functional state 
of the regulatory mechanisms in exchange microvessels may differ drastically in the 
initially homogeneous group of AH patients. This, in turn, not only has different 
hemodynamic and metabolic effects but quite evidently demands an individual 
approach to selecting antihypertensive therapy.
Let us consider the VN group in terms of the functional state of resistive arteri-
oles. This group has a moderate decrease in the endothelial vasomotion amplitude 
with a trend towards significance (p = 0.065), indicating vasomotor dysfunc-
tion of the microvascular endothelium, which is consistent with the previously 
obtained results [36]. The group also exhibits a significant reduction in the neu-
rogenic vasomotion amplitude (p < 0.002), which can be regarded as an increase 
in the sympathetic adrenergic tone. From the data obtained, it can be concluded 
that the functional state of resistive arterioles in AH patients with normal blood 
outflow from the capillary bed does not contradict Lang’s neurogenic theory and 
the current ideas about the role of endothelial dysfunction in the AH pathogenesis. 
In such a functional state of the resistive arterioles, the prescription of drugs which 
lead to a tone decrease through various regulatory mechanisms can be considered 
quite justified.
Now let us consider the VP group, which raises many more questions. Based on 
the precapillary arteriole functional state, it can be concluded that there is a sig-
nificant decrease in the basal tone of smooth muscle cells in arterioles and capillary 
sphincters. The insignificant (relative to NT) trend towards an amplitude increase 
(tone decline) of endothelial and neurogenic vasomotions can be explained in two 
ways: 1) changes in the regulatory systems themselves; 2) decreased smooth muscle 
cell sensitivity to the regulatory effects of the endothelium and the sympathetic 
adrenergic system. The hemodynamic consequences of the precapillary arteriolar 
tone are an increase in the arterial blood inflow (Ac), venular blood volume (Av), 
and as a result, tissue hyperperfusion, i.e. an increase in M.
Gryglewska et al. [37] also draw attention to a significant increase in the 
vasomotion amplitude in the neurogenic and myogenic activity range in patients 
with masked hypertension. The patients analyzed in that study were on average 
10 years younger than our subjects. The data presented by the authors demonstrate 
that a neurogenic tone decline is observed against the background of an increased 
norepinephrine level. One possible cause for the increased plasma norepinephrine 
is the neurotransmitter leakage from the neuro-muscular synapses in microvessels 
in AH patients when the sympathetic nervous system activity is enhanced. This 
phenomenon is well-established for skeletal muscles [38, 39], but not for the skin 
microvessels which are not subject to baroreflex regulation [40]. The authors of 
the study suggest that the vasomotion amplitude increase in patients with masked 
hypertension is of a compensatory nature, aimed at meeting the metabolic needs 
of tissues when there is a reduced number of functioning capillaries, while the 
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neurogenic vasomotions (An), which can be regarded as an increase in the sympa-
thetic adrenergic tone. Meanwhile, the basal tone of smooth muscle cells (Am) was 
unchanged and comparable to that in the control group (Figure 4B).
The tone-forming mechanisms were in a completely opposite state in the VP 
group. Relative to NT, there were no significant differences in the functional 
activity of the endothelial and neurogenic arteriolar tone regulation mecha-
nisms, although there was a trend towards a vasomotion amplitude increase by 
these regulatory mechanisms. However, the basal tone of the smooth muscle 
cells in precapillary arterioles and capillary sphincters was significantly reduced 
(p < 0.05), which was indicated by the myogenic vasomotion amplitude (Am) 
increase.
Thus, according to the functional state of the skin microcirculatory vessels, 
we obtained two completely opposite groups of patients with AH that initially 
seemed homogeneous. The differences between the groups were observed in all 
the six parameters analyzed: tissue perfusion (p < 0.002), amplitude of pulse 
(p < 0.002) and respiratory-associated (p < 0.000001) blood flow oscillations, 
amplitude of endothelial (p < 0.002), neurogenic (p < 0.003), and myogenic 
(p < 0.003) vasomotions.
From the data obtained it can be assumed that in AH patients without dis-
ruptions blood outflow from the capillary bed, hypertension is caused by an 
increase in the sympathetic adrenergic vascular tone regulation mechanism and 
by a vasomotor dysfunction of the microvascular endothelium. In patients with 
impaired blood outflow from the capillary bed associated with a decline in the 
myogenic tone of precapillary arterioles, an increase in the arterial blood inflow 
is observed.
The ABPM results were no less interesting. Figure 5 shows significantly 
higher BP during both day and nighttime in the VP patients relative to VN, 
except for the nocturnal diastolic BP. A paradoxical situation arose – BP was 
higher in patients with a reduced resistive arteriolar tone than in patients with an 
increased tone.
Figure 5. 
The results of 24-h arterial blood pressure monitoring (ABPM). (А) Systolic BP (SBP). (B) Diastolic BP 
(DBP). (C) Mean BP (MBP).
143
Functional State of the Microvascular Bed of the Skin in Essential Arterial Hypertension…
DOI: http://dx.doi.org/10.5772/intechopen.89852
3. Discussion
The pilot study of the functional state of the skin microvascular bed in essential 
arterial hypertension raised fundamental questions that require reflection and 
detailed consideration.
The first fundamental question is the validity of LDF in assessing the functional 
state of the resistive vascular bed in AH. On the one hand, there is no statistically 
significant correlation of BP with the functional activity of the tone-forming 
mechanisms in resistive arterioles. This can be explained by the absence of regula-
tory baroreflex mechanisms in the skin microvessels in contrast to microvessels in 
the striated muscle. On the other hand, the amplitude-frequency wavelet analysis 
of microcirculatory blood flow oscillations demonstrated that the functional state 
of the regulatory mechanisms in exchange microvessels may differ drastically in the 
initially homogeneous group of AH patients. This, in turn, not only has different 
hemodynamic and metabolic effects but quite evidently demands an individual 
approach to selecting antihypertensive therapy.
Let us consider the VN group in terms of the functional state of resistive arteri-
oles. This group has a moderate decrease in the endothelial vasomotion amplitude 
with a trend towards significance (p = 0.065), indicating vasomotor dysfunc-
tion of the microvascular endothelium, which is consistent with the previously 
obtained results [36]. The group also exhibits a significant reduction in the neu-
rogenic vasomotion amplitude (p < 0.002), which can be regarded as an increase 
in the sympathetic adrenergic tone. From the data obtained, it can be concluded 
that the functional state of resistive arterioles in AH patients with normal blood 
outflow from the capillary bed does not contradict Lang’s neurogenic theory and 
the current ideas about the role of endothelial dysfunction in the AH pathogenesis. 
In such a functional state of the resistive arterioles, the prescription of drugs which 
lead to a tone decrease through various regulatory mechanisms can be considered 
quite justified.
Now let us consider the VP group, which raises many more questions. Based on 
the precapillary arteriole functional state, it can be concluded that there is a sig-
nificant decrease in the basal tone of smooth muscle cells in arterioles and capillary 
sphincters. The insignificant (relative to NT) trend towards an amplitude increase 
(tone decline) of endothelial and neurogenic vasomotions can be explained in two 
ways: 1) changes in the regulatory systems themselves; 2) decreased smooth muscle 
cell sensitivity to the regulatory effects of the endothelium and the sympathetic 
adrenergic system. The hemodynamic consequences of the precapillary arteriolar 
tone are an increase in the arterial blood inflow (Ac), venular blood volume (Av), 
and as a result, tissue hyperperfusion, i.e. an increase in M.
Gryglewska et al. [37] also draw attention to a significant increase in the 
vasomotion amplitude in the neurogenic and myogenic activity range in patients 
with masked hypertension. The patients analyzed in that study were on average 
10 years younger than our subjects. The data presented by the authors demonstrate 
that a neurogenic tone decline is observed against the background of an increased 
norepinephrine level. One possible cause for the increased plasma norepinephrine 
is the neurotransmitter leakage from the neuro-muscular synapses in microvessels 
in AH patients when the sympathetic nervous system activity is enhanced. This 
phenomenon is well-established for skeletal muscles [38, 39], but not for the skin 
microvessels which are not subject to baroreflex regulation [40]. The authors of 
the study suggest that the vasomotion amplitude increase in patients with masked 
hypertension is of a compensatory nature, aimed at meeting the metabolic needs 
of tissues when there is a reduced number of functioning capillaries, while the 
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increase in blood pressure is due to the influence of various hormones, proinflam-
matory cytokines, and other humoral substances possibly secreted by the visceral 
adipose tissue [37].
Similar results for the functional state of the resistive skin microvessels in AH 
patients were also obtained also in another study [41]. In an age-matched group, 
Rossi et al. observed a significant increase in tissue perfusion compared to nor-
motensive subjects, associated with significantly higher vasomotion amplitudes 
within the range of the endothelial, neurogenic, respiratory (venular), and cardial 
blood flow modulation mechanisms. The authors explain the enhanced vasomotor 
function of the microvascular endothelium as a response to an increase in the shear 
stress at high BP values, and the higher vasomotion amplitude in the range of the 
neurogenic regulation mechanism as sympathetic nervous system activation. The 
authors consider the observed increase in the pulse oscillation amplitude a mani-
festation of a high BP level, and the rise in the respiratory-associated blood flow 
oscillation amplitude as a compensatory reaction aimed at extending the time for 
oxygen extraction by tissues under microvascular rarefication.
Hemodynamic changes at the MVB level entail significant metabolic changes. 
Of the three main metabolic mechanisms (diffusion, filtration-reabsorption, and 
vesicular), filtration-reabsorption depends directly on the hemodynamic param-
eters. This metabolic mechanism is described by the Starling equation and provides 
bidirectional transendothelial transport of water-soluble and low-molecular-weight 
substances due to the difference in the hydrostatic and colloid osmotic blood pres-
sures. Enhanced arterial blood inflow (Ac) with impaired venular outflow (Av) in 
VP patients can lead to a substantial rise in hydrostatic pressure in the capillaries, 
which is observed in far from all AH patients during direct pressure measurement 
in the nail bed capillaries [42–44]. An increase in the capillary hydrostatic pressure 
leads to a shift in the filtration-reabsorption metabolic mechanism towards the 
predominance of filtration, with developing hyperhydration of the interstitial space 
and latent fluid retention in the tissues [45, 46]. The hyperhydration of the inter-
stitial space increases the blood↔cell distance for nutrients and tissue metabolism 
products, leading to a disruption in the metabolic process rate.
Another very important issue is the choice of antihypertensive therapy in this 
group of patients. The choice of vasodilating drugs is highly dubious. An additional 
decline in the initially low resistive arteriolar tone can have a range of negative 
consequences, including orthostatic instability, syncope, peripheral edema, etc. The 
study by Makolkin et al. [47] is highly illustrative in this respect. The authors define 
several hemodynamic microcirculation types (normocirculatory, spastic, hyper-
emic, and congestive-stasical) and note the greatest effect of calcium antagonists in 
the spastic type, while these cause puffiness in the lower legs and feet, as well as hot 
flashes in the congestive-stasical type.
It can be speculated that patients in this group are poorly compliant with therapy 
due to low tolerability, or it is difficult to achieve the target BP. As Engholm et al. 
demonstrated in their study, in patients with a low systemic vascular resistance 
index (SVRI), additional administration of antihypertensive drugs from other 
groups (two-component therapy) significantly lowers BP without changing 
SVRI. There is also an insignificant trend towards an increase in the left atrial size 
with a decrease in the left ventricular stroke volume and cardiac index relative to 
patients with high SVRI [48]. Based on the functional state of the arteriolar and 
venular microvessels in the VP group, it can be assumed that in this case the pre-
scription of drugs with venotonic and/or diuretic effects will be most justified.
The next important question is the reasons for such a substantial difference in 
the functional state of the skin microvessels, when all the parameters analyzed 
by LDF differ significantly. It can be assumed that this is due either to different 
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etiological factors or to the pathological process duration. The early AH develop-
ment stages are not marked by elevated levels of endothelin, a marker of vasomotor 
endothelial dysfunction [49]. We were not able to assess the pathological process 
duration in the analyzed groups, which is one among many weaknesses of this pilot 
study, but it can be assumed, based on the significant reduction in the microvascu-
lar endothelial vasomotor function, that the pathological process had been develop-
ing longer in the VN patients.
The role of the temporal factor in the detected functional differences is sup-
ported by studies of vasomotor function of microvessels in different AH models 
in laboratory animals. Boegehold et al. demonstrated that a high-salt diet for 
6–7 weeks in healthy four-week old rats resulted in a significantly higher amplitude 
of vasomotions in the mesenteric arterioles with a diameter of 30 μm compared 
to the control group that did not received the salt load [50]. In another study in 
10–12 week-old spontaneously hypertensive rats (SHR), Noble et al. not only 
observed a significant rise in the vasomotion amplitude in the spinal skeletal muscle 
arterioles with a diameter of <30 μm relative to those in normotensive animals, but 
also a significant increase in the diameter of precapillary arterioles (6–15 μm) and 
postcapillary venules (15–40 μm) [51]. In another study of the cerebral microvascu-
lature in SHR, a significant increase in the vasomotion amplitude was demonstrated 
in micro- and larger (diameter 30–70 μm) vessels, where the smooth muscle layer 
is more pronounced and the neurogenic (sympathetic adrenergic) vascular tone 
regulation mechanism predominates [52]. The obtained experimental results in 
laboratory animals are quite consistent with the functional state of microvessels in 
the VP group, which may indirectly indicate the initial manifestations of the pathol-
ogy in this group of patients.
This hypothesis is also supported by the high correlation of Av with MBP 
obtained in the combined NT + VP group (n = 63): day time – r = 0.66 (p < 0.0001); 
night time – r = 0.76 (p < 0.0001). This relationship indicates that the progression 
of disorders in the venular-venous vascular bed is accompanied by an increase of 
BP. It can be hypothesized that first the renin-angiotensin system is activated to 
maintain tissue homeostasis and compensate the filtration-reabsorption imbal-
ance, leading to an increase in the resistive arteriolar tone, which in turn leads to a 
decrease in hydrostatic blood pressure in the capillaries. This regulatory mechanism 
restores the filtration-reabsorption metabolic balance but triggers a vicious circle 
which ultimately leads to structural microvascular changes. Based on this hypoth-
esis, it can be suggested that the VP patients are at the early AH stage (functional 
impairment stage), and the VN patients have a longer course of the pathological 
process with the development of structural changes. It is extremely difficult to 
determine the AH course duration since many patients do not feel elevated BP. In 
this study, in 23 patients (37%) from both groups AH was diagnosed incidentally 
without any previous suspicion on their part about the existence of a pathology.
Another important issue concerns the causes of disrupted blood outflow from 
the capillary bed, which may be due to several factors or their combination. One 
may be a disturbance in the functional state of the major veins which is observed 
both in laboratory animals [51] and in some AH patients and is expressed as a 
decrease in the venous wall elasticity with an elevation of their tone and the blood 
pressure in them [53–56]. Another cause may be an increase in the right atrial pres-
sure, which is observed in some AH patients [57, 58].
Another highly important issue concerns the BP level. What causes a higher BP 
level in VP patients relative to the VN group? The venular microvessels are gener-
ally believed to contribute not more than 8–9% of the PVR [59], although, as noted 
above, the contribution of the postcapillary section may be much higher [34]. 
But here another factor should be considered that significantly affects BP, i.e. the 
Basic and Clinical Understanding of Microcirculation
144
increase in blood pressure is due to the influence of various hormones, proinflam-
matory cytokines, and other humoral substances possibly secreted by the visceral 
adipose tissue [37].
Similar results for the functional state of the resistive skin microvessels in AH 
patients were also obtained also in another study [41]. In an age-matched group, 
Rossi et al. observed a significant increase in tissue perfusion compared to nor-
motensive subjects, associated with significantly higher vasomotion amplitudes 
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stress at high BP values, and the higher vasomotion amplitude in the range of the 
neurogenic regulation mechanism as sympathetic nervous system activation. The 
authors consider the observed increase in the pulse oscillation amplitude a mani-
festation of a high BP level, and the rise in the respiratory-associated blood flow 
oscillation amplitude as a compensatory reaction aimed at extending the time for 
oxygen extraction by tissues under microvascular rarefication.
Hemodynamic changes at the MVB level entail significant metabolic changes. 
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vesicular), filtration-reabsorption depends directly on the hemodynamic param-
eters. This metabolic mechanism is described by the Starling equation and provides 
bidirectional transendothelial transport of water-soluble and low-molecular-weight 
substances due to the difference in the hydrostatic and colloid osmotic blood pres-
sures. Enhanced arterial blood inflow (Ac) with impaired venular outflow (Av) in 
VP patients can lead to a substantial rise in hydrostatic pressure in the capillaries, 
which is observed in far from all AH patients during direct pressure measurement 
in the nail bed capillaries [42–44]. An increase in the capillary hydrostatic pressure 
leads to a shift in the filtration-reabsorption metabolic mechanism towards the 
predominance of filtration, with developing hyperhydration of the interstitial space 
and latent fluid retention in the tissues [45, 46]. The hyperhydration of the inter-
stitial space increases the blood↔cell distance for nutrients and tissue metabolism 
products, leading to a disruption in the metabolic process rate.
Another very important issue is the choice of antihypertensive therapy in this 
group of patients. The choice of vasodilating drugs is highly dubious. An additional 
decline in the initially low resistive arteriolar tone can have a range of negative 
consequences, including orthostatic instability, syncope, peripheral edema, etc. The 
study by Makolkin et al. [47] is highly illustrative in this respect. The authors define 
several hemodynamic microcirculation types (normocirculatory, spastic, hyper-
emic, and congestive-stasical) and note the greatest effect of calcium antagonists in 
the spastic type, while these cause puffiness in the lower legs and feet, as well as hot 
flashes in the congestive-stasical type.
It can be speculated that patients in this group are poorly compliant with therapy 
due to low tolerability, or it is difficult to achieve the target BP. As Engholm et al. 
demonstrated in their study, in patients with a low systemic vascular resistance 
index (SVRI), additional administration of antihypertensive drugs from other 
groups (two-component therapy) significantly lowers BP without changing 
SVRI. There is also an insignificant trend towards an increase in the left atrial size 
with a decrease in the left ventricular stroke volume and cardiac index relative to 
patients with high SVRI [48]. Based on the functional state of the arteriolar and 
venular microvessels in the VP group, it can be assumed that in this case the pre-
scription of drugs with venotonic and/or diuretic effects will be most justified.
The next important question is the reasons for such a substantial difference in 
the functional state of the skin microvessels, when all the parameters analyzed 
by LDF differ significantly. It can be assumed that this is due either to different 
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etiological factors or to the pathological process duration. The early AH develop-
ment stages are not marked by elevated levels of endothelin, a marker of vasomotor 
endothelial dysfunction [49]. We were not able to assess the pathological process 
duration in the analyzed groups, which is one among many weaknesses of this pilot 
study, but it can be assumed, based on the significant reduction in the microvascu-
lar endothelial vasomotor function, that the pathological process had been develop-
ing longer in the VN patients.
The role of the temporal factor in the detected functional differences is sup-
ported by studies of vasomotor function of microvessels in different AH models 
in laboratory animals. Boegehold et al. demonstrated that a high-salt diet for 
6–7 weeks in healthy four-week old rats resulted in a significantly higher amplitude 
of vasomotions in the mesenteric arterioles with a diameter of 30 μm compared 
to the control group that did not received the salt load [50]. In another study in 
10–12 week-old spontaneously hypertensive rats (SHR), Noble et al. not only 
observed a significant rise in the vasomotion amplitude in the spinal skeletal muscle 
arterioles with a diameter of <30 μm relative to those in normotensive animals, but 
also a significant increase in the diameter of precapillary arterioles (6–15 μm) and 
postcapillary venules (15–40 μm) [51]. In another study of the cerebral microvascu-
lature in SHR, a significant increase in the vasomotion amplitude was demonstrated 
in micro- and larger (diameter 30–70 μm) vessels, where the smooth muscle layer 
is more pronounced and the neurogenic (sympathetic adrenergic) vascular tone 
regulation mechanism predominates [52]. The obtained experimental results in 
laboratory animals are quite consistent with the functional state of microvessels in 
the VP group, which may indirectly indicate the initial manifestations of the pathol-
ogy in this group of patients.
This hypothesis is also supported by the high correlation of Av with MBP 
obtained in the combined NT + VP group (n = 63): day time – r = 0.66 (p < 0.0001); 
night time – r = 0.76 (p < 0.0001). This relationship indicates that the progression 
of disorders in the venular-venous vascular bed is accompanied by an increase of 
BP. It can be hypothesized that first the renin-angiotensin system is activated to 
maintain tissue homeostasis and compensate the filtration-reabsorption imbal-
ance, leading to an increase in the resistive arteriolar tone, which in turn leads to a 
decrease in hydrostatic blood pressure in the capillaries. This regulatory mechanism 
restores the filtration-reabsorption metabolic balance but triggers a vicious circle 
which ultimately leads to structural microvascular changes. Based on this hypoth-
esis, it can be suggested that the VP patients are at the early AH stage (functional 
impairment stage), and the VN patients have a longer course of the pathological 
process with the development of structural changes. It is extremely difficult to 
determine the AH course duration since many patients do not feel elevated BP. In 
this study, in 23 patients (37%) from both groups AH was diagnosed incidentally 
without any previous suspicion on their part about the existence of a pathology.
Another important issue concerns the causes of disrupted blood outflow from 
the capillary bed, which may be due to several factors or their combination. One 
may be a disturbance in the functional state of the major veins which is observed 
both in laboratory animals [51] and in some AH patients and is expressed as a 
decrease in the venous wall elasticity with an elevation of their tone and the blood 
pressure in them [53–56]. Another cause may be an increase in the right atrial pres-
sure, which is observed in some AH patients [57, 58].
Another highly important issue concerns the BP level. What causes a higher BP 
level in VP patients relative to the VN group? The venular microvessels are gener-
ally believed to contribute not more than 8–9% of the PVR [59], although, as noted 
above, the contribution of the postcapillary section may be much higher [34]. 
But here another factor should be considered that significantly affects BP, i.e. the 
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cardiac output. The cardiac output in AH patients may be elevated during venocon-
striction [60]. Based on the significantly lower peripheral vascular resistance, the 
VP patients can be hypothesized to have a hyperkinetic circulation type, and their 
higher BP values are due to a combination of two factors – an increase in the cardiac 
output, as noted in other studies [48], and a disruption of the blood outflow from 
the capillary bed with an increase in PVR at the postcapillary (venular) level.
Regardless of the reasons for the hindered blood outflow from the capillary 
bed, the mechanism that increases the amplitude of myogenic vasomotions in the 
precapillary arterioles and capillary sphincters is baffling. Normally, in a closed car-
diovascular system, an increase in the venous pressure results in a consecutive rise 
in the capillary and precapillary arteriolar pressure. The smooth muscle cells of the 
resistive microvessels respond to increased pressure and distension by contracting 
by the Ostroumov-Bayliss mechanism, which should lead to a rise in their tone with 
a decrease in the amplitude of myogenic vasomotions (Am). But in the VP group, 
the exact opposite effect is observed. How can we explain it?
It can be hypothesized that the precapillary arteriolar tone decline is of a com-
pensatory nature, aimed at overcoming the raised resistance at the postcapillary 
level. The increase in the arterial blood inflow is aimed at overcoming the impaired 
venous outflow. But from the metabolic expediency point of view, this compensa-
tion mechanism is extremely unfavorable. This can be assumed to be a consequence 
of the functional features of the smooth muscle cells in VP patients. Falcone et al. 
established in vivo that an increase in venous pressure in the cremaster muscle of 
SHR caused a more pronounced constriction reaction of the 15–100 μm arterioles 
than in normotensive animals [61]. Another research group demonstrated on mes-
enteric arterioles (diameter 100–150 μm) in vitro that in SHR the smooth muscle 
cells (lacking sympathetic innervation) develop a significantly higher vasomotion 
amplitude in response to norepinephrine compared to normotensive animals [62].
The results of this pilot study suggest that the contribution of the venular MVB 
to PVR is more substantial, and the generally accepted vascular resistance scale 
requires adjustment. In previous studies on healthy normotensive volunteers it was 
demonstrated that the blood volume in the skin venular microvessels has a posi-
tive correlation with BP, and a negative correlation not only with the magnitude of 
nocturnal BP decline, but also with the dilation response of MVB during the heat 
test, the nociception system activation, and post-occlusive reactive hyperemia [63, 
64]. MVB is anatomically located between the arterial and venous systems, and, as 
capillaries do not stretch, the disruptions in the outflow system naturally affect the 
inflow system to the exchange vessels with all the logical metabolic consequences. 
This state can be formulated simply as “no outflow – no inflow”.
The venular MVB itself deserves special attention. What is the physiological 
underpinning of the significantly larger vascular volume in the venular MVB 
than on the arteriolar side? This is what Nature intended, and therefore there is 
a physiological reason. Unlike arterioles, which only regulate blood inflow to the 
capillaries, many important functions are performed at the venular level. One is 
that mast cells are located in the immediate vicinity of venules with a diameter of 
40–80 μm. This protective system reacts to various chemical and biological noxious 
agents entering the systemic circulation and it is situated in the venular section 
of the MVB. Postcapillary venules provide the exchange of macromolecules and 
protein-bound substances in the bloodstream by vesicular transport. Recognition, 
immobilization, “unpacking” of transport molecules, and vesicle formation require 
some time and are facilitated by the hemodynamic conditions in the venular 
section of MVB, since it has the slowest blood flow in the entire cardiovascular 
system. The venular section occupies a strategic position and is the first to receive 
metabolic information.
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In the conducted studies it was discovered that any changes in venous MVB 
affect the functional state of the adjoining afferent arteriole and the effects are 
observed up to 12 mm from the stimulus applied. The following was revealed: 
constriction reactions of arterioles to intravenular administration of norepineph-
rine [65], dilation reactions to acetylcholine [66], adenosine [67], ATP  
[68], dilator prostanoids [69], and even to the metabolic stimulator 2,4-dini-
trophenol [70]. In response to an increase in shear stress, venular endothelium 
produces NO leading to a corresponding dilation of the adjoining arteriole [71]. 
There is an opinion that the arteriolar NO level is determined by its venular 
concentration, whose basal level is maintained by the secretory activity of the 
venular endothelium [72]. The endothelium of the venous bed is also sensitive 
to the blood gas composition. Tkachenko demonstrated that with blood O2 
saturation < 68% sympathetic stimulation leads to a contraction of the muscle 
veins (>100–150 μm), when O2 is in the range of 68–85%, the reaction can be 
both constriction and dilatation, but at saturation values of >85%, sympathetic 
stimulation causes only venous dilation [73].
4. Conclusion
LDF is a relatively new technique for studying microcirculation in humans 
which is going through the stages of adoption, data accumulation, and interpreta-
tion of the obtained results. A review of the scientific literature over the past 
20 years has identified only 143 studies of microcirculation in humans by LDF with 
wavelet analysis of blood flow oscillation. The total number of healthy subjects and 
patients with various organ and system diseases involved in the studies does not 
exceed 2600 [74].
The main aim of this pilot study was to evaluate the informativeness of LDF in 
assessing the functional state of the skin microvascular bed in patients with essen-
tial arterial hypertension. The study has many weaknesses, due to the retrospective 
data analysis and the inability to collect information on the central hemodynamic 
parameters and humoral status of the patients. Nevertheless, it can be concluded 
that the aim has been achieved. The obtained results are unexpected; however, they 
allow the microcirculatory blood flow problems in patients with AH to be viewed in 
an entirely new light.
Several quite precise conclusions can be made based on the study:
1. LDF is a very promising method to study the functional state of microcircula-
tion in humans and can be useful for the selection of personalized antihyper-
tensive therapy.
2. The functional activity of the tone-forming mechanisms (endothelial, neuro-
genic, myogenic) of the resistive arterioles in the skin is not correlated with BP 
according to ABPM data.
3. AH patients can differ significantly in their functional status of resistive mi-
crovessels. One half of the patients have an increased arteriolar tone without 
hemodynamic disruptions in the venular MVB. The other half of the patients is 
a complete opposite, that is, they exhibit a decrease in arteriolar tone associ-
ated with disrupted blood outflow from the capillaries. These functional differ-
ences must be considered when selecting antihypertensive therapy. This may 
assist in increasing the effectiveness of therapy and patient compliance with 
the treatment.
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cardiac output. The cardiac output in AH patients may be elevated during venocon-
striction [60]. Based on the significantly lower peripheral vascular resistance, the 
VP patients can be hypothesized to have a hyperkinetic circulation type, and their 
higher BP values are due to a combination of two factors – an increase in the cardiac 
output, as noted in other studies [48], and a disruption of the blood outflow from 
the capillary bed with an increase in PVR at the postcapillary (venular) level.
Regardless of the reasons for the hindered blood outflow from the capillary 
bed, the mechanism that increases the amplitude of myogenic vasomotions in the 
precapillary arterioles and capillary sphincters is baffling. Normally, in a closed car-
diovascular system, an increase in the venous pressure results in a consecutive rise 
in the capillary and precapillary arteriolar pressure. The smooth muscle cells of the 
resistive microvessels respond to increased pressure and distension by contracting 
by the Ostroumov-Bayliss mechanism, which should lead to a rise in their tone with 
a decrease in the amplitude of myogenic vasomotions (Am). But in the VP group, 
the exact opposite effect is observed. How can we explain it?
It can be hypothesized that the precapillary arteriolar tone decline is of a com-
pensatory nature, aimed at overcoming the raised resistance at the postcapillary 
level. The increase in the arterial blood inflow is aimed at overcoming the impaired 
venous outflow. But from the metabolic expediency point of view, this compensa-
tion mechanism is extremely unfavorable. This can be assumed to be a consequence 
of the functional features of the smooth muscle cells in VP patients. Falcone et al. 
established in vivo that an increase in venous pressure in the cremaster muscle of 
SHR caused a more pronounced constriction reaction of the 15–100 μm arterioles 
than in normotensive animals [61]. Another research group demonstrated on mes-
enteric arterioles (diameter 100–150 μm) in vitro that in SHR the smooth muscle 
cells (lacking sympathetic innervation) develop a significantly higher vasomotion 
amplitude in response to norepinephrine compared to normotensive animals [62].
The results of this pilot study suggest that the contribution of the venular MVB 
to PVR is more substantial, and the generally accepted vascular resistance scale 
requires adjustment. In previous studies on healthy normotensive volunteers it was 
demonstrated that the blood volume in the skin venular microvessels has a posi-
tive correlation with BP, and a negative correlation not only with the magnitude of 
nocturnal BP decline, but also with the dilation response of MVB during the heat 
test, the nociception system activation, and post-occlusive reactive hyperemia [63, 
64]. MVB is anatomically located between the arterial and venous systems, and, as 
capillaries do not stretch, the disruptions in the outflow system naturally affect the 
inflow system to the exchange vessels with all the logical metabolic consequences. 
This state can be formulated simply as “no outflow – no inflow”.
The venular MVB itself deserves special attention. What is the physiological 
underpinning of the significantly larger vascular volume in the venular MVB 
than on the arteriolar side? This is what Nature intended, and therefore there is 
a physiological reason. Unlike arterioles, which only regulate blood inflow to the 
capillaries, many important functions are performed at the venular level. One is 
that mast cells are located in the immediate vicinity of venules with a diameter of 
40–80 μm. This protective system reacts to various chemical and biological noxious 
agents entering the systemic circulation and it is situated in the venular section 
of the MVB. Postcapillary venules provide the exchange of macromolecules and 
protein-bound substances in the bloodstream by vesicular transport. Recognition, 
immobilization, “unpacking” of transport molecules, and vesicle formation require 
some time and are facilitated by the hemodynamic conditions in the venular 
section of MVB, since it has the slowest blood flow in the entire cardiovascular 
system. The venular section occupies a strategic position and is the first to receive 
metabolic information.
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In the conducted studies it was discovered that any changes in venous MVB 
affect the functional state of the adjoining afferent arteriole and the effects are 
observed up to 12 mm from the stimulus applied. The following was revealed: 
constriction reactions of arterioles to intravenular administration of norepineph-
rine [65], dilation reactions to acetylcholine [66], adenosine [67], ATP  
[68], dilator prostanoids [69], and even to the metabolic stimulator 2,4-dini-
trophenol [70]. In response to an increase in shear stress, venular endothelium 
produces NO leading to a corresponding dilation of the adjoining arteriole [71]. 
There is an opinion that the arteriolar NO level is determined by its venular 
concentration, whose basal level is maintained by the secretory activity of the 
venular endothelium [72]. The endothelium of the venous bed is also sensitive 
to the blood gas composition. Tkachenko demonstrated that with blood O2 
saturation < 68% sympathetic stimulation leads to a contraction of the muscle 
veins (>100–150 μm), when O2 is in the range of 68–85%, the reaction can be 
both constriction and dilatation, but at saturation values of >85%, sympathetic 
stimulation causes only venous dilation [73].
4. Conclusion
LDF is a relatively new technique for studying microcirculation in humans 
which is going through the stages of adoption, data accumulation, and interpreta-
tion of the obtained results. A review of the scientific literature over the past 
20 years has identified only 143 studies of microcirculation in humans by LDF with 
wavelet analysis of blood flow oscillation. The total number of healthy subjects and 
patients with various organ and system diseases involved in the studies does not 
exceed 2600 [74].
The main aim of this pilot study was to evaluate the informativeness of LDF in 
assessing the functional state of the skin microvascular bed in patients with essen-
tial arterial hypertension. The study has many weaknesses, due to the retrospective 
data analysis and the inability to collect information on the central hemodynamic 
parameters and humoral status of the patients. Nevertheless, it can be concluded 
that the aim has been achieved. The obtained results are unexpected; however, they 
allow the microcirculatory blood flow problems in patients with AH to be viewed in 
an entirely new light.
Several quite precise conclusions can be made based on the study:
1. LDF is a very promising method to study the functional state of microcircula-
tion in humans and can be useful for the selection of personalized antihyper-
tensive therapy.
2. The functional activity of the tone-forming mechanisms (endothelial, neuro-
genic, myogenic) of the resistive arterioles in the skin is not correlated with BP 
according to ABPM data.
3. AH patients can differ significantly in their functional status of resistive mi-
crovessels. One half of the patients have an increased arteriolar tone without 
hemodynamic disruptions in the venular MVB. The other half of the patients is 
a complete opposite, that is, they exhibit a decrease in arteriolar tone associ-
ated with disrupted blood outflow from the capillaries. These functional differ-
ences must be considered when selecting antihypertensive therapy. This may 
assist in increasing the effectiveness of therapy and patient compliance with 
the treatment.
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4. The role of the venular-venous vascular bed in AH is underestimated, and 
further studies in this area are required; this will contribute to solving many 
problems that cardiologists face today.
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Microcirculation is key to providing enough nutrition and oxygen from head to toe. 
This is possible only through an extensive network of blood vessels spread around the 
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